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Abstract 
Cranial cruciate ligament disease and rupture (CCLD/ R) is a common orthopaedic 
condition in dogs. CCLD/ R can be due to trauma (least common) or to non-contact 
injury (most common). Once the cranial cruciate ligament (CCL) is damaged 
complications such as stifle osteoarthritis can occur. Different dog breeds are at an 
altered risk to CCLD/ R. Previous biochemical and ultrastructural studies have found 
that glycosaminoglycans (GAGs) were altered in high risk dog breeds when 
compared to CCLs from a dog breed at low risk of ligament rupture. We hypothesise 
that proteoglycans and GAGs may vary between different anatomical regions of the 
CCL, and between differentially predisposed dog breeds to CCLD/ R. Proteoglycans 
were determined by semi-quantitative Western blotting, quantitative RT-PCR (qRT-
PCR), quantitative biochemistry, semi-objective histology scoring, and 
immunohistochemistry. Water and GAG content in the CCLs was also measured. 
Further qRT-PCR analysis was conducted to determine the expression of ECM 
proteases (ADAMTS -4 & -5) in the canine CCL. We showed with Western blot 
analysis that certain proteoglycans and GAGs were significantly different between 
anatomical regions of Staffordshire bull terrier CCLs. Data analysis between 
differentially predisposed dog breeds showed that the Staffordshire bull terrier CCLs 
(a moderate-high risk dog breed to CCLD/ R) had a significant increase in water 
content compared to greyhound CCLs (a low risk dog breed to CCLD/ R). Further, 
gene expression and Western blot analysis of fibromodulin, gene expression of 
aggrecan, and Western blot analysis of chondroitin-6 sulphate stubs were 
significantly increased in Staffordshire bull terrier CCLs compared to greyhounds. 
Decorin and ADAMTS-4 gene expression were significantly increased in 
greyhounds compared to Staffordshire bull terrier CCLs. Histology analysis showed 
that fibrocartilaginous regions were present in the CCL and were mainly observed in 
predisposed dog breeds to CCLD/ R. Furthermore, immunohistochemistry analysis 
showed that each proteoglycan had a different distribution throughout the CCL, 
which indicates that proteoglycans provide essential functionality to the CCL. The 
increase of certain proteoglycans and GAGs in CCLs of Staffordshire bull terriers 
might indicate increased fibrocartilage regions as a result of compressive loads. 
These changes in ECM content in the Staffordshire bull terrier indicate higher 
loading pressure on the CCL and could compromise the tissue, leading to increased 
incidence of disease and rupture. The increase of decorin in greyhounds could be 
essential for maintaining collagen fibril strength, whilst the increase of ADAMTS-4 
could indicate a higher rate of turnover to regulate normal CCL homeostasis.  
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Chapter 1: Introduction. 
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1.1      Ligament overview 
Ligaments are a unique type of connective tissue which function to stabilise the joint 
and have interesting biomechanical properties (Frank 2004). Ligaments have been 
shown to differ from one another in regard to their biochemical composition and 
structural morphology, depending on their location within the skeletal joint (Amiel, 
Frank et al. 1984; Rumian, Wallace et al. 2007).   
 
1.1.1 Gross appearance  
Ligaments can be classified into two subgroups that classify ligaments; skeletal 
ligaments which cross joints, and non-skeletal ligaments, which adhere to soft tissue 
such as abdominal suspensory ligaments (Frank, Amiel et al. 1985). A normal 
healthy skeletal ligament consists of a white, homogenous, dense connective tissue 
(Frank, Amiel et al. 1985). 
 
1.1.2 Hierarchical microstructure 
The hierarchical microstructure of ligaments is similar to what has been reported in 
tendon, consisting of collagen fibre bundles, fibres, subfibrils, microfibrils, and 
tropocollagen (Kastelic, Galeski et al. 1978) (Figure 1-1). In ligament, collagen fibre 
bundles are divided by cells (Amiel, Frank et al. 1984; Clark and Sidles 1990) and 
bundles are grouped into interdigitating structures named fascicles (Clark and 
Sidles 1990). Fascicles are separated by a septae (Clark and Sidles 1990), and are 
enveloped in a thin connective sheath named endoligament (Chowdhury, Matyas et 
al. 1991). The endoligament is connected to the epiligament, which is a vascular 
tissue (Chowdhury, Matyas et al. 1991). Collagen fibre bundles harbour a crimping 
pattern which is crucial for ligament elongation and recoiling without continuous 
damage (Frank, Amiel et al. 1985). 
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Figure 1-1: The hierarchical structure of tendons and ligaments. 
(Adapted from Kastelic, Galeski et al. 1978). 
 
1.1.3 Cells 
Cells in the ligament substance are primarily fibroblasts which can range in shape 
from spindle-shaped to rounded (Arnoczky 1983; Zhu, Zhang et al. 2012; Kharaz 
2015). These fibroblastic cells are named ligamentoblasts in immature tissue 
(Heffron and Campbell 1978). As the tissue matures, they appear spindled shaped 
and are then termed ligamentocytes (Heffron and Campbell 1978). In ligament, cells 
are known to harbour gap junctions, which allow direct cell to cell communication 
(Lo, Ou et al. 2002; Chi, Rattner et al. 2005). Gap junctions are found at the end of 
the cytoplasmic processes which form a 3-dimensional network within the tissue 
(McNeilly 1997; Lo, Marchuk et al. 2001). Long cytoplasmic processes that extend 
to adjacent cells have been observed in the healthy medial collateral ligament and 
cruciate ligaments (Lo, Ou et al. 2002; Smith, Vaughan-Thomas et al. 2012). 
 
1.1.4 Function 
Ligaments transfer load from bone to bone (Benjamin, Evans et al. 1986). They 
passively stabilise joints and so aid in regulating joint motion (Frank 2004). 
Ligaments are also viscoelastic in nature and this is essential for normal joint 
homeostasis, as they display a viscoelastic behaviour when they creep (stretching 
of the ligament with continuous load) and relax (the force necessary to maintain a 
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fixed position as it decreases overtime) (Frank 2004). Furthermore, they play a role 
in proprioception (Frank 2004; Birch, Thorpe et al. 2013), which is predominantly 
provided by the joint, muscle and cutaneous receptors (Frank 2004). 
Ligaments and tendons attach to bone in two different ways; either by a 
fibrocartilaginous attachment or a fibrous attachment (Benjamin and Ralphs 1998).  
The different mechanical environment of ligaments however, leads to the variation 
of their attachment sites (Benjamin, Qin et al. 1995). A fibrocartilaginous attachment 
has a role in dispersing stresses by supplying a gradual transition in mechanical 
properties between tendon/ ligament and bone (Benjamin, Evans et al. 1986; Woo, 
Maynard et al. 1988). The cruciate ligaments are a good example of a fibrocartilage 
attachment, as the cruciate ligaments attach to bone by four gradual stages; 
ligament, fibrocartilage, mineralised fibrocartilage, and finally bone (Benjamin, Qin 
et al. 1995). Fibrocartilage in tendon has a similar phenotype to cartilage, and can 
be distinguished from the non-fibrocartilage sites in tendon by four main 
characteristics; loss of the parallel arrangement of collagen fibre bundles; the 
presence of type I and type II collagen in similar ratios; the accumulation of the large 
aggregating proteoglycan aggrecan and; the presence of fibrocartilage cells 
(rounded nucleus with halo formation) (Vogel 2004), and these changes may also 
relate to fibrocartilaginous sites in ligament.  
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1.2     Cruciate ligaments 
 
1.2.1 Introduction  
The canine stifle joint is extremely complex and relies on ligamentous support to 
maintain its strength (Tirgari and Vaughan 1975). Within the stifle joint, there are 
four major ligaments that provide passive support to the canine stifle joint namely 
the cranial cruciate, caudal cruciate, medial collateral, and lateral collateral 
ligaments (Carpenter and Cooper 2000). The cruciate ligament (CL) complex in the 
dog is composed of two ligaments; cranial (CCL) and caudal (CaCL) (anterior (ACL) 
and posterior (PCL) for human and other species) (Arnoczky and Marshall 1977) 
(Figure 1-2). These two ligaments wrap around each other and lie underneath the 
femoral intercondylar notch (Arnoczky and Marshall 1977). The CL complex is vital 
in providing internal rotation and cranial-caudal support of the stifle (knee) joint 
(Arnoczky and Marshall 1977; Stouffer, Butler et al. 1983).   
      
 
Figure 1-2: Canine stifle joint anatomy. 
The patellar tendon has been removed to observe the cruciate ligaments. 
 
6 
 
1.2.2 Anatomy  
The CCL origin site starts from the medial side of the lateral femoral condyle and 
wraps around the CaCL (Arnoczky and Marshall 1977). The CCL runs cranially, 
medially, and distally to insert into the intercondylar areas of the tibia (Arnoczky and 
Marshall 1977). The canine CCL is distinguished by having a proximal to distal 
outward spiral appearance of approximately 90° (Arnoczky and Marshall 1977). This 
spiral configuration gives the CCL the appearance of two bands which alter in 
function with flexion and extension of the stifle joint; the craniomedial (CMB) and 
caudolateral (CLB) band (anteriomedial AMB and posteriolateral PMB in man and 
other species) (Arnoczky and Marshall 1977) (Figure 1-3). The CMB is spiral in 
shape and is in tension during extension and flexion, whereas the CLB is shorter 
and straighter and is under greatest tension during extension but becomes relaxed 
during flexion (Heffron and Campbell 1978; Arnoczky, Rubin et al. 1979). When 
comparing the two bands, the CMB is longer than the CLB (Heffron and Campbell 
1978; Arnoczky, Rubin et al. 1979). The CLs are known to be intra-articular, but 
they remain extra-synovial as the synovium surrounds the CLs (Arnoczky, Rubin et 
al. 1979). The anatomical location of the CaCL is different from the CCL as it 
originates from the medial aspect of the tibial popliteal notch and inserts into the 
lateral aspect of the medial femoral condyle (Arnoczky and Marshall 1977). The 
CaCL is comprised of two bands; the large cranial band and the smaller caudal 
band (Arnoczky and Marshall 1977). When the stifle joint is extended, the small 
caudal band is taut in flexion and loose in extension and the bigger cranial band is 
loose in flexion and taut in extension (Arnoczky and Marshall 1977). 
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Figure 1-3: Canine cranial cruciate ligament (CCL). 
A) CCL craniomedial band (black dashed line). B) CCL caudolateral band (black 
dashed line). 
 
1.2.3 Blood supply  
The middle genicular artery is the main blood supply for the canine stifle joint 
(Tirgari 1978; Arnoczky, Rubin et al. 1979). The blood supply of the cruciate 
ligaments comes primarily from the synovial vessels and infrapatellar fat pad (Tirgari 
1978, Arnoczky, Rubin et al. 1979). The CaCL synovial vessels are known to be 
more richly supplied compared to the CCL (Arnoczky, Rubin et al. 1979). The 
synovial vessels then transition into a finely meshwork network of periligamentous 
vessels which cover the CLs entirely (Arnoczky, Rubin et al. 1979; Kobayashi, Baba 
et al. 2006). Endoligamentous vessels are known to enrich the collagen fibrils of the 
cruciate ligaments (Arnoczky, Rubin et al. 1979). Epiligamentous vessels 
anastomose with the endoligamentous vessels by infiltrating transversely into the 
CLs (Arnoczky, Rubin et al. 1979; Kobayashi, Baba et al. 2006). The blood supply 
of the CL complex is minor due to its location in the transarticular area of the stifle 
joint (Clark and Sidles 1990; De Rooster, De Bruin et al. 2006), and both CCL and 
CaCLs are reported to have less blood supply in the core region (Tirgari 1978; 
Vasseur, Pool et al. 1985; Narama, Masuoka-Nishiyama et al. 1996). 
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1.2.4 Nerve supply  
The three major articular nerves that innervate the canine stifle joint are the 
saphenous nerve, tibial nerve, and the common peroneal nerve (O'Connor and 
Woodbury 1982). The largest nerve supply of the stifle joint is the medial articular 
nerve that originates from the major saphenous nerve (O'Connor and Woodbury 
1982). The nerve fibres of the CCL arise from the tibial nerve branches, as they 
enter the caudal joint capsule and pass along the ligament, and are surrounded by 
the synovial and periligamentous tissue (Arnoczky 1983). Mechanoreceptors play a 
role in proprioception of the knee joint (Johansson, Sjolander et al. 1991; Dhillon, 
Bali et al. 2012). It has been reported that the highest number of mechanoreceptors 
were found at the proximal one third of the CCL, whilst the lowest number of were 
found at the distal third of the CCL (Arcand, Rhalmi et al. 2000). Depletion of 
mechanoreceptors has been linked with ageing in rabbit anterior cruciate ligament 
(Aydog, Korkusuz et al. 2006). 
 
1.2.5 Functional anatomy 
The cruciate ligaments are very important for the maintenance of craniocaudal, 
mediolateral, and rotatory stability of the stifle joint (Arnoczky and Marshall 1977). 
They prevent cranial translation of the tibial on the femur and resist tibial rotation to 
a lesser degree (Arnoczky and Marshall 1977). During stifle flexion, the CMB is 
elongated and the CLB is shortened (Arnoczky and Marshall 1977; Heffron and 
Campbell 1978). The importance of the CaCL in knee stability is less clear, its 
primary function is to limit caudal translation of the tibia on the femur (Arnoczky and 
Marshall 1977). 
 
1.3      Ligament extracellular matrix components 
The biochemical composition of ligament has been well described (Frank 2004; 
Rumian, Wallace et al. 2007). Two-thirds of the wet weight of ligaments is 
composed of water with collagen being the principle solid component of the 
remainder, comprising 70-80 % of the ligament dry weight (Frank 2004).  Collagen 
type I is the predominant collagen in ligament (Frank 2004; De Rooster, De Bruin et 
al. 2006), accounting for nearly of 90% of the total collagen with the remainder 
commonly made up of types III, VI, V, XI and XIV (Frank 2004). 
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1.3.1 Collagen  
1.3.1.1     Collagen biosynthesis 
Fibril forming collagens are secreted as procollagens (Myllyharju and Kivirikko 
2004). Procollagen is composed of a C-terminal propeptide and an N-terminal 
propeptide (Myllyharju and Kivirikko 2004). Several enzymes associated with 
procollagen processing are involved in regulating the initial formation of collagen 
into fibrils. The C-propeptides are processed by tolloid family members including 
bone morphogenetic protein 1 (BMP-1), mammalian tolloid (mTLD), tolloid like 1 
(TLL-1) or furin (Scott, Blitz et al. 1999; Unsold, Pappano et al. 2002; 
Gopalakrishnan, Wang et al. 2004). N-propeptides processing is carried out by the 
disintegrin and metalloproteinase with thrombospondin like motifs proteases family 
(ADAMTS) namely ADAMTS-2, ADAMTS-3, and ADAMTS-14 (Colige, Li et al. 
1997; Fernandes, Hirohata et al. 2001; Colige, Vandenberghe et al. 2002). After 
propeptides are processed, collagen molecules can spontaneously assemble into 
fibrils with a distinctive  D-periodic surface structure (Canty and Kadler 2005). 
 
1.3.1.2     Collagen types 
The common collagen types in ligaments are similar to what has been reported for 
tendon (Birch, Bailey et al. 1999; Riley 2004; Riley 2005). The fibril forming collagen 
type I is the main collagen in tendon (Birch, Bailey et al. 1999; Kadler, Baldock et al. 
2007), The second most common is collagen type III, which is another fibril forming 
collagen and is known to regulate collagen type I fibrillogenesis (Riley 2005: Kadler, 
Baldock et al. 2007). Type II and XI are also fibril forming collagens, however, 
collagen type II is restricted to the fibrocartilaginous sites of tendon (Riley 2005). 
Type V collagen provides a template for fibril formation as it is commonly located in 
the core of type I fibrils (Riley 2004). Other types of collagen include those forming 
beaded filaments (type VI), and the fibril associated collagens with interrupted triple 
helices (type XIV) (Riley 2005).  
 
1.3.2 Elastin 
Elastic fibres are widely distributed in connective tissues such as skin, lungs and 
ligaments (Kielty, Sherratt et al. 2002). Their structural role is to provide tissues with 
elastic recoil and flexibility (Kielty, Sherratt et al. 2002). Elastin content varies 
between different ligament tissues and species (Uitto 1979; Nakagawa, Mikawa et 
al. 1994; Smith, Clegg et al. 2014; Kharaz 2015). In canine CCL, elastin has been 
shown to comprise approximately 10 % of its dry weight in greyhounds (Smith, 
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Clegg et al. 2014), and 4.6 % of its dry weight in Staffordshire bull terriers (Kharaz 
2015). 
 
1.3.3 Glycoproteins  
Glycoproteins are defined as a core protein covalently linked to a carbohydrate, and 
contain a monosaccharide or a polysaccharide (Sharon 1986). Proteoglycans are a 
subtype of glycoproteins where the core protein is attached to one or more 
polysaccharide chains consisting of amino sugars and termed glycosaminoglycans 
(Sharon 1986). 
 
1.3.4 Glycosaminoglycans  
Glycosaminoglycans (GAGs) are covalently attached to a proteoglycan core protein 
with the exception of hyaluronic acid (Hardingham 1981; Ajit Varki 2009). They 
consist of a long branched polysaccharide chain, and one or more of the repeating 
units containing either an acidic, carboxylate or sulphate group (Hardingham and 
Fosang 1992; Ajit Varki 2009). GAGs comprise a hexosamine (i.e, glucosamine 
(GlcN) or galactosamine (GalN)), an uronic acid (glucoronic acid (GlcUA) and or 
iduronic acid (IdUA)) or galactose (Gal) (Hardingham and Fosang 1992). The 
hexosamine composition of the repeating disaccharide is mostly N-acetylated and 
both sugar components of the disaccharide can be sulphated as well (Ajit Varki 
2009). These sugar and disaccharide units are linked by different glyosidic linkages 
(a1-4, b1-3, or b1-4) (Hardingham and Fosang 1992; Ajit Varki 2009). Within the 
sugar hydroxyl groups, the carboxyl groups of the two hexuronic acid isomers 
GlcUA and IdUA and the existence of sulphation on both or either of the 
disaccharide sugars produces a very strong negative charge on GAG chains 
(Hardingham and Bayliss 1990). This negative charge creates a high affinity for 
water and ment that GAGs bind to many cationic molecules present in cells and 
tissue matrices (Hardingham and Bayliss 1990). 
There are seven different types of GAGs in mammalian tissue, namely; hyaluronic 
acid or hyaluronan, chondroitin sulphate-4, chondroitin sulphate-6, dermatan 
sulphate, keratan sulphate, and heparin/heparan sulphate (Hardingham 1981).  
Unlike other types of GAGs, hyaluronic acid is not further processed by sulphation 
or by epimerisation of glucuronic acid to iduronic acid  (Ajit Varki 2009). The 
structures of GAGs are illustrated in Figure (1-4). GAGs have been shown to 
regulate collagen fibrillogenesis (Redaelli, Vesentini et al. 2003; Douglas, 
Heinemann et al. 2006; Ruehland, Schonherr et al. 2007).  
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Hyaluronic acid  
Hyaluronic acid is composed of repeating sugar units of glucuronic and N-acetyl 
glucosamine that are unsulphated, giving it a much less complex structure than the 
other sulphated GAGs (Hardingham and Fosang 1992; Ajit Varki 2009). Hyaluronan 
exhibits a high degree of viscosity and viscoelastic properties (Ajit Varki 2009). It is 
important for lubricating the vitreous humour of the eye and joints (Ajit Varki 2009). 
In the synovial fluid of articular joints, hyaluronan functions to transmit load during 
joint movement thus protecting the cartilage surface (Ajit Varki 2009).  
Keratan sulphate 
Keratan sulphate is composed of disaccharide repeats of N-acetyl glucosamine and 
galactose (Hardingham and Fosang 1992; Funderburgh 2000). The unique feature 
of keratan sulphate is that it does not contain an uronic acid (Funderburgh 2000). 
Within the mammalian tissue, there are three types of keratan sulphates namely 
keratan sulphate I (corneal keratan sulphate) (Antonsson, Heinegard et al. 1991; 
Hardingham and Fosang 1992), keratan sulphate II (skeletal keratan sulphate) 
(Hardingham and Fosang 1992; Fukuda, Tsuboi et al. 1999), and keratan sulphate 
III (found in the brain tissue) (Chai, Yuen et al. 1999).  
Chondroitin sulphate 
Chondroitin sulphate is abundant in bone and articular cartilage (Sato, Rahemtulla 
et al. 1985; Bayliss, Osborne et al. 1999). It is composed of disaccharide repeats of 
glucuronic acid and N-acetyl galacotosamine (Hardingham and Fosang 1992; Ajit 
Varki 2009).  
 
Dermatan sulphate 
Dermatan sulphate is an alternative form of chondroitin sulphate in which some of 
its glucuronic acid residues have undergone C-5 epimerisation into iduronic acid 
(Hardingham and Fosang 1992). It is composed of disaccharide repeats of iduronic 
acid and N-acetyl galacotosamine (Hardingham and Fosang 1992; Trowbridge and 
Gallo 2002). Dermatan sulphate is found in tendon, cartilage, skin, sclera and other 
connective tissues (Rosenberg, Choi et al. 1986). 2-sulphated residues are more 
commonly found with dermatan sulphate rather than chondroitin sulphate 
(Hardingham and Fosang 1992).  
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Heparin and Heparan sulphate 
Heparin and heparan sulphate are compound structures that consist of a repeating 
disaccharide unit of N-acetylated glucosamine or N-sulphated glucosamine, iduronic 
acid, and glucuronic acid (Hardingham and Fosang 1992). Some of the glucuronic 
acid residues may be epimerised to iduronic acid (Carlsson, Presto et al. 2008). 
Heparin and heparan sulphate differ in many aspects (Ajit Varki 2009). Heparin is 
synthesised in connective tissue mast cells, whilst heparan sulphate is found on cell 
surfaces and matrix proteoglycans (Hardingham and Fosang 1992; Ajit Varki 2009). 
Furthermore, the anticoagulant activity of heparan sulphate is much less than that of 
heparin (Ajit Varki 2009). In terms of biosynthesis, heparin undergoes more 
extensive sulphation and uronic acid epimerisation than that of heparan sulphate 
(Hardingham and Fosang 1992; Ajit Varki 2009).  
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Figure 1-4: The structural variations of glycosaminoglycans (GAGs). 
The disaccharide repeating units of hyaluronan (HA), keratan sulphate (KS), chondroitin 
sulphate (CS), dermatan sulphate (DS), and heparin (Hep)/ heparan sulphate (HS) contains 
of a hexosamine [either glucosamine (GlcN) or galactosamine (GalN) in squares], and a 
uronic acid [either glucuronic (GlcUA) or iduronic acid (IdUA) in triangles] or galactose (Gal) 
in circles. The hexosamine, uronic acid and galactose sugars in every disaccharide unit can 
be substituted as well with sulphate groups on the sugar hydroxyls at the 2-(2S), 3-(3S), 4-
(4S) and 6-(6S) sites. The hexosamine is regularly N-acetlyated (NAc), but in Hep⁄ HS, it can 
also be non-sulphated (NS) or present as a free amine (N). HA is the only GAG that is not 
sulphated and is not covalently attached to a proteoglycan core protein (Adapted from 
Hardingham and Fosang 1992). 
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1.3.4.1     Glycosaminoglycan biosynthesis  
Heparan sulphate & chondroitin sulphate/ dermatan sulphate 
The synthesis of chondroitin, dermatan, and heparan sulphate is initiated by the 
development of a neutral trisaccharide of galactose-galactose-xylose at the 
reducing terminal of the GAG chain (Hardingham 1981). The GAGs are linked by 
serine or threonine residue that is attached to xylose via an O-linked 
oligosaccharide (Hardingham 1981). The synthesis begins by transferring xylose to 
a serine residue, and is catalysed by the enzyme xylosyltranferases (Gotting, Kuhn 
et al. 2000). Furthermore, two galactose residues are inserted by the activation of 
galactosyltranferase I (Almeida, Levery et al. 1999; Okajima, Yoshida et al. 1999) 
and galactosyltransferase II (Bai, Zhou et al. 2001). The linkage region is complete 
by the addition of one glucuronic acid that is catalysed by the enzyme 
glucuronosyltransferase I (Kitagawa, Tone et al. 1998). A diagram illustrating the 
trisaccharide linkage region process is shown in Figure 1-5. The enzymes 
responsible for the sulphation of chondroitin sulphate N-acetyl galactosamine are 4-
O-sulfotransferases and 6-O-sulfotransferases, whereas N-deacetylase and N-
sulfotransferases are responsible for the generation of N-sulphated glucosamine 
units present on N-acetyl galactosamine of heparan sulphate (Ajit Varki 2009). 
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Figure 1-5: Diagrammatic illustration of the biosynthesis process of the heparin 
sulphate, chondroitin sulphate, and the dermatan sulphate GAG. 
The biosynthesis of heparan sulphate, chondroitin sulphate, and dermatan sulphate are 
initiated by the formation of a linkage region trisaccharide. The GAGs are linked by serine 
residue that is attached to xylose via an O-linked oligosaccharide. The further addition of two 
galatose (Gal) and one glucuronic acid (GlcUA) completes the linkage region process. 
Afterwards, the GAG chains are polymerised to form heparan sulphate, chondroitin sulphate, 
and dermatan sulphate. The addition of the first hexosamine determines the GAG to be 
chondroitin sulphate (N-acetyl galactosamine (GalNac)) or heparin sulphate (N-acetyl 
glucosamine (GlcNac)). Epimerisation of some of the chondroitin sulphate glucuronic acid 
hexosamines into iduronic acid (IdUA) forms the GAG dermatan sulphate.  The following 
enzymes are essential for the formation of the GAG linkage region; XYLT= 
xylosyltransferases; B4GALT7= galactosyltransferase I; B3GALT6= galatosyltransferase II; 
B3GAT3= glucuronosyltransferase I (Adapted from Malfait, Kariminejad et al. 2013). 
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Keratan sulphate  
Keratan sulphate does not contain a neutral trisaccharide (Hardingham 1981). The 
linkage region of keratan sulphate varies according to the keratan sulphate type 
(Hardingham 1981). Keratan sulphate I is linked via an N-glycosylamine binding 
from N-acetyl galactosamine to asparagine (Antonsson, Heinegard et al. 1991; 
Hardingham and Fosang 1992: Ajit Varki 2009). N-linked oligosaccharides have 
been found on keratan sulphate proteoglycans such as fibromodulin (Plaas, Neame 
et al. 1990), lumican, and keratocan (Dunlevy, Neame et al. 1998). In addition, 
different lengths of keratan sulphate chains have been found on the N-linked 
oligosaccharide of fibromodulin (Plaas, Neame et al. 1990). Keratan sulphate II is 
linked by an O-glycosidic bond between N-acetylgalactosamine to serine or 
threonine (Hardingham and Fosang 1992; Fukuda, Tsuboi et al. 1999; Ajit Varki 
2009). Keratan sulphate III is linked via 2-O-mannose, and is attached to the protein 
core via a serine residue (Chai, Yuen et al. 1999). A diagram illustrating the linkage 
region process of the three different keratan sulphate types is shown in Figure 1-6.  
The two enzymes known to catalyse the sulphation reaction for keratan sulphate 
hexosamines are N-acetyl glucosamine 6-O sulfotransferases and galactose 6-O 
sulfotransferases (Ajit Varki 2009). N-acetyl glucosamine 6-O sulphation only occurs 
at the non-reducing terminal of N-acetyl galactosamine residue, whereas galactose 
6-O sulphation occurs at both of the non-reducing terminal and internal galactose 
residue (Ajit Varki 2009). 
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Figure 1-6: Diagrammatic illustration of the biosynthesis process of the keratan 
sulphate GAG. 
The oligosaccharides linking the core protein to keratan sulphate determine the three types 
of keratan sulphate. Keratan sulphate I is attached to asparagine residue via N-linked 
oligosaccharides, whereas keratan sulphate II is O-linked to N-acetyl galactosamine to 
serine or threonine residue via a mucin like core-2 structure. Keratan sulphate III is linked to 
the protein core by mannose O-linked to serine (Modified from Hardingham and Fosang 
1992; Funderburgh 2000). 
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Hyaluronic acid 
Hyaluronic acid biosynthesis occurs at the inner surface of the plasma membrane in 
eukaryotes, and hyaluronic acid synthases is the main enzyme in catalysing 
hyaluronic acid (Ajit Varki 2009). Unlike other GAGs, hyaluronic acid biosynthesis 
does not occur on core proteins of proteoglycans (Ajit Varki 2009). 
 
1.3.5 Proteoglycans 
Proteoglycans are widely distributed in mammalian tissues and are a large family of 
macromolecules. However, there are four major classes of proteoglycans; the 
intracellular, cell-surface, pericellular and ECM proteoglycans (Iozzo and Schaefer 
2015; Schaefer and Schaefer 2010). Once proteoglycans are synthesised and 
secreted into the extracellular matrix (ECM), they are important in contributing to 
the tensile strength of skin and tendon, transparency of the cornea, viscoelasticity 
of blood vessels, compressive properties of cartilage, and mineralisation of bone 
matrices (Iozzo 1999; Iozzo and Schaefer 2015). Proteoglycans are also involved 
in regulating  growth factors and cytokines (Iozzo 1999; Iozzo and Schaefer 2015). 
These molecules are extremely hydrophilic, and are important for hydrating the 
ECM.  
 
1.3.5.1     Proteogycan biosynthesis in skeletal tissues 
The original proteoglycan core protein is synthesised within the rough endoplasmic 
reticulum where N-linked mannose oligosaccharides are attached (Hassell, Kimura 
et al. 1986). Most of the posttranslational modification occurs in the Golgi complex 
which involves one or more of the followings (Figure 1-7) (Hassell, Kimura et al. 
1986).  
1. Insertion of the glycosaminoglycan chain onto a suitable serine or threonine 
residue. 
2. Insertion of O-linked oligosaccharide onto suitable serine or threonine residues. 
3. Alteration of high mannose N-linked oligosaccharides into compound forms. 
4. Potential processing of the protein by elimination of portions of the polypeptide. 
Once a proteoglycan is formed within the Golgi complex, it is processed depending 
on the function and the cell type. For example, proteoglycans may be packaged 
within storage granules as it is the case for heparan sulphate proteoglycans in mast 
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cells or they may be transported via secretary vesicles to the extracellular space to 
perform structural roles within connective tissues (Hassell, Kimura et al. 1986). 
 
Figure 1-7: Proteoglycan biosynthesis in the skeletal tissue. 
 (Adapted from Hassell, Kimura et al. 1986).  
 
1.3.5.2     Hyalectans: proteoglycans interacting with hyaluronan and lectins 
This family is composed of four different types of proteoglycans; versican, aggrecan, 
neurocan, and brevican (Iozzo and Murdoch 1996; Iozzo 1998; Iozzo and Schaefer 
2015). Hyalectans share common features in which they bind to hyaluronan via their 
globular 1 (G1) domains at their N-terminal regions. They also carry a C-type lectin 
domain, and an elongated central region that contains the majority of the GAG 
chains (Iozzo and Murdoch 1996; Iozzo 1998; Iozzo and schaefer 2015). A detailed 
structure representing the hyalectans can be shown in Figure 1-8. 
 
1.3.5.2.1 General structural features of hyalectans 
Versican 
Versican is the largest proteoglycan member of the hyalectan family (Krusius, 
Gehlsen et al. 1987) and is also the major hyalectan in bovine collateral ligament 
(Ilic, Carter et al. 2005). Versican globular domain 1 (G1) consist of an N–terminal 
G1 domian that binds to hyaluronan, and a C-terminal G3 domain that contains a C-
type lectin region near to the complementary regulatory like domain and the 
epidermal growth factor regions (Naso, Zimmermann et al. 1994). In the middle part 
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of versican, two large exons are present which code for the glycosaminoglycan 
chondroitin sulphate, and are called α GAG and β GAG (Dours-Zimmermann and 
Zimmermann 1994). Versican has four mRNA transcript variants (v) that arise as a 
result of alternative splicing which are v0, v1, v2, and v3 (Dours-Zimmermann and 
ZimmermannS 1994; Ito, Shinomura et al. 1995; Iozzo 1998; Schmalfeldt, Dours-
Zimmermann et al. 1998). The largest versican variant is variant 0, and  variant 0 
and 1 are believed to be the major variants in dense connective tissue (Schmalfeldt, 
Dours-Zimmermann et al. 1998). A diagram illustrating versican structure is shown 
in Figure 1-8. 
 
Aggrecan 
Aggrecan is the main proteoglycan of cartilage (Iozzo 1998), and is the second 
largest proteoglycan in ligament (Ilic, Carter et al. 2005). Its core protein molecular 
weight is about 250 000 to 350 000 (Hardingham 1981). Aggrecan interacts with 
hyaluronan and link protein to form aggregates (Hardingham and Muir 1974; 
Hardingham, Bayliss et al 1990), and link protein functions to stabilise aggregate 
formation (Hardingham and Bayliss 1990) (Figure 1-3). These aggregates are non-
covalently bound to hyaluronic acid and link protein (Hardingham and Bayliss 1990). 
Aggrecan is mostly attached to chondroitin sulphate chains, and the remainder are 
keratan sulphate chains and O- and N- linked oligosaccharides (Hardingham and 
Fosang 1992). Aggrecan contains three domains (G1, G2, and G3) (Doege, 
Garrison et al. 1994). The region between the G1 domain and the G2 domain is 
called the interglobular domain (Doege, Garrison et al. 1994). The G3 domain is 
located at the carboxylic terminus of the core protein, and is known to be essential 
for normal post-translational processing of the aggrecan core protein molecule 
(Zheng, Luo et al. 1998).  
 
Neurocan 
Neurocan is a chondroitin sulphate proteoglycan found in early postnatal brain, and 
plays a role in inhibiting neurite outgrowth in vitro (Liu, Cafferty et al. 2006; Tang, 
Yang et al. 2009). Neurocan’s amino and carboxyl – terminal globular domains are 
homologous with those in aggrecan and versican, sharing 60% similarity (Margolis 
and Margolis 1994). The interglobular domain is unique however, containing up to 7 
GAG attachment sites and shows no homology to other hyalectans (Margolis and 
Margolis 1994). Neurocan is catabolised during tissue maturation, which results in 
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loss of its amino terminal globular domain due to proteinase cleavage (Rauch, 
Karthikeyan et al. 1992).   
 
Brevican  
Brevican is the most recently discovered hyalectan of the central nervous system, 
and is also a chondroitin sulphate proteoglycan, and it contains the shortest GAG-
binding domain amongst the hyalectan family (Yamada, Watanabe et al. 1994). 
Similarly to neurocan, brevican is present in vivo either as a full-length proteoglycan 
or as a processed form (Yamanda, Wantanabe et al. 1994). 
 
 
 
Figure 1-8: A schematic representation of the hyalectan family. 
Hyalectans commonly carry hyaluronan and lectin-binding modules and consist of aggrecan, 
versican splice variants, neurocan and bervican (Modified from Iozzo and Schaefer 2015). 
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1.3.5.2.2 Expression and functional control of hyalectans 
 
Versican 
The different transcripts of versican vary within their expression in tissues. For 
example, versican V0 and V1 are present in fibroblasts, chondrocytes, hepatocytes, 
myocytes (Dours-Zimmermann and Zimmermann 1994), and tenocytes (Samiric, Ilic 
et al. 2004), whereas keratinocytes only express versican V1 (Dours-Zimmermann 
and Zimmermann 1994). In ligament, the three expressed versican variant 
transcripts are; V0, V1, and V2 (Ilic, Carter et al. 2005).  
It has been shown that versican is expressed in tensional and compressional 
regions of tendon (Vogel and Heinegård 1985; Waggett, Ralphs et al. 1998) 
Furthermore, versican organises the tendon cells in linear arrays between collagen 
fascicles present in the pericellular matrix (Ritty, Roth et al. 2003). It interacts with 
proteins associated with elastin and elastic fibers (Isogai, Aspberg et al. 2002), and 
interacts with a number of growth factors, such as trasforming growth factor beta 
TGF-β and platelet derived growth factor (PDGF) (Schonherr, Jarvelainen et al. 
1991). 
 
Aggrecan 
Aggrecan is predominantly expressed in cartilage (Hardingham 1981), tendon 
(Rees, Flannery et al. 2000), and ligament (Clements, Carter et al. 2008). 
In cartilage, the multiple chondroitin sulphates adhered to aggrecan core protein 
create a negatively-charged molecule which acts to hydrate the cartilage tissue and 
regulate its normal homeostasis (Hardingham and Bayliss 1990). When anionic 
proteoglycans are present in high concentrations, the tissue starts to create a large 
osmotic swelling pressure drawing water into the tissue which allows the tissue to 
expand and swell, and this is essential for cartilage to withstand high compressive 
forces (Hardingham and Bayliss 1990; Kiani, Chen et al. 2002). Aggrecan has also 
been shown to withstand compressive forces in tendon (Vogel and Heinegård 1985; 
Waggett, Ralphs et al. 1998). Figure (1-9) shows an example of the components of 
an aggregating cartilage proteoglycan, aggrecan. 
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Figure 1-9: Aggrecan in articular cartilage. 
The main components of articular cartilage are aggrecan and collagen. The tensile strength 
of collagen fibres, osmotic swelling pressure, and high quantities of negatively charged 
aggrecan gives cartilage the ability to withstand compressive forces. Aggrecan forms 
aggregates with hyaluronic acid and link protein forming a stable meshwork within the matrix 
(Modified from Kiani, Chen et al. 2002). 
 
 
 
 
 
 
 
 
 
 
24 
 
Neurocan and brevican 
Nuerocan and brevican are expressed in the brain tissue (Oohira, Matsui et al. 
1994; Yamada, Watanabe et al. 1994). Neurocan interacts with the ECM protein 
tenascin-R (Grumet, Milev et al. 1994). It also binds and regulates neural cells 
(Grumet, Flaccus et al. 1993). Similar to neurocan, brevican has been shown to 
bind to tenascin–R mediated by a protein-protein interaction (Aspberg, Miura et al. 
1997). 
 
1.3.5.3     Small leucine rich-proteoglycan (SLRPs) 
The SLRP family has been classified into five groups (Iozzo 1999; Schaefer and 
Iozzo 2008). These groupings are determined by the number and size of exons, the 
presence of the N-terminal cysteine rich clusters, and chromosomal orientation 
(Iozzo 1999). The five groups can be divided into two categories; the canonical 
(class I-III) and non-canonical (class IV and V) SLRPs (Figure 1-10). Class I-III 
SLRPs have been found to be present in ligament, tendon, cartilage, eye, and 
kidney (Waggett, Ralphs et al. 1998; Schaefer and Iozzo 2008; Schaefer 2011; 
Yang, Culshaw et al. 2011).  
 
Figure 1-10: A comprehensive category of the small leucine rich proteoglycans 
(SLRPs) based on their sequence homology. 
 (Adapted from Schaefer and Iozzo 2008). PRELP= prolargin. 
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The leucine rich repeat (LRR) structure in SLRPs is flanked by an N- and C-terminal 
domain at either end of the repeats (Iozzo 1999). SLRPs contain four structural 
domains (Iozzo 1998). Domain I contains the single peptide and a propeptide (Iozzo 
1998). The propeptide is only present in class I SLRPs (Fisher, Termine et al. 
1989). Domain II consists of the glycosaminoglycan attachment site and four equally 
spaced cysteine residues (Iozzo 1998). Domain III contains the LRRs which function 
to interact with various proteins, and domain IV contains two cysteine residues 
(Iozzo 1998). A detailed diagram of the four domains of decorin is shown in Figure 
1-11. 
 
 
Figure 1-11: Decorin classical four domain structure. 
The glycosaminglycans and N-linked oligosaccharide are shown as circles. The consensus 
sequences of the cysteine residues as well for the leucine rich repeat are indicated (Adapted 
from Iozzo 1998). SP= single peptide, PP= propeptide, Cys= cysteine region, LRR= leucine 
rich repeat. 
 
LRRs have been reported to be folded containing both concave and convex 
surfaces. In addition, the LRRs of SLRPs have been provided with a “horseshoe” 
shaped structure (Scott 1996; Weber, Harrison et al. 1996). However, X-ray data 
indicate that decorin 12 LRRs have a “banana-shaped” structure (Scott, McEwan et 
al. 2004), and it has been described that decorin LRRs are short which might be 
responsible for the banana shaped structure (McEwan, Scott et al. 2006). This 
suggests that SLPRs other than decorin might also have a bannana shaped 
structure.  
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Decorin LRR 11 extends laterally where its C-terminal conserved cysteine residue 
forms a disulphide bond with another cysteine residue in the last LRR 12 therefore 
creating an “ear repeat”. This “ear repeat” feature has been similarly shown for other 
SLRPs (class I-III) where their C-terminal conserved cysteine residue spans from 
the beginning to the last LRR (Scott, McEwan et al. 2004). It has been proposed 
that decorin dimerises through the concave surfaces of its LRR domains, and this 
could indicate that other SLRPs dimerise as well (Scott, McEwan et al. 2004). The 
dimerisation of decorin could be essential for its role in collagen fibrillogenesis 
(Weber, Harrison et al. 1996). 
 
1.3.5.3.1 Structural differences between class I-III SLRPs 
Class I  
This class contains decorin, biglycan, and asporin (Iozzo 1999; Schaefer and Iozzo 
2008). Their unique feature is that they contain a typical cysteine cluster that forms 
two disulphide bonds (Iozzo 1999; Schaefer and Iozzo 2008). Decorin consists of 
one GAG attachment site which is either linked to a chondroitin or dermatan 
sulphate chain (Hardingham and Fosang 1992; Schaefer and Iozzo 2008). Decorin 
molecular weight has been found to be approximately 40 kDa in cartilage, tendon 
and ligament (Rees, Flannery et al. 2000; Melrose, Fuller et al. 2008; Yang, 
Culshaw et al. 2011).  
Biglycan carries two chondroitin or dermatan sulphate chains (Hardingham and 
Fosang 1992; Schaefer and Iozzo 2008). The molecular weight of biglycan has 
been found to be similar to decorin (approximately 40 kDa) in cartilage, tendon and 
ligament (Rees, Flannery et al. 2000; Melrose, Fuller et al. 2008; Yang, Culshaw et 
al. 2011). Asporin is known to be an exception for this class, as it does not carry 
glycosaminoglycan side chains (Schaefer and Iozzo 2008). A diagram of class I and 
II SLRPs is shown in Figure 1-12. 
 
Class II  
This class includes fibromodulin, lumican, keratocan, osteoadherin, and prolargin 
(PRELP) (Schaefer and Iozzo 2008; Iozzo and Schaefer 2015). They are linked to 
keratan sulphate or polylactosamine, a non-sulphated form of keratan sulphate 
(Schaefer and Iozzo 2008). All class II SLRPs contain a tyrosine rich domian with 
the exception of PRELP. The molecular weights for fibromodulin and lumican are 
around 50 kDa in cartilage and ligament (Melrose, Fuller et al. 2008; Yang, Culshaw 
et al. 2011), whilst the molecular weight of keratocan has been found to be 30 kDa 
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in cartilage and tendon after enzymatic removal of its keratan sulphate chains 
(Melrose, Fuller et al. 2008; Rees, Wagget et al. 2009). A diagram of class I and II 
SLRPs is shown in Figure 1-12. 
 
Class III  
This class consists of epiphycan, opticin, and osteoadherin (Schaefer and Iozzo 
2008; Iozzo and Schaefer 2015). They contain a low number of leucine rich repeats 
(seven leucine rich repeats) and have a genomic organisation of seven exons 
(Schaefer and Iozzo 2008). 
     
 
Figure 1-12: Domain structure of class I and II SLRPs. 
 (Modified from Iozzo and Murdoch 1996). 
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1.3.5.3.2 Role of SLRPs in collagen fibrillogenesis 
The GAG chain of decorin and its important role in collagen fibrillogenesis has been 
well studied (Redaelli, Vesentini et al. 2003; Ruehland, Schonherr et al. 2007). A 
three dimentional cell culture model was used to study the effect of the glycosylated 
(with GAG chain) and non-glycosylated (without GAG chains) decorin on collagen 
fibrillogenesis, and it was found that non-glycosylated decorin had produced 
irregular diameters collagen fibril sizes compared to the glycosylated decorin, which 
had a uniform size of collagen fibrils (Ruehland, Schonherr et al. 2007). 
Computational studies have shown that chondroitin-6-sulphate regulates collagen 
fibril length, and is predicted to facilitate lateral force transfer between nearby fibrils, 
thereby providing collagen fibrils with mechanical strength (Redaelli, Vesentini et al. 
2003).  
The protein cores of decorin, lumican, and fibromodulin are also known to bind to 
collagen at specific sites and regulate collagen fibrillogenesis (Vogel, Paulsson et al. 
1984; Scott and Haigh 1988; Pringle and Dodd 1990; Scott 1996; Miyagawa, 
Kobayashi et al. 2001; Orgel, Eid et al. 2009). Vesentini and others have shown with 
molecular modelling that decorin core protein had a stronger molecular binding 
force to collagen type I fibrils than its GAG chains (Vesentini, Redaelli et al. 2005). 
Morphometric analysis and polypeptide sequencing showed that decorin can bind to 
two neighbouring collagen molecules, thus aiding in stabilising and aligning collagen 
fibrils (Scott 1996). In addition, biochemical analysis, immunohistochemistry, and 
transmission electron microscopy (TEM) showed that decorin inhibits lateral fusion 
during collagen fibril growth and tendon maturation in situ (Birk, Nurminskaya et al. 
1995). Other studies have also suggested a role for decorin in inhibiting lateral 
fusion of collagen fibrils (Danielson, Baribault et al. 1997; Doughlas, Heinemann et 
al. 2006). TEM revealed that chondroitin/ dermatan sulphate proteoglycans in rat tail 
tendon have a role in bridging between collagen fibrils, and may therefore contribute 
to tendon strength (Cribb and Scott 1995). Weber and others showed that decorin is 
able to accommodate a single collagen triple helix (Weber, Harrison et al. 1996). 
TEM of the rabbit and bovine corneal collagen fibres showed that the keratan 
sulphate proteoglycans and chondroitin/ dermatan sulphate proteoglycans are 
located at different collagen fibril bands, where the chondroitin/ dermatan sulphate 
proteoglycans were located at the d and e band of collagen fibrils, and the keratan 
sulphate proteoglycans were located at the a and c bands (Scott and Haigh 1988). 
Using similar methods, Miyagawa and others also confirmed that keratan sulphate 
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proteoglycans are located at the a and c band of the D periodic collagen fibrils of the 
human cornea (Miyagawa, Kobayashi et al. 2001). In addition, 
Immunoelectromicroscopy analysis showed that decorin was located near the d and 
e bands of the D periodic collagen fibrils of adult bovine tail tendon (Pringle and 
Dodd 1990). Hedbom and others also confirmed with collagen binding assays that 
decorin and fibromodulin bind to separate sites on both collagens I and II (Hedbom 
and Heinegard 1993).  
SLRPs have been shown to bind to collagen fibrils via their leucine rich repeats. For 
example, decorin binds to collagen by its leucine rich repeats 4-6 (Svensson, 
Heinegard et al. 1995), and asporin via its leucine rich repeats 10-12 (Kalamajski, 
Aspberg et al. 2009). Fibromodulin and lumican have been shown to bind to the 
same region on collagen type I (Svensson, Narlid et al. 2000), and both 
proteoglycans compete for collagen binding between with their leucine rich repeats 
5-7 (Kalamajski and Oldberg 2009). Fibromodulin contains another binding site for 
collagen at its leucine rich repeat 11, between the Glu-353 and Lys-355 region 
(Kalamajski and Oldberg 2007). The two different attachment sites present on 
fibromodulin suggest that it has a higher affinity for collagen binding (Kalamajski and 
Oldberg 2009).  
Douglas and others investigated the influence of decorin and biglycan on collagen I, 
II, and III binding during fibrillogenesis in vitro (Douglas, Heinemann et al. 2006). 
Interestingly, biglycan had a higher affinity to all three types of collagen compared to 
decorin. Furthermore, biglycan had a higher affinity for collagen type II binding 
compared to type I and III (Douglas, Heinemann et al. 2006). In the same study, 
turbidity measurements were performed to determine the effect of SLRPs on 
collagen binding and the rate of fibrillogenesis, and was found that biglycan did not 
have any effect on collagen fibril diameter or the rate of fibrillogenesis, however, 
decorin reduced the fibril diameter for all three collagens suggesting its essential 
role in inhibiting lateral collagen fibril growth (Douglas, Heinemann et al. 2006). 
Taken together, these studies indicate that the biglycan core protein may not have a 
role in collagen fibrillogenesis. However, its high quantity of GAG chains compared 
to decorin may result in higher affinity for all three collagen types (Douglas, 
Heinemann et al. 2006).  
Solid phase assays have shown decorin core protein binding to the beaded filament 
forming collagen type VI which may suggest that decorin has a role in regulating 
collagen VI activity (Bidanset, Guidry et al. 1992). In addition, TEM suggests that 
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decorin and biglycan bind near to the N-terminal region of type VI collagen triple 
helix (Wiberg, Hedbom et al. 2001). Fibril associated collagens with interrupted 
triple helices are also shown to interact with SLRPs such as collagen type XIV 
(binds to decorin) (Font, Aubert-Foucher et al. 1993; Ehnis, Dieterich et al. 1997), 
and type XII (binds to decorin and fibromodulin) (Font, Eichenberger et al. 1996). 
Furthermore, ECM molecules such as tropoelastin, microfibril-associated 
glycoprotein-1 complex (Reinboth, Hanssen et al. 2002) and aggrecan (Wiberg, 
Klatt et al. 2003; Dunlevy and Rada 2004) have been shown to interact with SLRPS. 
 
1.3.5.3.3 The effect of SLRPs on the extracellular matrix 
Knockout mouse studies suggest that altered expression of SLRPs disrupts matrix 
integrity, and knockout mice been assessed using ultrastructural observations, 
Western blot analysis, gene expression analysis, biochemical analysis, and fibril 
diameter analysis (Danielson, Baribault et al. 1997; Svensson, Aszódi et al. 1999; 
Chakravarti, Petroll et al. 2000; Ezura, Chakravarti et al. 2000; Corsi, Xu et al. 2002; 
Chakravarti, Paul et al. 2003; Liu, Birk et al. 2003; Zhang, Chen et al. 2009). 
Decorin has been shown to have a role in regulating collagen fibrilllogenesis in 
tendon, as the tensile strength of tendon was shown to be reduced in the decorin 
null mice (Danielson, Baribault et al. 1997). In addition, ultrastructural analysis with 
tendon cross sections showed that collagen fibres had an irregular outline and 
varied in size, whilst wild type mice had a regular collagen fibre outline that was 
uniform in size (Danielson, Baribault et al. 1997). 
Fibromodulin knockout mice had revealed thinner and weaker collagen fibrils in 
tendon. In addition, irregular outlines of collagen fibrils were observed in TEM cross-
sections (Svensson, Aszódi et al. 1999). This indicates that fibromodulin has a 
similar role to decorin in that it inhibits lateral fusion of collagen fibrils. Furthermore, 
fibromodulin knockout mice resulted in increased expression of lumican, which 
suggests that these two proteoglycans compensate for one another (Svensson, 
Aszódi et al. 1999). A further study has analysed the differential expression of 
fibromodulin and lumican during tendon growth and maturation of postnatal mice at 
day 4, day 10, 1 month, and 3 months, and it was found that lumican functions 
during early stages in fibrillogenesis, while fibromodulin functions throughout this 
period with a more prominent role in regulation of the later stages of collagen fibril 
assembly, furthermore, lumican knockout mice in early stages had collagen fibril 
alterations (Ezura, Chakravarti et al. 2000). However, in mature tendons, lumican 
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deficient mice exhibit similar features to wild type mice, whilst fibromodulin knockout 
mice had deceased collagen fibril size and integrity (Ezura, Chakravarti et al. 2000). 
The compensatory role of fibromodulin and lumican in developing tendon has also 
been similarly shown for decorin and biglycan, as biglycan expression decreases 
during tendon maturation and decorin expression increases (Zhang, Ezura et al. 
2006). In addition, biglycan expression has been shown to increase when the 
decorin gene is knocked down in tendon (Zhang, Ezura et al. 2006) and in corneal 
tissue (Zhang, Chen et al. 2009). 
Corsi and others studied the different roles of decorin and biglycan in mouse skin, 
tendon and bone (Corsi, Xu et al. 2002). The findings revealed that decorin 
knockout mice specifically exhibited skin laxity and fragility, whilst biglycan knockout 
mice had abnormal bone mass and reduced skeletal growth (Corsi, Xu et al. 2002). 
Reduced growth rates and a decrease in bone mass of biglycan knockout mice has 
also been confirmed previously by Xu and others (Xu, Bianco et al 1998). 
Decreased rates of bone formation and mineral apposition are also found in 
keratocan knockout mice (Igwe, Gao et al. 2011). The effect of biglycan and 
fibromodulin single and double knockouts on the knee joint has also been 
investigated, where the quadriceps tendons, menisci, cruciate ligaments, and 
patellar ligaments showed signs of ectopic ossification. In addition, the cruciate 
ligament was found to be ruptured (Kilts, Ameye et al. 2009). These finding suggest 
that fibromodulin and biglycan are essential in regulating tendon and ligament 
normal homeostasis.  
In cornea, decorin and biglycan knockout mice exhibit an increase in collagen fibril 
diameter, and the collagen fibrils are irregular in both anterior and posterior stroma 
(Zhang, Chen et al. 2009). However, collagen fibril abnormalities in lumican knock 
out mice are only observed in the posterior stroma, indicating that lumican could 
only regulate collagen fibrils of the posterior stroma (Chakravarti, Petroll et al. 
2000).  
Fibromodulin knockout mice showed a decrease in collagen fibril diameter of the 
sclera, suggesting its important role the maturation and assembly of the scleral 
collagen fibrils (Chakravarti, Paul et al. 2003). Keratocan knockout mice displayed 
abnormal diameter of corneal collagen fibres, thinner corneal stroma, and abnormal 
packing of the stromal collagen (Liu, Birk et al. 2003). These results suggest that 
SLRPs play a significant role in corneal fibrillogenesis and developement. 
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Several mutations in the SLRP genes have been associated with eye alterations in 
humans. For instance, the three frameshift mutations in the C-terminal region of 
decorin structure have been linked with congenital stromal corneal dystrophy in 
humans which leads to corneal opacity (Bredrup, Knappskog et al. 2005). In 
addition, corneal plana (a congenital malformation of the cornea) has been linked to 
missense or frameshifts mutations in the keratocan gene (Lehmann, El-ashry et al. 
2001). High myopia (increased ocular axial length, thin sclera, and retinal 
detachment) has been linked to single nucleotide polymorphisms (SNPs) and intron 
variations in fibromodulin, prolargin and opticin genes (Majava, Bishop et al. 2007). 
In addition, mice deficient in dermatan sulphate epimerase-1 have a disorganised 
collagen structure in skin (Maccarana, Kalamajski et al. 2009). 
SLRPs knockout mice are also known to exhibit signs similar to human disorders 
(Ameye, Aria et al. 2002; Corsi, Xu et al. 2002; Jepsen, Wu et al. 2002). Double 
knockouts of the decorin and biglycan gene results in sever skin fragility and 
marked osteopenia, thus mimicking clinical signs of Ehlers-Danlos syndrome (Corsi, 
Xu et al. 2002). Double knockouts of lumican and fibromodlin carry a syndrome of 
joint laxity, tendinopathy (Jepsen, Wu et al. 2002), and high myopia (Chakravarti, 
Paul et al. 2003). Furthermore, biglycan or fibromodulin deficient mice exhibit 
abnormal collagen fibrils in tendon which leads to gait impairment, ectopic 
ossification, and osteoarthritis (Ameye, Aria et al. 2002).  
 
1.3.5.3.4 The role of SLRPS in tendon/ ligament biomechanics  
Several studies have suggested that chondroitin and dermatan sulphate GAGs play 
a biomechanical role in tendon (Millesi, Reihsner et al. 1995; Legerlotz, Riley et al. 
2013; Rigozzi, Muller et al. 2013) and ligament (Henninger, Underwood et al. 2010). 
Millesi and others showed that the digestion of GAGs reduced the viscoelasticity of 
the palmaris longus muscle tendon of human (Millesi, Reihsner et al. 1995). GAG 
removal has also an impact on the permeability of the tissue and the dynamic 
compressive modulus of the porcine medial collateral ligament (Henninger, 
Underwood et al. 2010). In addition, reduction of GAGs caused alterations in stress 
relaxation of the bovine extensor tendon fascicles (Legerlotz, Riley et al. 2013). 
Achilles tendons from mice showed higher levels of collagen fibril strains compared 
to non-enzymatic digested tendons, and suggested that the GAG content in native 
tendon is related to lower collagen strains (increased collagen fibril stretching and a 
decrease in collagen fibril sliding) (Rigozzi, Muller et al. 2013). However, other 
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studies have showed that GAG removal had no effect on the elastic modulus or 
viscoelastic response during compressive or tensile loading in mice tail tendon 
fascicles (Fessel and Snedeker 2009), or the viscoelastic and quasi-static elastic 
material properties of human medial collateral ligament (Lujan, Underwood et al. 
2007; Lujan, Underwood et al. 2009). 
The biomechanical properties of tendon have been tested in decorin and biglycan 
knockout mice models (Robinson, Huang et al. 2005; Dourte, Pathmanathan et al. 
2013). Robinson and others have analysed three different types of tendon (tail 
tendon, flexor digitorium tendon, and patellar tendon) from decorin and biglycan 
knockout mice. Interestingly, the loss of decorin in patellar tendon created an 
increase in stress relaxation and modulus but had no effect when it was double 
knocked out with biglycan, whilst biglycan knockout mice caused the flexor 
digitorium tendon to decrease in its maximum stress and modulus (Robinson, 
Huang et al. 2005).  The mechanical properties of tendon in decorin and biglycan 
knockouts have also been studied by Dourte and others, where tendons showed a 
significant increase in the viscoelastic and tensile dynamic modulus in biglycan null 
and heterozygous mice compared to wild type. In addition, decorin null mice 
exhibited a decrease in collagen content (Dourte, Pathmanathan et al. 2013). 
Furthermore, decorin heterozygous mice showed a significant decrease in 
viscoelastic and tensile dynamic modulus (Dourte, Pathmanathan et al. 2013). This 
indicates that decorin and biglycan may have different effect on the mechanical 
properties of tendon and ligament.  
Other reports showed that GAGs and certain proteoglycans contribute to the 
biomechanical properties of tendons at different anatomical regions (Buckley, 
Huffman et al. 2013). Biglycan knockout mice showed a decrease in mechanical 
properties and tensile dynamic modulus in the mice flexor carpi ulnaris tendons, 
especially at the middle anatomical region compared to the insertion region 
(Buckley, Huffman et al. 2013). Further to this, sGAGs depletion resulted in a 
significant decrease in tensile dynamic modulus in mouse Achilles tendon that was 
specific to the bony attachment region (Rigozzi, Muller et al. 2009). These studies 
suggest that the mechanical enviroment of the tendon or ligament may result in 
certain proteoglycans and GAGs to residing in different anatomical regions in order 
to contribute to the biomechanical properties of the tendon or ligament at that 
location. 
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1.3.5.4     The role of proteoglycans in different anatomical regions in 
ligament/ tendon 
 GAGs were found to be more abundant in the fibrocartilaginous region of the 
porcine deep and superficial digital flexor tendon (where tendon wraps around 
bone) (Feitosa, Reis et al. 2006). This may suggest that GAGs levels are elevated 
in fibrocartilage sites as a result of tendon/ ligament compression. Certain 
proteoglycans have also been shown to increase in the compressive sites (Vogel 
and Koob 1989; Evanko and Vogel 1993; Feitosa, Reis et al. 2006; Rees, Wagget 
et al.2009) and tension sites (Evanko and Vogel 1993; Vogel, Sandy et al. 1994; 
Vogel and Petres 2005) of the tendon.  
In compressive sites of tendons, aggrecan gene expression was elevated at the 
tendon to bone attachment region of the rabbit Achilles tendon (Huisman, 
Andersson et al. 2014). In addition, biglycan was found to increase with aggrecan 
under cyclic compressive loading in a tendon in vitro model (Evanko and Vogel 
1993). Vogel and others have also found that certain proteoglycans (aggrecan, 
versican, biglycan and type II collagen) were increased in the compressive sites of 
bovine tendon (Vogel and Koob 1989). Keratocan has also been reported to 
increase in the compressed region of bovine tendon compared to its tensional 
region (Rees, Wagget et al. 2009). Versican was also found to be a major 
component in the tensile region of tendon (Vogel, Sandy et al. 1994; Vogel and 
Petres 2005).  Decorin, on the other hand, is especially located at the tensional sites 
of tendon (Evanko and Vogel 1993; Vogel and Petres 2005; Matuszewski, Chen et 
al. 2012). These results indicate that certain proteoglycans and GAGs might play a 
significant role in specific anatomical regions of tendon and ligament. 
 
1.3.5.5     The role of proteoglycans in ligament/ tendon pathology  
GAGs have been shown to play a role in tendon/ ligament pathology (Riley, Harral 
et al. 1994a; Comerford, Innes et al. 2004; Halper, Kim et al. 2006; Fu, Chan et al. 
2007; Samiric, Parkinson et al. 2009).  Dermatan sulphate was found to increase in 
human pathological patellar tendons (Fu, Chan et al. 2007). Furthermore, 
chondroitin sulphate, dermatan sulphate, and hyaluronic acid have been shown to 
be significantly increased in human supraspinatus tendinitis (Riley, Harral et al. 
1994a). In ligament, an increase in GAGs have been found in equine suspensory 
desmitis (Halper, Kim et al. 2006), and in human patellar tendinopathy (Samiric, 
Parkinson et al. 2009). 
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Proteoglycans have also been found to increase in pathological tendons and 
ligaments (Lo, Marchuk et al. 1998; Corps, Robinson et al. 2006; Clements, Carter 
et al. 2008;  Samiric, Parkinson et al. 2009). 
Gene expression of aggrecan, versican, fibromodulin, biglycan was found to 
increase in human patellar tendinopathy. However, the gene expression of decorin 
showed no increase in these diseased tendons (Samiric, Parkinson et al. 2009). In 
addition, another study indicated a significant increase in gene expression levels for 
aggrecan and biglycan in the fibrocartilage site (where tendon attaches to bone) of 
human Achilles tendinopathy, however, versican and decorin showed no increase 
(Corps, Robinson et al. 2006). In human ruptured ACL, biglycan mRNA expression 
levels were found to be significantly increased compared to intact ACLs (Lo, 
Marchuk et al. 1998), whereas in the dog, lumican and aggrecan mRNAs were 
found to be significantly increased in ruptured CCLs of the Labrador retriever in 
comparison to intact CCLs (Clements, Carter et al. 2008). These results 
demonstrate that the increase of proteoglycans in pathological tendon and ligament 
is variable and could be dependent on the tissue type and anatomical region. 
 
1.3.5.6     Role of extracellular matrix proteases in proteoglycan degradation 
 
1.3.5.6.1  Disintegrin and metalloproteinase domain with a thrombospondin 
motif   
The ADAMTS are muti-domain metalloproteases that are released into the 
extracellular space as furin-actived proteases (Kashiwagi, Enghild et al. 2004). The 
domain structure of ADAMTSs comprises a single peptide, prodomain, 
metalloproteinase domain, disintegrin-like domain, a cysteine rich domain, spacer 
region, and thrombospondin motif and sub-motifs (Jones and Riley 2005; Apte 
2009) (Figure 1-13). It has been shown that removal of the prodomain for ADAMTS-
4 (Longpre, McCulloch et al. 2009) and ADAMTS-5 (Tortorella, Arner et al. 2005) is 
essential for cleaving aggrecan. ADAMTS aggrecanase family members (which 
cleaves aggrecan and other proteoglycans) are ADAMTS-1, ADAMTS-4, ADAMTS-
5, ADAMTS-8, ADAMTS-9, ADAMTS-15, and ADAMTS-20 (Porter, Clark et al. 
2005; Kelwick, Desanlis et al. 2015).   
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ADAMTS degradation of the large aggregating proteoglycans 
ADAMTS-1, -4, -5, -8, -9, -15 are known to cleave aggrecan (Porter, Clark et al. 
2005). ADAMTS-5 null mice in tendon have increased levels of aggrecan deposition 
in the pericellular and interfibrillar matrix of tendon, with an increase in collagen fibril 
diameter (Wang, Bell et al. 2012). In addition, the biomechanical properties of 
tendon are also altered with a higher tensile modulus and weakened enthesis. This 
data suggest that ADAMTS-5 is important in regulating the tendon collagen 
architecture and aggrecan turnover (Wang, Bell et al. 2012). It has also been 
reported that versican is a substrate for ADAMTS-1, -4, -5, -9, -15, and -20 (Sandy, 
Westling et al 2001; Kelwick, Desanlis et al. 2015). 
 
ADAMTS degradation in small leucine rich proteoglycans 
Biglycan, decorin, and fibromodulin have both been shown to be substrates for 
ADAMTS-4 (Porter, Clark et al. 2005; Melching, Fisher et al. 2006), whilst biglycan 
is known to be a substrate for ADAMTS-4 and -5 (Kashiwagi, Enghild et al. 2004). 
 
 
Figure 1-13: Schematic representation of the domain structure of ADAMTS4 and 
ADAMTS5. 
 (Adapted from Jones and Riley 2005; Apte 2009) 
 
1.3.5.6.2  Matrix metalloproteinases 
It has been reported that decorin is cleaved by gelatinase A (MMP-2), stromelysin 
(MMP-3), and matrylisin 1 (MMP-7) (Imai, Hiramatsu et al. 1997). In addition, 
decorin, biglycan, lumican, and fibromodulin have been shown to be cleaved by 
collagenase 3 (MMP-13) in cartilage (Monfort, Tardif et al. 2006). MMP-7 has been 
also indicated to be more efficient in cleaving versican more than other MMPs 
(Halpert, Sires et al. 1996). Despite the degradation of SLRPs by MMPs, SLRPs 
can also protect the degradation of collagen by MMPs in vitro (Sztrolovics, White et 
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al. 1999; Geng, McQuillan et al. 2006; Pietraszek, Chatron-Colliet e al. 2014), as 
decorin, lumican and fibromodulin can protect the surface of collagen fibrils from 
cleavage by collagenase-1 (MMP-1) and MMP-13 (Geng, McQuillan et al. 2006). 
Lumican has also shown to protect collagen from cleavage by the membrane type 
MMP (MMP-14) (Pietraszek, Chatron-Colliet e al. 2014).  
 
1.4 Aetiopathogenesis of cranial cruciate ligament disease and rupture 
(CCLD/ R) 
Cranial cruciate ligament disease and rupture (CCLD/ R) is one of the most 
common orthopaedic conditions to affect dogs leading to stifle joint osteoarthritis 
(Bennett, Tennant et al. 1988). CCLD/ R is defined as a spontaneous degeneration 
of the CCL (Vasseur, Pool et al. 1985; Narama, Masuoka-Nishiyama et al. 1996) 
eventually leading to rupture secondary to minor trauma. Certain dog breeds are at 
differing risk of ligament rupture (Duval, Budsberg et al. 1999; Whitehair, Vasseur et 
al. 1993).  
In humans, this condition is known as non-contact ACL injury and has been 
commonly shown to affect woman athletes (Renstrom, Ljungqvist et al. 2008). 
However, the majority of human injuries are via contact injury (Goldberg, Burstein et 
al. 1982; Klein, Player et al. 1982).  
 
1.4.1 Epidemiology 
 
1.4.1.1     Bodyweight, age and breed 
CCLD/ R is known to affect larger dog breeds at a younger age (Duval, Budsberg et 
al. 1999), and it has been reported that dogs over four years of age were 
significantly more prone to develop CCLD/ R (Witsberger, Villamil et al. 2008). 
Another study examined a population of 328 dogs and found that the average age 
of CCL rupture in large breeds (>15 kg) was 5.5 years, whereas the smaller breeds 
(<15 kg) had a mean age of 7.4 years (Harasen 2008). The prevalence of CCL 
rupture in certain dog breeds has also been well documented (Whitehair, Vasseur et 
al. 1993; Duval, Budsberg et al. 1999). Labrador Retrievers, Rottweilers, and 
Newfoundland’s are the breeds most commonly affected with CCLD/ R (Witsberger, 
Villamil et al. 2008). However, other dog breeds are also considered to be high at 
risk of CCLD/ R (Wustefeld-Janssens, Pettitt et al. 2015). CCLD/ R has also known 
to be increased in obese dogs (Barnes 1977; Vasseur, Pool et al. 1985; Bennett, 
Tennant et al. 1988; Whitehair, Vasseur et al. 1993).  
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1.4.1.2     Gender and neuter status  
Neutered females are reported to have a higher risk of CCLD/ R (Doverspike, 
Vasseur et al. 1993; Whitehair, Vasseur et al. 1993; Slauterbeck, Pankratz et al. 
2004; Harasen 2008). Obesity may be one of the factors leading to CCLD/ R, as 
neutered females tend to be overweight (Edney and Smith 1986). In humans, 
increased oestrogen levels in the pre-ovulatory phase of the menstrual cycle in 
female athletes has been linked to non-contact ACL injury (Renstrom, Ljungqvist et 
al. 2008).  
 
1.4.1.3     Genetics 
Genetics has been studied in breeds predisposed  to CCLD/ R (Nielen, Knol et al. 
2003; Wilke, Conzemius et al. 2006; Baird, Carter et al. 2014a; Baird, Carter et al. 
2014b). Dogs predisposed to CCLD/ R were found to have a  heridability estimate of 
0.27 in Newfoundlands (Wilke, Conzemius et al. 2006), and 0.28 in Boxers (Nielen, 
Knol et al. 2003). Genotypic mapping has been perform in Newfoundlands and has 
found that chromosome 3, 5, 13 were associated with CCLD/ R (Baird, Carter et al. 
2014a). In addition, certain genes (collagen type V alpha 1 and 2, collagen type I 
alpha 1, collagen type XI alpha 1, collagen type III alpha 1, fibrillin 1, lysyle oxidase, 
latent transforming growth factor beta binding protein-2) were found to be 
significantly associated with CCLD/ R in four highly predisposed dog breeds (Baird, 
Carter et al. 2014b). 
 
1.4.1.4     Exercise  
A study found that sGAGs were increased around the lateral condyles and patellar 
surface of the femur in young beagles that had undergone exercise, and suggested 
that the increase of sGAG content could be due to alterations of the biological 
properties of cartilage at regions bearing high loads (Kiviranta, Tammi et al. 1988). 
In addition, Newton and others performed an exercise regime persistently on two 
groups of dogs (Newton, Mow et al. 1997). The first groups had a restricted activity, 
whereas the other group had an unlimited activity to the treadmill (Newton, Mow et 
al. 1997). Results indicated that there were no cartilage erosions, osteophytes, 
ligament or meniscal injuries present in the stifle joints of dogs that have undergone 
exercise (Newton, Mow et al. 1997). In addition increased ACL stiffness and 
strength has been shown in rats that had undergone an endurance-type exercise 
(Cabaud, Chatty et al. 1980). Overall, these studies demonstrate that exercise has 
beneficial effects on ACL/ CCL and should be recommended on a regular basis. 
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1.4.2 Compromise of blood supply  
The lack of blood supply and its contribution to CCLD/ R remains unclear (Vasseur, 
Pool et al. 1985). The middle anatomical region of the CCL has been shown to have 
a reduced vascular supply in comparison to other parts of the CCL and could 
therefore be more susceptible to rupture (Paatasma 1952; Arnoczky, Rubin et al. 
1979).  It has been reported in the CCL that free passage of macromolecules occurs 
from the synovial fluid into the blood (Kobayashi, Baba et al. 2006). Therefore, 
changes in osmotic pressure could be another factor that can alter the blood supply 
in the CCL. 
 
1.4.3 Cruciate ligament cells 
Variation in cell morphology has been identified in two dog breeds with a different 
predisposition to CCLD/ R (Smith, Vaughan-Thomas et al. 2012). The greyhound 
CCL cells (low risk to CCLD/ R) commonly had longer cytoplasmic processes 
ranging from 100-200 μm and were accompanied with narrowed and very long 
nuclei, whereas the Labrador retrievers CCL cells (high in risk to CCLD/ R) 
contained shorter, thicker, and frequently extended cytoplasmic processes (Smith, 
Vaughan-Thomas et al. 2012). The longer cell processes found in the low risk 
greyhound may strengthen the cell-to-cell communication, thereby decreasing the 
risk to CCLD/ R. The smaller cell processes in the high risk Labrador retriever might 
indicate poor communication between cells and might therefore predispose this high 
risk dog breed to CCLD/ R (Smith, Vaughan-Thomas et al. 2012). 
Fibrocartilage-like cells (rounded cells with a surrounding halo) have been identified 
in intact CCL tissues of the Labrador retriever and greyhound. It was proposed that 
fibrocartilage in the Labrador retriever could be a degenerative sign progressing to 
CCLD/ R, whereas this fibrocartilage change in the greyhound could be an 
adaptation to tensile or compressive loading thus protecting its CCL from disease 
and rupture (Comerford, Tarlton et al. 2006b).  
Fibrocartilaginous change has also been found to occur in CCLs of young laboratory 
beagles and was considered to be an early degenerative change due to the lack of 
exercise (Narama, Masuoka-Nishiyama et al. 1996). In addition, it has been 
reported that in dogs over 5 years of age with an increase in bodyweight (15> kg) 
had a reduction in CCL mechanical properties as well as histological signs of 
fibrocartilage, therefore, age and bodyweight may also be important (Vasseur, Pool 
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et al. 1985). In ruptured CCLs decreased cellularity accompanied by the occurrence 
of fibrocartilage-like cells with a disorganised collagen fibril architecture has been 
also described in the middle anatomical where damage occurred (Hayashi, Frank et 
al. 2003). Loss of cells as a result of apoptosis or necrosis has also been studied in 
ruptured and partially ruptured canine CCLs (Hayashi, Frank et al. 2003; Gyger, 
Botteron et al. 2007; Krayer, Rytz et al. 2008). Reduced cell density has been found 
to occur as a consequence of ageing in normal (Murray and Spector 1999), and 
degenerative human ACLs (Hasegawa, Otsuki et al. 2012; Hasegawa, Nakahara et 
al. 2013), and has been accompanied with fibrocartilage looking cells and a 
disruptive collagenous matrix (Hasegawa, Otsuki et al. 2012).  
 
1.4.4 Extracellular matrix  
It has been reported that proteoglycans (aggrecan, decorin, lumican), collagens 
(collagen I alpha 2, collagen III alpha I), and proteases (such as cathepsins B and D 
and MMPs -2 and -9)  were significantly increased in ruptured CCLs of the Labrador 
retriever (high risk to CCLD/ R) compared to its non-ruptured CCLs (Clements, 
Carter et al. 2008). These findings may suggest that these ECM molecules are 
associated with pathology. Furthermore, a significant increase of sGAGs, water 
content, MMP-2, and MMP-9 were found in ruptured compared to intact Labrador 
retriever CCLs (Comerford, Innes et al. 2004). The significant elevation of these 
ECM molecules in ruptured ligaments suggests that they could be involved in the 
pathology of CCLD/ R. In addition, reduced gene expression of decorin, biglycan 
and lumican were observed in pregnant rabbit ACLs, and it has been suggested that 
the ACL during pregnancy could exhibit signs of knee joint laxity, thus contributing 
to CCL rupture (Hart, Sciore et al. 1998).  
 
1.4.5 Bilateral and unilateral CCL rupture 
The prevalence of bilateral CCL rupture is between 59% to 61% (Cabrera, Owen et 
al. 2008; Buote, Fusco et al. 2009), and  22% to 54% of patients with unilateral CCL 
rupture consequently rupture their contralateral CCL (Doverspike, Vasseur et al. 
1993; Moore and Read 1995; De Bruin, De Rooster et al. 2007; Cabrera, Owen et 
al. 2008; Buote, Fusco et al. 2009; Grierson, Asher et al. 2011; Muir, Schwartz et al. 
2011). In addition, survival analysis performed on a large group of dogs showed that 
patients with unilateral CCL rupture consequently rupture their contralateral joint 
within a median of 947 days (Muir, Schwartz et al. 2011). Subsequent contralateral 
CCL rupture has also been significantly associated with the severity of radiographic 
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stifle effusion and osteophytosis in the contralateral stifle joint (Chuang, Ramaker et 
al. 2014). Radiographic effacement of the infrapatellar fat pad has been known to 
appear with CCL rupture and inflammation of the stifle joint, and has been termed 
the infrapatellar fat pad sign (Widmer, Buckwalter et al. 1994). The fat pad sign is a 
predominant risk factor associated with subsequent CCL rupture of the contralateral 
stifle joint (Fuller, Hayashi et al. 2014). 
 
1.4.6 Stifle joint factors 
 
1.4.6.1     Mechanics 
The structural (load of failure and deformation) and material (tangent modulus and 
ultimate stress) properties of the canine CCL have been studied (Butler and Stouffer 
1983; Wingfield, Amis et al. 2000a). CCLs from the greyhound (low risk to CCLD/ R) 
were shown to have significantly greater material and structural properties when 
compared to CCLs of the Rottweiler (high risk to CCLD/ R) (Wingfield, Amis et al. 
2000a). Craniocaudal laxity of the canine stifle joint has also been studied in dog 
breeds at a high and low risk of CCLD/ R (Wingfield, Amis et al. 2000b; Comerford, 
Tarlton et al. 2005). Wingfield and others showed that the high risk Rottweiler had a 
greater stifle joint laxity compared to the low risk greyhound (Wingfield, Amis et al. 
2000b) and this was further confirmed by Comerford and others where they 
compared the stifle joint laxity and CCL properties of the Labrador retriever (high 
risk to CCLD/ R) to greyhounds (low risk to CCLD/ R). These authors found that 
Labradors had a significantly greater anterior-posterior stifle joint laxity and weaker 
CCL material properties (ultimate tensile stress) compared to the greyhounds 
(Comerford, Tarlton et al. 2005).  
 
1.4.6.2     Proprioception  
Lack of proprioception and its role in contributing to CCLD/ R in the dog is not well 
understood (O'Connor and Woodbury 1982). Stifle joint and CCL innervation is 
compulsory for optimal postoperative rehabilitation and joint damage prevention 
(Salo 1999).  
The impact of denervation on the injured rabbit medial collateral ligaments has been 
previously studied (Ivie, Bray et al. 2002; Beye, Hart et al. 2006). The first study 
found that innervated injured medial collateral ligaments had a higher density of 
blood vessels and a higher blood flow rate compared to injured ligaments that were 
denervated (Ivie, Bray et al. 2002). In addition, biomechanical testing showed that 
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injured innervated medial collateral ligaments had a significantly higher force for 
ultimate failure and a significantly lower static and total creep compared to injured 
denervated medial collateral ligaments (Ivie, Bray et al. 2002). A further study has 
examined the gene expression of several ECM proteins in innervated and 
denervated injured medial collateral ligaments of the rabbit, and found that several 
genes of interest were significantly upregulated in injured deneravted ligaments at 
two weeks post injury (collagen I, collagen III, TGF-β, MMP-13, TIMP-3, and 
angiogenesis inhibitor thrombospondin-1 (TSP-1)) compared to innervated injured 
medial collateral ligaments (Beye, Hart et al. 2006). These studies further suggest 
that innervation is necessary for healing and normal ligament function.  
 
1.4.6.3     Conformational variation 
Deformity of the proximal tibial has been associated with CCLD/ R in dogs (Read 
and Robins 1982; Selmi and Padilha Filho 2001; Macias, McKee et al. 2002).  
CCLD/ R and excessive tibial plateu angle of the stifle joint has been found to occur 
as consequence of early neutering in large dog breeds (Duerr, Duncan et al. 2007).  
A narrowed intercondylar notch (ICN) has been linked to human ACL injuries 
(Laprade and Burnett 1994; Shelbourne, Davis et al. 1998). In the dog, narrowing of 
the intercondylar notch has been associated with CCLD/ R and osteoarthritis (Aiken, 
Kass et al. 1995; Wada, Tatsuo et al. 1999). In addition, ACL function is impeded 
when it passes through a narrowed intercondylar notch causing damage and knee 
joint laxity (Muneta, Takakuda et al. 1997).  
The intercondylar notch index and femoral condyle height and width have been 
shown to be significantly lower in Labrador retriever and Golden retriever (high risk 
breeds to CCLD/ R) compared to greyhounds (low risk breed to CCLD/ R) 
(Comerford, Tarlton et al. 2006a). In addition, immature collagen cross-links, matrix 
metalloproteinase-2 and sulphated glycosaminoglycans (sGAGs) are significantly 
increased in the CCL impingement region of high risk dog breeds compared to low 
risk dog breeds. These findings may indicate that CCL structure is altered in the 
high risk Labrador retriever with a narrowed ICN therefore predisposing it to CCLD/ 
R (Comerford, Tarlton et al. 2006a).  
The tibial plateau angle (TPA) was compared in intact and ruptured CCLs from the 
Labrador retriever (high risk to CCLD/ R), however, the study found no correlation 
between the magnitude TPA and CCLD/ R (Reif, Probst et al. 2003). TPA and CCL 
stress can also be altered with muscular force, body size, obesity, rapid weight gain, 
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relative inactivity, and exercise in dogs (Colborne, Innes et al. 2005). In human 
ACLs, it has been shown that narrowing of the intercondylar notch and increased 
TPA may be associated with ACL injuries in both males and females. Furthermore, 
reduced intercondylar notch index has found to be linked with knee joint 
osteoarthritis (Quasnichka, Anderson-MacKenzie et al. 2005; Stein, Li et al. 2010).  
The effect of ruptured CCLs on hind limb conformation has been studied in the high 
risk Labrador retriever CCLs (Ragetly, Griffon et al. 2008; Mostafa, Griffon et al. 
2009; Ragetly, Griffon et al. 2010). Ragetly and others studied the body segment 
parameters (mass, mass moment of inertia, centre of mass) for the foot, crus and 
thigh in Labrador retriever patients with and without CCLD/ R, and found that the 
thigh and crus weighed less in limbs with CCLD/ R compared to their non-ruptured 
contralateral limbs, whereas only the thigh weighed less in limbs with CCLD/ R 
compared to dogs without CCLD/ R. In addition, the thigh moment of inertia was 
less in limbs with ruptured CCLs compared to their non-ruptured contralateral limbs, 
and the crural centre of mass was positioned more distally in dogs without CCLD/ R 
compared with dogs with CCLD/ R (Ragetly, Griffon et al. 2008). The same authors 
investigated hind limb mechanics and kinematics, and found that dogs exhibited 
hindlimb lameness with a tendency to apply force across the contralateral limb 
(Ragetly, Griffon et al. 2010). In addition, Mostafa and others have found that the 
cranial angulation of the proximal portion of the tibia and excessive TPA were highly 
associated in Labrador retriever patients with CCLD/ R (Mostafa, Griffon et al. 
2009). Overall, these studies indicate that such anatomical variations in high risk 
dog breeds could contribute to CCLD/ R. 
 
1.4.7 Healing potential  
Poor healing of the ACL is one of the main reasons why ruptured ACLs fail to 
undergo primary repair (Arnoczky, Rubin et al. 1979; Frank, Amiel et al. 1985). The 
mechanisms of poor ACL healing include intrinsic defects of cellular migration and 
proliferation (Nagineni, Amiel et al. 1992; Geiger, Green et al. 1994; Spindler, 
Andrish et al. 1996). An in vitro injured model of both ACL and medial collateral 
ligament found that matrix metalloproteinase-2 gene expression was significantly 
increased in the rat ACL when compared to its medial collateral ligament (Tang, 
Yang et al. 2009) suggesting that an increase in MMP-2 might contribute to poor 
ACL healing. 
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Loss of the provisional scaffold (fibrin-platelet plug) has been shown to occur in the 
CCL when compared to the medial collateral ligament, suggesting that the loss of 
provisional scaffolds could be one of the mechanisms which impairs CCL healing 
(Murray, Spindler et al. 2007). A lack of provisional scaffold production 
accompanied with low levels of ECM proteins and cytokines were found to occur 
within the wounded CCL (Spindler, Devin et al. 2006). In human ACLs urokinase 
plasminogen activator can prevent arthrofibrosis (Rosc, Powierza et al. 2002). 
However, elevated levels of urokinase plasminogen activator may impair the ACL 
normal production of provisional scaffolds leading to further ACL trauma and rupture 
(Rosc, Powierza et al. 2002).  
Inorganic free radical nitric oxide has been associated with CCLD/ R in the dog 
(Spreng, Sigrist et al. 2000; Jauernig, Schweighauser et al. 2001). There are two 
type of nitric oxide synthase; constitutive and inducible (Nathan 1992). Inducible 
nitric oxide synthase levels are increased in ruptured and intact CCLs compared to 
other ligaments of the stifle joint (Spreng, Sigrist et al. 2000; Jauernig, 
Schweighauser et al. 2001), and have also been shown to increase in CCL explants 
in vitro when exposed to an inducible nitric oxide synthase cocktail (tumor necrosis 
factor, interlukin-1, and lipopolysaccharide), whilst levels did not increase with other 
ligament explants (medial collateral or ligament of the femoral head) (Louis, Remer 
et al. 2006). Proteoglycan and collagen production might also be hindered by the 
increase of inducible nitric oxide levels in the ACL (Cao, Stefanovic-Racic et al. 
2000). Overall, these studies suggest that CCL/ ACL produces high levels of 
inducible nitric oxide synthase that may affect the normal metabolism of 
proteoglycan and collagen, and therefore may compromise the ligament to rupture.  
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1.5 HYPOTHESIS  
This thesis examines the hypothesis that GAGs/ proteoglycans may have a role in 
different anatomical regions of the canine CCL that may experience different 
tensional and compressional loads. We further hypothesise that GAG/ proteoglycan 
content may differ between dog breeds with a differing predisposition to CCLD/ R. 
 
1.6 AIMS AND OBJECTIVES 
The project aims to identify GAGs/ proteoglycans in different anatomical regions in 
the canine CCL, and identify the alterations with disease and breed variation with 
different risks of CCLD/ R. The aims will be addressed with two key objectives; 
 
1. To determine whether there are regional differences in canine CCL GAG/ 
proteoglycan composition by performing quantitative real time RT-PCR analysis, 
semi-quantitative western blotting, quantitative biochemistry, semi-objective 
histology scoring, and immunohistochemistry staining.  
2. To determine whether there are differences in GAGs/ proteoglycans in the 
CCL in dogs with a low predisposition compared to dogs with a high predisposition 
to CCLD/ R by performing quantitative real time RT-PCR analysis, semi-quantitative 
western blotting, quantitative biochemistry, semi-objective histology scoring, and 
immunohistochemistry staining. 
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Chapter 2: Materials and methods. 
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2.1       Tissue collection 
 
2.1.1 Cruciate ligaments obtained from Staffordshire bull terrier dogs 
Cranial cruciate ligaments (CCLs) were harvested from Staffordshire bull terrier 
dogs. For experimental procedures, ligaments were either divided into three regions 
(origin, middle, and insertion) or processed without cutting (Figure 2-1). Cruciate 
ligaments (CL) were obtained from stifle joints with no macroscopic evidence of joint 
pathology. The dogs were euthanised for purposes not related to this study and 
were clinical waste material donated to the University of Liverpool. Ethical approval 
for use of this material in this project was granted by the Veterinary Research Ethics 
Committee, School of Veterinary Science (RETH0000553 and VREC65). 
 
2.1.2 Cruciate ligaments obtained from greyhounds and Labrador Retrievers 
CCLs obtained from greyhound and Labrador retriever dogs (Figure 2-2) were 
archived samples sourced from Prof. Eithne Comerford. Ligaments samples were 
previously obtained from the craniomedial and caudolateral band of each of these 
two dog breeds. Additional archived samples of greyhounds were divided into two 
sections (femoral end (origin), tibial end (insertion)). A summary of the cruciate 
ligament samples collected from different dog breeds are documented beside their 
usage in each experimental procedure are shown in Tables 1-1, and 2-1. 
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Figure 2-1: Sample collection obtained from the Staffordshire bull terrier. 
The Figure shows a cranial view of the canine stifle joint after removal of the collateral 
ligaments. The Figure illustrates CCL preparation from Staffordshire bull terriers. Ligaments 
were either separated into origin, middle, and insertion (A) or were harvested as an entire 
ligament without cutting (B) (produced by paint software). (O= origin; M= middle; I= insertion; 
CCL= cranial cruciate ligament). 
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Figure 2-2: Sample collection obtained from the Labrador retriever and greyhound. 
The Figure shows a craniomedial (A, B) and a cranial view (C) of the canine stifle joint after 
removal of the collateral ligaments. The graph demonstrates archived CCL samples from 
greyhounds and Labrador retriever. Ligaments were preserved as craniomedial (A) and 
caudolateral bands (B) (Adapted from Arnoczky and Marshall 1977). Other CCLs from 
greyhounds were collected from the origin and insertion anatomical regions (C) (produced 
by paint software). (O= origin; I= insertion; CMB= craniomedial band; CLB= caudolateral 
band; CCL= cranial cruciate ligament; L= lateral view; M= medial view). 
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Sample No. Ligament Breed Procedure 
1 CCL SBT  
 
 
 
 
SDS-PAGE and 
Western blot  
2 CCL SBT 
3 CCL SBT 
4 CCL SBT 
5 CCL SBT 
6 CCL SBT 
7 CCL SBT 
8 CCL SBT 
9 CCL SBT 
10 CCL SBT 
11 CCL SBT 
12 CCL SBT 
13 CCL SBT  
 
          
Real time RT-qPCR 
14 CCL SBT 
15 CCL SBT 
16 CCL SBT 
17 CCL SBT 
28 CCL SBT 
19 CCL  SBT       
 
      Biochemistry 
20 CCL  SBT 
21 CCL  SBT 
22 CCL  SBT 
23 CCL  SBT 
24 CCL SBT           
 
         
         Histology 
25 CCL SBT 
26 CCL SBT 
27 CCL SBT 
28 CCL SBT 
29 CCL SBT 
30 CCL  SBT           
          
Immunohistochemistry  
31 CCL  SBT 
32 CCL  SBT 
33 CCL  SBT 
34 CCL  SBT 
35 CCL SBT 
 
Table 2-1: Details of CCLs obtained from SBT along with their related experimental 
procedures. 
(SBT= Staffordshire bull terrier; CCL= cranial cruciate ligament). 
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Sample No. Ligament Breed           Procedure 
36 CCL GH  
 
 
 
 
SDS-PAGE and Western 
blot 
37 CCL GH 
38 CCL GH 
39 CCL GH 
40 CCL GH 
41 CCL GH 
42 CCL GH 
43 CCL GH 
44 CCL GH 
45 CCL GH 
46 CCL GH  
 
          
            RT-qPCR 
47 CCL GH 
48 CCL GH 
49 CCL GH 
50 CCL GH 
51 CCL  GH       
 
        Biochemistry 
52 CCL  GH 
53 CCL  GH 
54 CCL  GH 
55 CCL  GH 
68 CCL GH  
69 CCL GH  
 
           Histology  
                 &  
Immunohistochemistry  
70 CCL GH 
71 CCL GH 
72 CCL GH 
73 CCL GH 
74 CCL GH 
75 CCL GH 
76 CCL LR  
           Histology  
                 
           
   
             
 
77 CCL LR 
78 CCL LR 
79 CCL LR 
80 CCL LR 
81 CCL LR 
82 CCL LR 
 
Table 2-2: Detail of CCLs obtained from GH and LR along with their related 
experimental procedures. 
(GH= greyhound; LR= Labrador retriever; CCL= cranial cruciate ligament). 
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2.2       Reagents  
All reagents were purchased from Sigma, UK unless stated. For more details, see 
Appendix I. 
 
2.3       Biochemical assays to measure glycosaminoglycans 
CCLs from Staffordshire bull terriers (n=5) samples were cut into three sections 
(origin, middle, and insertion), snap frozen in liquid nitrogen and then stored at -
20°C until use. Other archived CCLs from greyhounds (n=5) that were cut into 
femoral end (origin) and tibial end (insertion) were also used. 
 
2.3.1 Water content  
Samples were allowed to thaw at room temperature and the CCL wet weight was 
measured. In order to obtain the CCL dry weight, the samples were freeze dried 
overnight and then the CCL weight was measured the next day. The water content 
% was calculated using the following equation; 
 
Water content % = ([wet weight – dry weight] / wet weight) x 100 
 
2.3.2 Sulphated glycosaminoglycan (sGAG) assay 
CCL samples were digested for 24 hours with 10 unit/ ml papain in 100 mM sodium 
acetate, 2.4 mM EDTA and 5 mM cysteine HCl at 60οC. sGAG content in the 
samples was determined using the 1, 9-dimethlylmethylene blue (DMMB) dye 
binding assay (Farndale, Buttle et al. 1986). 40 µl duplicates of papain-digested 
ligament samples were immediately analysed at 570 nm following the addition of 
250 µl of DMMB dye. Shark chondroitin sulphate was used as a standard over a 
concentration range of 0-70 µg/ ml (Figure 2-3) and sGAG concentrations were 
calculated by comparison with the standard curve. In order to determine the 
proportion of chondroitin sulphate (CS) and dermatan sulphate (DS) in each 
sample, samples were digested at 37οC for 24 hours with 0.05 U/ ml of 
chondroitinase ABC (ChABC) prior to the DMMB assay (Riley, Harrall et al. 1994a). 
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Figure 2-3: An example of a standard curve for the quantification of sulphated 
glycocaminoglycans (sGAGs). 
Chondroitin shark sulphate was used as a standard ranging from 0-70 µg/ ml. 
 
2.3.3 Uronic acid assay  
Uronic acid (UA) levels were quantified using the methodology described by Bitter 
and others (Bitter and Muir 1962). UA assay solution was prepared by liquefying 
0.05 M Sodium tetraborate in 50 ml concentrated sulphuric acid (Fisher Scientific, 
UK), followed by dissolving 1.7 mM carbazole in the solution to form the UA assay 
formula. 150 µl of the solution was placed in 96 microtiter well plates and stored at -
80oC for 24 hours. Next, 30 µl standards or papain digested samples CCLs were 
cooled with ice and added to the UA assay formula, mixed and then heated at 80οC 
for one hour. Glucuronic acid lactone was used as a standard at concentrations 
from 0-70 µg/ ml (Figure 2-4) and UA concentrations of papain digests were 
obtained by comparison with the standard curve. Standards and samples were then 
measured at a wavelength of 530 nm. The UA concentration was presented as µg 
per mg dry weight of tissue. The concentration of hyaluronic acid (HA) in the tissue 
was indirectly estimated using the following equation;  
 
[HA] = [UA] - ([Total sGAG] x 0.36)  
 0.45 
This calculation assumed that UA comprised 36 % of the dry weight of GAGs and 
45 % of the dry weight of HA (Riley, Harrall et al. 1994).  
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Figure 2-4: An example of a standard curve for uronic acid quantification. 
Glucuronic acid lactone was used as a standard at concentrations ranging from 0-70 µg/ml. 
 
2.3.4 Competitive enzyme linked immunosorbent assay for keratan sulphate 
Keratan sulphate levels were measured using the methodology obtained from 
Caterson and others (Caterson, Cristner et al. 1983). Bovine articular cartilage 
aggrecan and keratan sulphate monoclonal antibody 5D4 were materials kindly 
provided by Prof. Bruce Caterson. In brief, ELISA plates were coated with the 
antigen solution, which consisted of 131.6 µg of GAG/ ml of bovine articular 
cartilage aggrecan, by passive adsorption overnight at 4oC. The plates were 
washed with PBS-sodium azide, and blocking solution (1 % BSA/ PBS-sodium 
azide) then added for one hour at 37οC. A 1:16000 dilution of the 5D4 monoclonal 
primary antibody in 1 % BSA/ PBS-sodium azide was then added to both standards 
and ligament samples in 1.5 ml centrifuge tubes and incubated for 1 hour at 37°C. 
Standards were prepared by diluting bovine articular cartilage aggrecan solution in 
PBS-sodium azide in order to produce concentrations ranging from 13.6-0 µg GAG/ 
ml in a 1:3 dilution series. The standard concentration of 0 µg GAG/ ml was the non-
competing antigen for the assay. After discarding the blocking solution, the 
previously incubated standards and samples with the primary antibody were then 
added to the plate in duplicate and incubated again for 1 hour at 37°C. The main 
principle of this assay is that the greater the antigen concentration present in the 
sample, the fewer antibodies will be able to attach to it. Each well was then washed 
three times in PBS-sodium azide to remove any unbound antibody. The secondary 
antibody was alkaline phosphatase conjugated goat anti-mouse IgG was diluted 
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1:5000 in 1 % BSA/ PBS-sodium azide TSA and added to the plate to be incubated 
for an additional hour at 37°C. Each well was then washed three times in PBS-
sodium azide. 1mg/ ml of P-nitrophenyl alkaline phosphatase (PNPP) substrate 
(Fisher scientific, UK) were then dissolved in 1x diethanolamine buffer and 
incubated for 30-60 min at 37°C until sufficient colour developed. The more 
chromogenic signal detected on samples/ standards indicated less antibody binding 
to the antigen. The ELISA plate was measured at 405 nm when the non-competing 
antigen reached an optical density (OD) of 1. Standard dilutions were calculated 
against ligament sample concentrations (µg GAGs/ ml) after obtaining the reciprocal 
of each absorbance measurement (Figure 2-5). At the beginning of the assay, initial 
experiments were carried out to assess both optimal primary antibody concentration 
(1:16000) and antigen coating (1:250) of the non-competing antigen as this was 
essential for ideal assay reproducibility and sensitivity. 
 
Figure 2-5: An example of a standard curve for keratan sulphate quantification. 
The standard was obtained from bovine articular cartilage aggrecan at concentrations 
ranging from 13.6 µg to 0 µg GAGs.
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2.4       Western blot analysis to detect proteoglycans and GAGs 
CCL samples from Staffordshire bull terriers (n=12) were either divided into three 
regions (origin, middle and insertion; n=5) or harvested intact (n=7). All samples 
were snap frozen in liquid nitrogen and then stored at -80°C until required. Archived 
intact CCLs from greyhounds (n=10) were also used for this study. 
 
2.4.1 Protein extraction  
Samples were immersed in liquid nitrogen and pulverised whilst frozen with a 
dismembrator (B. Brown Biotech Micro Dismembrator, U.S.A). Proteins were 
extracted twice in 15 volumes (w/ v) of 4M guanidinium HCl (Sigma, UK) containing 
complete protease cocktail inhibitor tablets (Roche, UK) using end-over-end mixing 
for 24 hours at 4oC. After extraction, the soluble fraction (containing proteins) was 
removed following centrifugation at 13000 x g for 15 min at 4oC. Ligament extracts 
were dialysed in a 20,000 kD cut-off membrane (Spectrapor, Breda, NL) for 24 h at 
4oC against sodium acetate buffer containing 100 mM 6-aminohexanoic acid, 5 mM 
benzamidine and 10 mM N-ethylmaleimide as proteinase inhibitors, all from Sigma, 
UK. The dimethymethylene blue (DMMB) dye binding assay based on Farndale and 
others was used to determine the sulphated glycosaminoglycan content when 
required (Farndale, Buttle et al. 1986). Samples were then digested for 24 hours at 
37oC with the glycosaminoglycan-digesting enzymes as followed; Chondroitinase 
ABC (Yamagata, Saito et al. 1968) (0.00001IU/ 10 µg) (Sigma, UK); Keratanase I 
(Fukuda 2001) (0.1IU/ 10 µg) (AMS); and or Keratanase II (Yamagishi, Suzuki et al. 
2003) (0.01IU/ 10 µg) (AMS). Enzyme units were adapted from Rees and others 
(Rees, Flannery et al. 2000). Samples were finally dialysed in ultrapure water, 
freeze dried and reconstituted in 1x SDS sample buffer containing 0.0625 M Tris-
HCL (pH 6.8) with 2 % SDS (w/v), 10 % (v/v) Glycerol, and 0.005 % (w/v) 
Bromophenol Blue. 
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2.4.2 Sodium dodecyl sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE)  
Samples were heated either under reduced or non-reduced conditions and loaded 
onto a 4-12 % Nupage Bis-Tris gel (Invitrogen). Samples were loaded as mg per 
equal wet weight of tissue (Melrose, Fuller et al. 2008; Plaas, Sandy et al. 2011). 
Loading with equal wet weight is more effective than other conventional methods 
(e.g. loading with equal protein, and equal GAG) as it is the most appropriate way of 
normalising the highly hydrated, heterogeneous tissue components. Samples were 
prepared and denatured by heating at 90oC for 10 minutes. Where required, 
samples were reduced by adding 5 % of 2-mercaptoethanol to 1x SDS sample 
buffer. Samples and pre-stained molecular weight markers (Fisher scientific, UK) 
were loaded and run on NuPAGE 4-12 % bis-tris Gels (Life Technologies, UK) at 
200V for 35 minutes, and then transferred to nitrocellulose membranes (Whatman, 
UK) in an X-Cell blot module (Life technologies, UK) at 35V for 90 minutes. 
Membranes were then blocked in phosphate-buffered saline (PBS) containing 5 % 
skimmed milk powder (blocking buffer) for one hour at room temperature with gentle 
agitation. The milk is used to block the membrane with non-specific protein, 
reducing the likelihood of the primary or secondary antibodies from non-specifically 
binding to the membrane. The membranes were then incubated in blocking buffer 
containing primary antibody and 0.05% Tween-20 (Sigma, UK) overnight at 4oC with 
agitation. Primary antibodies and the concentrations in which they were used are 
presented (Table 2-3). The primary antibody was removed and the membranes 
washed for five minutes three times with PBS + 0.05 % Tween (PBS-T) before 
adding the appropriate secondary antibody (Table 2-4). Secondary antibodies were 
diluted in blocking buffer + 0.05 % Tween and incubated with the membrane at 
room temperature for one hour with gentle agitation. The membrane was again 
washed three times in PBS-T. Antibody localisation was visualised using an 
enhanced chemiluminescent detection kit (ECL Plus Western Blotting Detection 
Reagents Perkin Elmer, U.S.A). Enhanced luminol and oxidizing reagent were 
mixed in equal ratios before adding them to the membrane. The membrane was 
shaken vigorously for one minute then wrapped in clear plastic with luminescence 
being visualised using a UVP ChemiDoc-it Imaging System (UVP, UK). Images 
were acquired using VisionWorksLS image acquisition and analysis software (UVP, 
U.S.A). A summary of the Western blotting procedure is shown in Figure 2-6.                                                                                                                                    
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Table 2-3: Primary antibodies used in Western blotting. 
 
*Kindly donated by Prof. Bruce Caterson and Dr. Clare Hughes  
**Kindly donated by Prof. Peter Roughly 
Antibody Isotype Proteoglycan/ GAG Dilution Label Antibody recognition site 
Mouse monoclonal IgG Decorin 1:200 *DECN 70.6 Specific for the core protein of decorin 
Mouse monoclonal IgG Biglycan 1:200 **PR8A4 C-terminal amino acid sequence of human biglycan  
Mouse monoclonal IgM Lumican 1:100 *LUM1 Unknown 
Mouse monoclonal IgG Keratocan 1:200 *KER1 Specific for the core protein of keratocan 
Rabbit polyclonal IgG Fibromodulin 1:500 **PR184 C-terminal amino acid sequence of human fibromodulin 
Mouse monoclonal IgG Versican 1:200 12C5 G1 domain of versican 
Mouse monoclonal IgG Aggrecan  1:500 *7D1 G1 and chondroitin sulphate attachment domains 
Mouse monoclonal  IgG Chondroitin-0-sulphate stub 1:200 *1B5 Chondroitinase ABC-generated-0 sulphated CS stub 
Mouse monoclonal IgG Chondroitin-4-sulphate stub 1:200 *2B6 Chondroitinase ABC-generated-4 sulphated CS stub 
Mouse monoclonal  IgG Chondroitin-6-sulphate stub 1:200 *3B3 Chondroitinase ABC-generated-6 sulphated CS stub 
Mouse monoclonal  IgG Keratan sulphate stub 1:200 *BKS1 Keratanase generated keratan sulphate stub 
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Table 2-4: Secondary antibodies used in Western blotting.  
Secondary antibody Dilution Concentration 
Peroxidase conjugated Rabbit anti-mouse IgG  1:1000 5 µg/ ml 
Peroxidase conjugated goat anti-mouse IgM 1:1000 5 µg/ ml 
Peroxidase conjugated rabbit-anti goat IgG 1:2000 5 µg/ ml 
 
 
Figure 2-6: Representative image of the Western blot methodology. 
The primary antibody is attached to the antigen on the nitrocellulose membrane. The 
membrane is then washed to remove unbound antibodies. The secondary antibody 
conjugated with the enzyme horseradish peroxidase attaches to the primary antibody and is 
followed by another washing step. A chemiluminescent substrate is then added in order to 
react with horseradish peroxidase conjugate and produce a light signal. The signal is then 
detected by capturing the blot with VisionWorksLS image acquisition and analysis software 
package system.
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2.4.3 Detecting the linear response of the Western blot signal 
Lumican antibody was used to validate the linearity of the Western blot signal by 
undertaking a series of 1:2 serial dilutions with a 4 molar guanidine extract sample 
of CCL (Figure 2-7). The intensity of Western blot signal is also demonstrated in 
Figure 2-8. 
 
Figure 2-7: An example of a standard curve of the CCL proteins extracted with 4 molar 
guanidine HCL. 
The graph shows a linear response of the Western blot signal. 
 
 
Figure 2-8: Gradual intensity changes of the Western blot signal. 
A serial dilution of 1:2 was performed that ranged from a sequence from 1 to 8. The intensity 
is altered with decreasing protein load. The CCL protein sample transferred into the blot 
membrane has been probed with lumican antibody. The numbers on the Figure represents 
the log2 of the dilution. 
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2.4.4 Western blot quantification  
1- Data were analysed using VisionWorksLS (UVP, USA) image acquisition and 
analysis software package. 
2- The area density was measured for each band to detect differences in GAGs 
and proteoglycans between CCL anatomical regions of Staffordshire bull terrier 
and in between dog breeds with a differing predisposition to CCL rupture 
(Staffordshire bull terrier vs. greyhound).   
3- Two 10 well NuPAGE 4-12 % Bis-Tris Gels (Life Technologies, UK) were used 
to detect differences for GAGs and proteoglycans between CCL anatomical 
regions of Staffordshire bull terrier. The values were normalised between the 
two gels by loading one of the same samples into each gel (Figure 2-9). 
4- One 12 well NuPAGE 4-12 % Bis-Tris Gel (Life Technologies, UK) was used to 
detect differences for GAGs and proteoglycans between Staffordhsire bull terrier 
and greyhound. Mean density value was measured without using a sample 
standard as all samples were loaded into the same gel  (Figure 2-10). 
 
 
Figure 2-9: Area density measurement for lumican core protein in different anatomical 
regions of the CCL from Staffordshire bull terrier. 
The anatomical regions of the CCL were obtained from the Staffordshire bull terrier (n=5). In 
order to calculate the results, values were standardised by loading one of the same samples 
to each gel (O= origin; M= middle; I=  insertion). 
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Figure 2-10: Area density measurement for lumican core protein fromStaffordshire 
bull terrier and greyhound CCLs. 
CCLs were obtained from Staffordshire bull terrier and greyhound (n=5). The mean density 
was calculated without normalising with a standard as all samples were loaded into the 
same gel (G= greyhound; S= Staffordshire bull terrier). 
 
2.5       Histology and immunohistochemistry 
CCLs (n=12) harvested from Staffordshire bull terriers were fixed in 4% 
paraformaldyhyde overnight at 4°C then processed and embedded in paraffin wax. 
Other archived tissue blocks from greyhound (n=8) and Labrador retriever (n=7) 
CCLs were also used for this study. 4 µm sections of these tissues were cut and 
mounted onto “POLY FROST”, poly lysine coated slides (Solmedia, UK). Images 
were captured (x10 and x40 magnifications) using a Nikon Eclipse 80i microscope 
(Nikon, Japan).  
 
2.5.1 Histology 
2.5.1.1     Haematoxylin and Eosin stain 
Slides were stained with Haematoxylin and Eosin (H&E) to assess cell morphology 
and tissue architecture, and to investigate whether there were any signs of 
degeneration of the tissue. Slides were also stained with Toluidine blue or Alcian 
blue to allow distribution of sGAGs in the tissue to be identified. The ligaments 
stained included CCL sections from Labrador retrievers (n=8) and greyhounds 
(n=13).  
 
2.5.1.2     Toluidine blue stain 
The Toluidine blue staining protocol was adapted from Schmitz and others 
(Schmitz, Laverty et al. 2010). Sections were rehydrated (Table 2-5) then stained 
from 5-10 minutes with 0.04 % Toluidine blue in 0.2 M acetate buffer solution; pH 
3.75-4.25. Slides were then rinsed with tap water before being dehydrated (table 2-
5) and mounted under coverslips with Di-n-butyl phthalate in xylene (D.P.X).   
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2.5.1.3     Alcian blue stain 
This method was based on one previously described by Vogel and others (Vogel 
and Petres et al. 2005). Tissue sections were rehydrated (Table 2-5) and immersed 
for 3 minutes in 3% acetic acid; pH 2.5, followed by staining with Alcian blue 
solution for 1 hour at 25 oC. Slides were then counterstained with Eosin Y, rinsed 
under tap water, dehydrated (Table 2-5) and mounted under coverslips with D.P.X.  
 
Table 2-5: Rehydration and dehydration steps used prior to staining of tissue sections 
in both histology and immunohistochemistry techniques. 
Rehydration (time) Dehydration (time) 
Xylene x2 10 minutes Distilled water x2 5 minutes 
100 % Alcohol x2 10 minutes 95 % Alcohol x2 10 minutes 
95 % Alcohol x2 10 minutes 100 % Alcohol x2 10 minutes 
Distilled water x2 5 minutes Xylene x2 10 minutes 
 
Table 2-6: Tris buffered saline solution used in immunohistochemistry.  
10x TBS 0.06 M Trizma, 1:3 dilution of 1 M HCL, pH 7.6 
1X TBS TWEEN 1:10 dilution of 10x TBS, 0.0072 M NaCl, 0.05 % TWEEN,  
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2.5.1.4     Histology scoring  
Histology scoring was performed with 2 different scoring schemes. All CCL tissue 
sections were assessed twice, at least one week apart, by two independent 
observers that were blinded to dog breed and tissue location. Calculated scores 
from each observer were averaged as the final result. The agreement between inter 
and intra-observer scores was assessed using Kendall’s coefficient of concordance. 
The H&E scoring sheet included 12 categories (Table 2-7), whilst for Toluidine blue 
and Alcian blue, the scoring criteria involved 7 categories (Table 2-8). A score from 
0-3 was assigned for each category as follows; 0= 0% absence of factor, 1= 0-25% 
factor present up to one quarter of tissue, 2= 25-50% factor present up to half of 
tissue, 3= >50% factor present above 50 % of tissue. Each factor had a range of 
percentages of the amount of tissue section affected; 0 %, 0-25 %, 25-50 %, and 
>50 % depending on extent of presence or absence of each component.
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           H&E scoring: 
Collagen architecture                                                             >50    25-50    0-25    0     
Normal collagen architecture 
                                                                       
Reduced collagen architecture   
 
Abnormal collagen architecture     
                 
Cellular distribution and shape 
Cell shape                                                                                >50    25-50    0-25    0       
Spindle                                                                                                           
Mixed (spindle and rounded cells)     
Rounded                                    
Cell distribution                                                                      >50    25-50    0-25    0                                                                                                     
Normal distribution of cells                                                             
Formation of cell chains                                 
Vascularity of the ligament substance                                 >50    25-50    0-25    0 
                                                                                                                    
Low vascularisation                                                                      
Moderate to high vascularisation                    
 Inflammation                                                                          >50    25-50    0-25    0                                                                                               
 No evidence of inflammatory cells                                                                                
Increased numbers of inflammatory cells       
 
Table 2-7:  Haematoxylin and Eosin scoring sheet. The scoring system gives a range 
from 0-3. 3= 50 % present, 2= 25-50 % present, 1= 25 % present, 0= absent. 
 (Adapted from Kharaz 2015). 
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Toluidine blue and Alcian blue scoring: 
sGAG distribution and location  
Overall                                                                                     >50    25-50    0-25    0                                                                                          
Marked staining                                                                                          
Faint staining                                       
Location                                                                                   >50    25-50    0-25    0        
Interfascicular 
Interbundle 
Ligament substance                                      
Location of stain with cells                                                   >50    25-50    0-25    0    
Around the cells  
Within the cells  
 
Table 2-8: Toluidine blue and Alcian blue scoring system sheet. The scoring system 
gives a range from 0-3. 3= 50 % present, 2= 25-50 % present, 1= 25 % present, 0= 
absent.  
 (Adapted from Kharaz 2015). 
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2.5.2 Immunohistochemistry 
Slides were rehydrated as described previously (Table 2-5) and endogenous 
peroxidase activity was blocked by incubating tissue sections with 3 % H2O2 for 10 
minutes at room temperature. Prior to their localisation, tissue sections were 
washed in water, followed by pre-digestion with chondroitinase ABC solution for 30 
minutes at room temperature (0.5 units/ ml of ChABC in 100 mM Tris HCL, pH 7.2-
7.4). Non-specific binding was blocked using 20 % goat serum in 1x Tris buffered 
saline-TWEEN (TBS-T) (solution described in Table 2-2) for 10 minutes at room 
temperature. The serum was removed by washing sections in TBS-T (Table 2-8) 
and sections were then incubated overnight at 4oC with primary antibody diluted 
1:50 in TBS-T (Table 2-9). Following incubation, sections were washed in TBS-T 
and then incubated with secondary antibody (Table 2-10). All secondary antibodies 
were diluted in 20 % swine or goat serum in TBS-T for 30 minutes at room 
temperature. Finally, after further washes in TBS-T, a pair of diaminobenzidine 
tablets was dissolved in 5 ml ultrapure water solution for one minute. The solution 
was then added to the section until a brown colour developed, sections were rinsed 
in distilled water. Sections were counterstained with Haematoxylin, dehydrated 
(Table 2-5) and cover slipped with D.P.X mounting solution. A schematic of the 
principles of immunohistochemistry is illustrated in Figure 2-11.  
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Table 2-9: Primary antibodies used for immunohistochemistry. 
 
** Kindly donated by Prof. Peter Roughly  
*Kindly donated by Prof. Bruce Caterson and Dr. Clare Hughes  
 
Table 2-10: Secondary antibodies used for immunohistochemistry. 
Secondary antibody Dilution Concentration 
Peroxidase conjugated Rabbit anti-mouse IgG 1:50 5 µg/ ml 
Peroxidase conjugated goat anti-mouse IgM 1:50 5 µg/ ml 
Peroxidase conjugated rabbit-anti goat IgG 1:50 5 µg/ ml 
 
 
Antibody isotype Proteoglycan/ GAG Label Antibody recognition site 
Mouse monoclonal IgG Decorin *DECN 70.6 Specific for core protein of decorin  
Mouse monoclonal IgG Biglycan **PR8A4 C-terminal amino acid sequence of human biglycan  
Mouse monoclonal IgM Lumican *LUM1 Unknown 
Mouse monoclonal IgG Keratocan *KER-1 Specific for the core protein of keratocan 
Rabbit polyclonal IgG Fibromodulin **PR184 C-terminal amino acid sequence of human fibromodulin 
Mouse monoclonal IgG Versican 12C5 G1 domain of versican 
Mouse monoclonal IgG Aggrecan  *7D1 G1 and chondroitin sulphate attachment domains 
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Figure 2-11: Representative image of the immunohistochemistry methodology. 
The primary antibody binds to the antigen on the tissue section, and slides are then rinsed to remove unattached antibodies. The secondary 
antibody that carries the enzyme horse radish peroxidase (HRP) binds to the primary antibody. The slides are washed again before adding the 
substrate of 3, 3′-Diaminobenzidine tablets (DAB) substrate. Once DAB is added, it reacts with HRP enzyme and transforms the DAB substrate into 
a brownish precipitate in the tissue at the reaction site that can be visualised by microscopy. 
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2.6       Reverse transcription quantitative real time polymerase chain reaction 
(RT-qPCR) 
CCL samples obtained from Staffordshire bull terrier dogs (n=6) were cut into three 
sections (origin, middle, and insertion). Archived CCLs from greyhound (n=5) were 
obtained from either the caudolateral or caudomedial band. All samples were 
immersed in RNA later overnight at 4°C then stored at -20°C until required.    
 
2.6.1 Ribonucleic acid (RNA) isolation 
Frozen samples were pulverised with a dismembrenator (B. Brown Biotech Micro 
Dismembrator, U.S.A). A low temperature was achieved by cooling the instrument 
components and tissue using liquid nitrogen. RNA was extracted from the samples 
by incubating them in 1 ml of TRIzol reagent for one hour at room temperature. 0.1 
ml of 1-bromo-2 chloropropane was then added to each sample with gentle shaking 
for 15 seconds. Samples were rested for 3 minutes at room temperature and were 
placed in centrifuge at 12,000 x g for 20 minutes at 4°C. The clear, aqueous top 
phase that formed after centrifugation was removed and then added to a clean 
RNAse-free 1.5 ml centrifuge tube. To precipitate ribonucleic acid (RNA), 250 μl of 
isopropanol was added to the aqueous phase and incubated at room temperature 
for 10 minutes.  2 μl of GlycoBlue (Ambion, UK) was also added to the samples to 
be used as a co-precipitant for RNA. Samples were then centrifuged at 12,000 x g 
for 20 minutes at 4°C, and the supernatant removed leaving a visible RNA pellet. 
The pellet was washed with 1 ml of 75 % ethanol and centrifuged at 12,000 x g for 5 
minutes at 4°C. Finally, RNA was air-dried, reconstituted in Tris-EDTA (TE) buffer 
(Ambion, UK) and concentrations determined by measuring the absorbance 
between 260 and 280 nm using a NanoDrop spectrophotometer (ND-1000, Thermo 
scientific, U.S.A). RNA quality was confirmed using an optical density 260:280 ratio 
between 1.8-2.1. All products were from Sigma, UK unless noted. 
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2.6.2 Deoxyribonuclease treatment 
Deoxyribonuclease (DNase) treatment was performed to prevent contaminating 
genomic DNA interfering with downstream qPCR assays. In order to degrade 
single- and double-stranded DNA, samples were incubated with an endonuclease 
(DNase I). DNase buffer (10X diluted to 1X) and 4U DNase I enzyme (both from 
Ambion, UK) were combined with 10ug total RNA in a 50 μl final volume and 
incubated at 37°C for 30 minutes. RNA samples were brought up to 100 μl by 
adding RNAse-free water, and then an equal volume of phenol: chloroform was 
added to stop the DNase I activity (Ambion, UK). Samples were then centrifuged at 
12,000 x g for 5 minutes at 4°C. The upper aqueous phase was removed and added 
to a clean 1.5 ml centrifuge tube. 10 μl of ammonium acetate (Ambion, UK) and 300 
μl of 100 % ethanol were then added to precipitate the RNA (Ambion, UK), followed 
by 2 µl of GlycoBlue as a co-precipitant. Samples were mixed and then incubated 
on ice for 30 minutes. Next, the samples were centrifuged at 12,000 x g for 20 
minutes at 4°C, the supernatant removed and the RNA pellet rinsed with 1 ml of 75 
% ethanol. Following a final centrifugation step at 12,000 x g for 5 minutes at 4°C, 
the RNA pellet was air-dried, reconstituted in Tris EDTA Buffer (Ambion, UK) and 
the concentration determined using a NanoDrop spectrophotometer (ND-1000, 
Thermo scientific, U.S.A). 
 
2.6.3 Reverse transcription of DNase treated RNA 
1 μg of total RNA was reverse transcribed to cDNA. For the annealing step, random 
primers (2μg/ μl) were added to 1 μg of total RNA, the solution heated for 5 minutes 
at 70°C and then directly transferred onto ice for one minute. For the extension step, 
Molony murine leukemia virus reverse transcriptase (M-MLV-RT) (200u/ μl), 5x M-
MLV-RT buffer, 0.6 μl (40u/ μl) RNasin® Plus RNase Inhibitor, and 100 Mm dNTP 
mix were all combined into a total volume of 11.6 μl (all from Promega, UK) and 
added to the RNA samples. cDNA was synthesised by incubating the reactions at 
37°C for 60 minutes. The mixture was then heated to 90°C for 5 minutes to 
deactivate the reverse transcriptase enzyme, and then stored at -20°C until 
required. 
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2.6.4 Amplification of RT-qPCR  
Reverse transcription quantitative real-time-PCR (RT-qPCR) was performed to 
quantify the expression of the genes. cDNA samples were diluted to a final 
concentration of 10ng/ μl with RNase-free water. RT-qPCR was performed in a 25 
μl volume containing; 50 ng cDNA, 6 pmol/ μl forward and reverse primers designed 
for the particular gene of interest (Eurogentic, UK), and GoTaq(R) qPCR Master Mix 
(Promega, UK) diluted to 1x. Samples were run in duplicate with non-template 
control on an Applied Biosystems 7300 Real-Time PCR using the given 
amplification conditions as represented in table 2-11. 
 
Table 2-11: Amplification process for Applied Biosystems 7300 Real-Time PCR.  
 
The SYBR Green RT-qPCR procedure is shown in Figure 2-12. SYBR Green is a 
dye that interacts with double-stranded DNA to generate a fluorescent signal, and 
RT-qPCR measures the amount of the amplified product while the reaction occurs. 
The increase of florescent dye is directly related to the amplified product. The 
threshold cycle (CT) is the quantitative endpoint for RT-qPCR, as the amount of 
starting material to be amplified is inversely related to the numerical value of the CT. 
For example, the greater the original amount of target sequence, the lower the CT 
value will be. Primer efficiencies were validated performing a sequence (1 to 8) of 
1:2 serial dilutions, and were compared with those targeting two reference gene 
(GAPDH and B2M). All primers were found to lie within 10 % of GAPDH and B2M 
percentage (see appendix II). Primers (Table 2-12) were then chosen to be 
normalised against GAPDH, and the fold change in gene expression level 
calculated using the Δ CT method (Schmittgen and Zarkrajsek 2000). For melt curve 
analysis, see appendix III. 
 
 
Phase Period Temperature Number of cycles 
AmpErase Uracil N-
Glycosylase (UNG) 
2 minutes 50°C 
x1 
AmpliTaq Gold® DNA 
Polymerase Activation 
10 minutes 95°C 
x1 
Denaturation 15 seconds 95°C x40 
 
Annealing 60 seconds 60°C 
Extension 60 seconds 60°C 
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Figure 2-12: Amplification process for Real-time RT-PCR. 
The Figure demonstrates RT-PCR with SYBR GREEN to detect gene expression levels. 
During the annealing step, SYBR GREEN interacts with double-stranded DNA. This 
interaction causes SYBR GREEN to fluoresce. As the fluorescent dye accumulates, the 
PCR cycle continues and the amplified product is measured at the end point of each cycle 
(Adapted from Williamson 2012). 
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Table 2-12: Reference and target gene sequences for primers used in real time RT-
qPCR. 
Gene Sequence Reference 
GAPDH Forward 5' CTGGGGCTCACTTGAAAGG 3' / Reverse 5' 
CAAACATGGGGGCATCAG 3' 
(Clements, Carter 
et al. 2006) 
Aggrecan 
Forward 5' GGGACCTGTGTGAGATCGAC 3' /  Reverse 5' 
GTAACAGTGGCCCTGGAACT 3' 
(Clements, Carter 
et al. 2006) 
Versican 
Forward 5' GGGACCTGTGTGAGATCGAC 3' /  Reverse 5' 
GTAACAGTGGCCCTGGAACT 3' 
(Clements, Carter 
et al. 2006) 
Decorin 
Forward 5' CGCTGTCAGTGCCATCTC 3' / Reverse  5' 
GGGGGAAGATCTTTTGGTACTT 3' 
(Clements, Carter 
et al. 2006) 
Biglycan 
Forward 5' CAGAACAACGACATCTCAGAGC 3' / Reverse 5' 
TCACCAGGACGAGAGCGTA 3' 
(Clements, Carter 
et al. 2006) 
Lumican 
Forward 5' ACCTGGAAATTCTTTTAATGTATCATC 3' / 
Reverse 5' CGGTATGTTTTTAAGCTTATTGTAGGA 3' 
(Clements, Carter 
et al. 2006) 
Fibromodulin 
Forward 5' CCTCCAAGGCAATAGGATCA 3' / Reverse 5' 
GAAGTTCATGACGTCCACCAC 3' 
(Yang, Culshaw et 
al. 2012) 
ADAMTS-4 
Forward 5' GACCAGTGCAAACTCACCTG 3' /  Reverse 5' 
CAGGGAGTCCCATCTACCAC 3' 
(Clements, Carter 
et al. 2008) 
ADAMTS-5 
Forward 5' TGGGTTCCCAAATATGCAG 3' / Reverse 5' 
CTGTCCCATCCGTCACCT 3' 
(Clements, Carter 
et al. 2006) 
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Chapter 3: Characterising regional and 
breed differences in the proteoglycan 
and glycosaminoglycan content of the 
canine cranial cruciate ligament. 
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3.1        Introduction  
Proteoglycans consist of a core protein attached to one or more glycosaminoglycan 
(GAG) chains and perform both structural and regulatory functions (Iozzo 1998; 
Iozzo and Schaefer 2015). The small leucine rich proteoglycan (SLRPs), such as 
decorin, biglycan and fibromodulin bind to collagen fibrils and organise collagen 
fibrillogenesis (Scott and Haigh 1988; Iozzo 1999; Douglas, Heinemann et al. 2006). 
Aggrecan and versican are known as the large aggregating proteoglycans (Iozzo 
and Murdoch 1996). Aggrecan allows tendon the capacity to withstand compressive 
forces associated with loading (Vogel and Koob 1989; Evanko and Vogel 1993; 
Huisman, Andersson et al. 2014). Versican, on the other hand, regulates cell 
migration, adhesion, and contributes to the extracellular matrix (ECM) structural 
properties (Dours-Zimmermann and ZimmermannS 1994; Isogai, Aspberg et al. 
2002).  
A disintegrin-like and metalloproteinase with thrombospondin motifs -4 and -5 
(ADAMTS-4 and -5) are ECM proteases that are known to cleave proteoglycans, 
such as aggrecan, versican, decorin, biglycan, and fibromodulin (Sandy, Westling et 
al 2001; Kashiwagi, Enghild et al. 2004; Porter, Clark et al. 2005; Melching, Fisher 
et al. 2006). Several studies have detected the presence of decorin, biglycan, and 
fibromodulin catabolic products in tendon explant cultures without a catabolic 
stimulus (Rees, Flannery et al. 2000; Rees, Dent et al. 2009), which suggests that 
ADAMTS -4 and -5 may be required for normal functioning of SLRPs in tendon.  
Proteoglycan and GAG deposition have been shown to vary accordingly to the 
anatomical regions of tendon (Vogel, Ordog et al. 1993; Feitosa, Reis et al. 2006; 
Matuszewski, Chen et al. 2012; Buckley, Huffman et al. 2013). Despite this, it is still 
unknown whether proteoglycans and GAGs exhibit regional variations in the canine 
cranial cruciate ligament (CCL). For more details, see Chapter 1 - Section 1.3.5.3.4 
& 1.3.5.4.  
Previous studies using Western blot analysis have identified SLRPs, large 
aggregating proteoglycans, and GAGs in different anatomical regions of tendon 
tissues (Robbins, Evanko et al. 1997; Waggett, Ralphs et al. 1998; Rees, Flannery 
et al. 2000; Samiric, Ilic et al. 2004; Ilic, Carter et al. 2005; Rees, Wagget et al. 
2009). Decorin, biglycan, and chondroitin -6, -4, and -0 sulphate stubs have been 
investigated in bovine young and mature tendon in regions subjected to tension and 
compression (Rees, Flannery et al. 2000). Aggrecan and aggrecanase fragments of 
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the aggrecan core protein were also found in tendon (Rees, Flannery et al. 2000). In 
addition, aggrecan, biglycan, and keratocan were previously found to be expressed 
in tendon especially within sites subjected to compression (Robbins, Evanko et al. 
1997; Rees, Wagget et al. 2009). However, none of these studies have performed 
densitometry analysis on the molecular weight bands of proteoglycans and GAGs to 
fully quantify the differences between compressional and tensional regions of 
tendon. Overall, these studies may suggest that proteoglycans and GAGs may vary 
in different anatomical regions (tension vs. compression) of tendon and ligament in 
order to adjust for their mechanical and biological needs. 
Certain GAGs and proteoglycans have been shown to increase in tendon/ ligament 
pathology (Riley, Harral et al. 1994a; Lo, Marchuk et al. 1998; Corps, Robinson et 
al. 2006; Halper, Kim et al. 2006; Fu, Chan et al. 2007; Samiric, Parkinson et al. 
2009) (See Chapter 1 - Section 1.3.5.5 for details). Aggrecan, versican, 
fibromodulin, biglycan gene expression were increased in human patellar 
tendinopathy, however, decorin gene expression levels did not (Samiric, Parkinson 
et al. 2009). Another study have reported increased aggrecan and biglycan gene 
expression levels in the compressed region (where tendon attaches to bone) of 
human Achilles tendinopathy, however, versican and decorin gene expression 
levels were not increased (Corps, Robinson et al. 2006). These findings suggest 
that increased levels of certain proteoglycans and GAGs may lead to tendon and 
ligament pathology. 
Increased proteoglycan levels have been shown to be linked to CCLD/ R in the dog, 
where lumican and aggrecan gene expression levels were found to be significantly 
increased in ruptured CCLs of the Labrador retrievers (high risk breeds to CCLD/ R) 
in comparison to their intact CCLs (Clements, Carter et al. 2008).  
In the dog, narrowing of the intercondylar notch has been associated with CCLD/ R 
and osteoarthritis (Aiken, Kass et al. 1995; Wada, Tatsuo et al. 1999). In addition, 
ACL normal function has been shown to be impeded when it passes through a 
narrowed intercondylar notch, and therefore damage occurs to the ACL (Muneta, 
Takakuda et al. 1997). The intercondylar notch index and femoral condyle height 
and width have been shown to be significantly lower in the Labrador retriever and 
golden retriever (high risk to CCLD/ R) compared to the greyhound (low risk to 
CCLD/ R) (Comerford and Tarlton et al. 2006a).  
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A previous study has shown a significant increase in sulphated glycosaminoglycans 
(sGAGs) content in the high risk Labrador retriever CCLs compared to those of the 
low risk greyhound at the region where the CCL is compressed by the intercondylar 
notch (Comerford, Tarlton et al. 2006a). The increased compression in the high risk 
Labrador retriever CCL could result in the deposition of proteoglycans and GAGs 
associated with compressive sites of tendon and ligament.  
We hypothesise that the content and metabolism of proteoglycans and GAGs vary 
in different anatomical regions of the Staffordshire bull terrier CCL and in different 
dog breeds (Staffordshire bull terrier vs. greyhound) with an altered predisposition 
to CCLD/ R. 
The Staffordshire bull terrier is a breed with moderate-high risk for CCLD/ R, 
therefore, it was selected as a good model to determine the proteoglycan/ GAG 
content and gene expression within anatomical regions of the CCL. In order to 
compare proteoglycan/ GAG content and gene expression between two 
differentially predisposed dog breeds to CCLD/ R, we have chosen Staffordshire 
bull terrier CCLs (moderate-high risk to CCLD/ R) and compared it to greyhounds 
(low risk to CCLD/ R).  
Therefore, the aim of this work was to use Western blot analysis to identify and 
measure whether there are regional differences in proteoglycans and GAGs in the 
CCL. Furthermore, the aim was to identify and measure whether there are 
differences in proteoglycans and GAGs between dog breeds with a differing 
predisposition to CCLD/ R. We further aimed to use real time RT-PCR to 
characterise proteoglycans and ECM proteases (ADAMTS 4 & 5) between two dog 
breeds with a different predisposition to CCLD/ R. 
 
 
 
 
 
  
 
79 
 
3.2       Materials and methods 
3.2.1 Canine sample collection 
CCLs were harvested from Staffordshire bull terriers (n=17) with no macroscopic 
evidence of stifle joint pathology or any other musculoskeletal disease. Archived 
samples from ex racing greyhounds (n=15) were used for this study. These samples 
were obtained with ethical permission and full owner consent where appropriate. 
Inclusion/ exclusion criteria for samples and ethical permission are described in 
Chapter 2 - Table 2-1 and 2-2. 
CCL samples for Western blot analysis were dissected from Staffordshire bull 
terriers (n=5) and separated into origin, middle and insertion parts in order to detect 
specific proteoglycans and GAGs in different anatomical regions of the CCL. In 
addition, other CCLs from Staffordshire bull terriers (n=5) and greyhounds (n=5) 
were obtained without dividing them into separate ligament regions, and this was 
performed in order to detect specific proteoglycans and GAGs in two dog breeds 
with a different predisposition to CCLD/ R. Samples were snap frozen in liquid 
nitrogen and stored in -80oC until required. 
For real time RT-PCR analysis, CCLs from Staffordshire bull terriers (n=5) and 
greyhounds (n=5) were similarly collected as described above. Samples were 
immersed in RNA later overnight at 4oC in liquid nitrogen and stored in -80oC until 
required. 
 
3.2.2 Western blot analysis 
CCL samples were extracted with 4M guanidine hydrochloride and digested with 
enzymes specific for eliminating GAG chains. Enzymes used were chondroitinase 
ABC (to eliminate dermatan and chondroitin sulphate chains), keratanase I (to 
eliminate keratan sulphate I chains), and keratanase II (to eliminate keratan 
sulphate II chains). These enzymes are necessary in order to detect the 
proteoglycan core protein and GAG stubs (See Appendix I for product 
manufacturers). Samples were heated either under reducing or non-reducing 
conditions and loaded onto a 4-12 % Nupage Bis-Tris gel (Invitrogen). Details for 
Western blot analysis procedure are described in Chapter 2 - Section 2.4. The 
monoclonal/ polyclonal antibodies specific for the proteoglycans and GAG stubs are 
listed in details in Chapter 2 - Table 2-3. 
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3.2.3 Real time RT-qPCR  
Ribonucleic acid (RNA) was extracted from CCL samples with 1 ml of TRIzol 
reagent. Complementary deoxyribonucleic acid (cDNA) was reverse transcribed 
with 1 μg of total RNA in order to be amplified. Primers were normalised against 
GAPDH, and the fold change in gene expression level was calculated using the Δ 
CT method (Schmittgen and Zarkrajsek 2000). The primers specific for 
proteoglycans and ADAMTS’s are shown in Chapter 2 - Table 2-12.   
 
3.3       Statistical analysis  
Statistical analysis was performed on gene expression data and Western blot 
densitometry results. Data were primarily tested for normality using Kolmogorov-
Smirnov test. Statistical analysis involved comparing three groups (origin, middle, 
and insertion parts of Staffordshire bull terrier CCL) or two groups (Staffordshire bull 
terrier vs. greyhound). If data had a normal distribution, the three groups were 
tested by performing a one-way ANOVA followed by a Bonferroni post-hoc test for 
multiple comparisons, whereas the two groups were tested by selecting a student t-
test. When data did not have a normal distribution, the three groups were tested by 
performing a Kruskal-Wallis test followed by a Dunn’s test for multiple comparisons, 
while the two groups were tested by selecting a Mann Whitney U test. Results are 
presented as mean values ± standard error of the mean (SEM). Exact p-values are 
presented and a significance level of p <0.05 was used. Graphpad Prism (Version 
6, GraphPad Software, La Jolla California, USA) software was used for statistical 
analysis of all data.  
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3.4       Results  
3.4.1 Canine CCL data summary 
The history of canine cadavers was recorded which consisted of the dog breed, 
age, bodyweight and gender where applicable. 
Table 3-1: Summary of the age, bodyweight and gender of canine cadaveric CCL 
samples selected for Western blot and RT-PCR analysis.  
(SBT= Staffordshire bull terrier; GH= greyhound; N/ A= not available). 
Procedure Breed Ligaments Age Weight (Mean ± SEM)  Male Female 
Western 
blot 
SBT n= 12 2-5 years 20.3 ± 2.8 kg 12 0 
GH n= 10 3-5 years N/ A  N/ A N/ A 
RT-PCR SBT n= 5 2-5 years 19 ± 1.7 kg 5 1 
GH n= 5 3-5 years 25 ± 1.2 kg N/ A N/ A 
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3.4.2 Western blot analysis 
3.4.2.1     Negative controls 
Negative controls for Western blot analysis were performed by omitting the addition 
of the primary antibody. No or non-specific bands were detected in the absence of 
primary antibodies. Negative control Figures are provided in appendix IV. 
 
3.4.2.2     Comparison between different anatomical regions of Staffordshire 
bull terrier 
3.4.2.2.1 Large aggregating proteoglycans 
Analysis using the anti-aggrecan antibody did not consistently detect aggrecan in 
any regions of the CCL. Despite the high concentrations of the antibody that were 
able to produce a non-specific inverted signal (white bands on blots in Figure 3-1 A), 
no positive signal was observed at the expected high molecular weights. The only 
positive signal was observed was in Figure 3-1 A, where an approximately 55 kDa 
protein was identified, which might represent a degradation product contained within 
the tissue. Analysis with anti-versican antibody revealed that versican is present in 
the anatomical regions of the Staffordshire bull terrier CCL at molecular weights 
ranging from 40 to 260 kDa and above (Figure 3-1 B). To compare relative amounts 
of these proteoglycans between different anatomical regions of the CCL, 
densitometry was carried out. The extent of each lane included is indicated by the 
green bar in Figure 3-1 B. Versican was found to be significantly lower in origin 
(p=0.003) and insertion (p=0.003) anatomical regions compared to the middle 
(p=0.16) region (Figure 3-5). 
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Figure 3-1: Western blot analysis of aggrecan and versican in different anatomical 
regions of the Staffordshire bull terrier CCL. 
The Figure shows A) Aggrecan mAb 7D1 and B) Versican mAb 12C5. Lanes are labelled 
with sample identifiers as follows; O= origin; M= middle; and I= insertion whilst the number 
refers to the donor animals, n= 5. The core protein fragments of versican (40-260 kDa) are 
marked in green. 
 
 
 
 
 
 
 
 
 
 
* 
* 
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3.4.2.2.2 Chondroitin/ dermatan sulphate proteoglycans 
Analysis using the anti-decorin antibody revealed that decorin is present in different 
anatomical regions of the Staffordshire bull terrier at molecular weights ranging from 
40-50 kDa which corresponds with the expected size of the decorin core protein 
(Figure 3-2, A). Other molecular weight bands of interest for decorin were at 80 kDa 
(blue arrow). Western blotting using anti-biglycan antibody revealed that biglycan is 
present in different anatomical regions of the Staffordshire bull terrier CCL at 
molecular weights ranging from 40-50 kDa which corresponds to the expected size 
of the biglycan core protein (Figure 3-2 B). To compare relative amounts of these 
proteoglycans between different anatomical regions of the CCL, densitometry was 
carried out. The extent of each lane included is indicated by the green bar in Figure 
3-2 A, B. Densitometric analysis showed that there was no statistically significant 
differences in the levels of decorin and biglycan core proteins between the 
anatomical regions examined. 
 
Figure 3-2: Western blot analysis of decorin and biglycan in different anatomical 
regions of the Staffordshire bull terrier CCL. 
The Figure shows A) Decorin mAb 70.6 and B) Biglycan mAb PR8A4. Lanes are labelled 
with sample identifiers as follows; O= origin; M= middle; and I= insertion whilst the number 
refers to the donor animals, n= 5. The core protein of decorin (40-50 kDa) and biglycan (40-
50 kDa) proteoglycans are marked in green. Other bands of interest are the 80 kDa band 
(blue arrow) in decorin. 
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3.4.2.2.3 Keratan sulphate proteoglycans  
Analysis using anti-fibromodulin and anti-lumican antibody revealed that 
fibromodulin and lumican were present in different anatomical regions of the 
Staffordshire bull terrier at a molecular weight of 50 kDa corresponding to their 
expected size (Figure 3-3 A, B). Further analysis using an anti-keratocan antibody 
revealed that keratocan was present between different anatomical regions of the 
Staffordshire bull terrier CCL at a molecular weight of 30 kDa corresponding to its 
expected size (Figure 3-3 C). To compare relative amounts of these proteoglycans 
between different anatomical regions of the CCL, densitometry was carried out. The 
extent of each lane included is indicated by the green bar in Figure 3-3 A, B, C. 
Densitometric analysis showed that keratocan protein levels were significantly lower 
in the origin anatomical region compared to the middle region (p=0.046) of the 
Staffordshire bull terrier CCL  (Figure 3-5). 
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Figure 3-3: Western blot analysis of lumican, fibromodulin, and keratocan in different 
anatomical regions of the Staffordshire bull terrier CCL. 
The Figure shows A) Lumican mAb LUM-1, B) Fibromodulin mAb  PR184, and C) Keratocan  
mAb KER-1. Lanes are labelled with sample identifiers as follows; O= origin; M= middle; and 
I= insertion whilst the number refers to the donor animal, n= 5. The core proteins of lumican 
(50 kDa), fibromodulin (50 kDa), and keratocan (30kDa) are marked in green. 
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3.4.2.2.4 Glycosaminoglycans 
Analysis using the anti-chondroitin-6 sulphate stub antibody detected chondroitin-6 
sulphate stub in different anatomical regions of the Staffordshire bull terrier CCL at a 
range of molecular weights from 80-260 kDa (Figure 3-4 A). Analysis using an anti-
chondroitin-4 sulphate stub antibody detected stubs in different anatomical regions 
of the Staffordshire bull terrier across a wide spectrum of sizes ranging from 80-260 
kDa, which were termed high molecular weight bands (Figure 3-4 green, lane B). 
The chondroitin-4 sulphate stub antibody also detected a more discretely sized set 
of stubs of around 40-50 kDa that were termed low molecular weight bands (Figure 
3-4, purple, lane B). Analysis using anti-chondroitin-0-sulphate stub antibody 
revealed that chondroitin-0 sulphate stubs between the different anatomical regions 
of the Staffordshire bull terrier ranged from 260 kDa and above (Figure 3-4 C). 
Analysis using anti-keratan sulphate stub antibody revealed that keratan sulphate 
stubs ranged between 80-260 kDa by Western blotting (Figure 3-4 D). To compare 
relative amounts of these proteoglycans between different anatomical regions of the 
CCL, densitometry was carried out. The extent of each lane included is indicated by 
the green or purple bar in Figure 3-4 A, B, C, D. There were no statistically 
significant differences between anatomical regions examined in regards to 
chondroitin -0 sulphate stub, chondroitin -6 sulphate stub, chondroitin -4 sulphate 
low molecular weight stub, and keratan sulphate stubs between anatomical regions 
examined. However, chondroitin -4 sulphate high molecular weight stubs were 
found to be significantly higher in middle (p=0.01) and insertion (p=0.003) 
anatomical regions in relation to the origin (Figure 3-5). 
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Figure 3-4: Western blot analysis of chondroitin and keratan sulphate stubs in 
different anatomical regions of Staffordshire bull terrier CCL. 
The Figure shows A) chondroitin-6-sulphate stubs mAb 3B3, B) chondroitin-4-sulphate stubs 
mAb 2B6, C) chondroitin-0-sulphate stubs mAb 1B5, and D) keratan sulphate stubs mAb 
5D4. Lanes are labelled with sample identifiers as follows; O= origin; M= middle; and I= 
insertion whilst the number refers to the donor animal, n= 5. The high molecular weights of 
chondroitin -6, -4, keratan sulphate stubs (80-260 kDa), and chondroitin-0 sulphate stubs 
(260 and above) are marked in green, and the low molecular weight stubs of chondroitin-4 
sulphate stub (40-50 kDa) are highlighted in purple. 
 
89 
 
 
  
Figure 3-5: Densitometry analysis of proteoglycans and GAGs in different anatomical regions of Staffordshire bull terrier CCL. 
A) Densitometry of proteoglycans between different anatomical regions of the Staffordshire bull terrier CCL, n= 5. Versican was signficantly 
higher  in middle anatomical regions compared to origin (p=0.003) and insertion (p=0.003). Keratocan was found to be  significantly higher in  
middle in relation to origin (p=0.046) anatomical region. B) Densitometry analysis of GAG stubs between between different anatomical 
regions of the Staffordshire bull terrier CCL, n= 5. Chondroitin-4-sulphate higher molecular weight stub was significantly higher in middle 
(p=0.01), and insertion (p=0.003) regions in relation to origin anatomical region. (CS0=chondroitin-0 sulphate stubs; CS4=chondroitin-4 
sulphate stubs; CS6=chondroitin-6 sulphate stubs; KS= keratan sulphate stubs; MW= molecular  weight; SBT= Staffordshire bull terrier). * 
indicates a significant difference at p < 0.05. Comparisons should be made between samples and not between antibodies as the efficiencies 
of the primary antibodies vary from one another.
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Table 3-2: Densitometry results for Western blot analysis of proteoglycans and GAGs found in the different anatomical regions of the Staffordshire 
bull terrier CCL.  
Values shown as mean ± SEM of Arbitary units, n= 5. * indicates a significant difference at p < 0.05. 
                                              Proteoglycan       Origin arbitrary units     Middle arbitrary units  Insertion arbitrary units 
Aggrecan core protein fragment at 50 kDa N/ A N/ A N/ A 
Versican core protein fragment at 40-260 kDa*  0.9 ± 0.04 1.5 ± 0.2 0.9 ± 0.1 
Decorin core protein at 40-50 kDa 0.9 ± 0.04 0.9 ± 0.1 0.9 ± 0.1 
Biglycan core protein  at 40-50 kDa 0.8 ± 0.1 0.9 ± 0.3 0.4 ± 0.1 
Lumican core protein at 50 kDa 3.6 ± 1.4 8.6 ±2 9.2 ± 1.02 
Fibromodulin core protein at 50 kDa 0.7  ± 0.2 0.6 ± 0.03 0.8 ± 0.1 
Keratocan core protein at 30 kDa* 1.0 ± 0.2 2.2 ± 0.5 1.6 ± 0.3 
Chondroitin-0-sulphate stub at 260 kDa and above 0.5 ± 0.1 0.6 ± 0.2 0.2 ± 0.04 
Chondroitin-4-sulphate stub  (high molecular weight 80-260 kDa)* 0.6 ± 0.1 0.9 ± 0.03 1.0 ± 0.1 
Chondroitin-4-sulphate stub (low molecular weight 40-50 kDa) 1.5 ± 0.1 1.2 ± 0.1 1.4 ± 0.2 
Chondroitin-6-sulphate stub at 80-260 kDa 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.04 
 Keratan sulphate stub at 80-260 kDa 0.6 ± 0.2 0.5 ± 0.1 0.3 ± 0.1 
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3.4.2.3     Comparison between two dog breeds differentially predisposed to 
CCLD/ R. 
3.4.2.3.1 Large aggregating proteoglycans  
Analysis of anti-aggrecan antibody showed a band at 55 kDa that appeared to be 
different between the two dog breeds, and corresponded to one of its expected 
fragment sizes (Figure 3-6 A). Anti-versican antibody showed a similar molecular 
weight size between the two dog breeds (Figure 3-6 B) compared to what has been 
already observed between the anatomical regions of Staffordshire bull terrier CCLs 
(Figure 3-1 B). To compare relative amounts of these proteoglycans between the 
two dog breeds, densitometry was carried out. The extent of each lane included is 
indicated by the green bar in Figure 3-6 A, B. There were no statistically significant 
differences in versican or aggrecan core protein fragments between the two dog 
breeds. 
 
Figure 3-6: Western blot analysis of aggrecan and versican in two differentially 
predisposed dog breeds. 
The Figure shows A) Aggrecan mAb 7D1 and B) Versican mAb 12C5. This Figure compares 
two dog breeds with a different predisposition to CCLD/ R. The number refers to the donor 
animal, n= 5. The core protein fragment(s) of aggrecan (50 kDa) and versican (40-260 kDa) 
are labelled in green. (S= Staffordshire bull terrier; G= greyhound). 
 
 
 
 
 
 
 
92 
 
3.4.2.3.2 Chondroitin/ dermatan sulphate proteoglycans 
Analysis using anti-decorin antibody and anti-biglycan antibody showed a similar 
molecular weight between the two dog breeds (Figure 3-7 A, B) compared to what 
has been already observed between different anatomical regions of the 
Staffordshire bull terrier (Figure 3-2 A, B). However, we detected a prominent 
catabolic fragment below the decorin core protein at 30 kDa in greyhounds 
compared to Staffordshire bull terrier CCLs (Figure 3-7 A, black arrow). The decorin 
band at 80 kDa, which corresponded to its expected dimer size, was also quantified 
as it appeared to be significantly different between the two dog breeds. To compare 
relative amounts of these proteoglycans between the two dog breeds, densitometry 
was carried out. The extent of each lane included is indicated by the green bar in 
Figure 3-7 A, B. Statistical analysis showed that there were no statistically 
significant differences between the two dog breeds in terms of monomeric decorin 
core protein. However, decorin dimeric core protein was significantly higher in the 
greyhound compared to the Staffordshire bull terrier CCLs (p=0.008) (Figure 3-10). 
There were no statistically significant differences in the biglycan core protein 
between the two dog breeds. However, there was some variations observed in the 
biglycan band density in different greyhound samples (Figure, 3-7 B).  
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Figure 3-7: Western blot analysis of decorin and biglycan in two differentially 
predisposed dog breeds. 
The Figure shows A) Decorin mAb 70.6 and B) Biglycan mAb PR 8A4. This Figure 
compares two dog  breeds with a different predisposition to CCLD/ R.  The number refers to 
the donor animal, n= 5. The core proteins of decorin (40-50 kDa) and biglycan (40-50 kDa) 
are highlighted in green. Other bands of interest are the 80 kDa band highlighted in purple 
(blue arrow) and the catabolic product (30 kDa) prominent in greyhound (black arrow). (S= 
Staffordshire bull terrier; G= greyhound). 
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3.4.2.3.3 Keratan sulphate proteoglycans  
Analysis using anti-lumican antibody, anti-fibromodulin antibody and anti-keratocan 
antibodies showed that the size of each of these proteoglycans showed a similar 
molecular weight between the two dog breeds compared to what has been already 
observed between different anatomical regions of the Staffordshire bull terrier CCLs 
(Figure 3-3 A, B, and C). To compare relative amounts of these proteoglycans 
between the two dog breeds, densitometry was carried out. The extent of each lane 
included is indicated by the green bar in Figure 3-8 A, B, and C. There were no 
statistically significant differences for the content of and keratocan between dog 
breeds. However, fibromodulin was significantly higher in the Staffordshire bull 
terrier CCLs compared to those of the greyhounds (p=0.02) (Figure 3-10). 
 
Figure 3-8: Western blot analysis of lumican, fibromodulin and keratocan between two 
differentially predisposed dog breeds. 
The Figure shows A) Lumican mAb LUM1, B) Fibromodulin pAb PR184, and C) Keratocan 
mAb KER-1. This Figure compares two dog breeds with a different predisposition to CCLD/ 
R. The number refers to the donor animal, n= 5. The core proteins of lumican (50 kDa), 
fibromodulin (50 kDa), and keratocan (30 kDa) are marked in green. (S= Staffordshire bull 
terrier; G= greyhound). 
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3.4.2.3.4 Glycosaminoglycans 
Analysis using anti-chondroitin-0-sulphate stub antibody, anti-chondroitin-6-sulphate 
stub antibody, anti-chondroitin-4-sulphate stub antibody, and anti-keratan sulphate 
stub antibody showed a similar molecular weight between the two dog breeds 
compared to what has been already observed between different anatomical regions 
of the Staffordshire bull terrier CCLs (Figure 3-4). Levels of chondroitin-0-sulphate 
as well as keratan sulphate found on high molecular weight proteoglycans exhibited 
a considerable variability between the Staffordshire bull terrier donors (Figure 3-9 C, 
D). To compare relative amounts of these proteoglycans between the two dog 
breeds, densitometry was carried out. The extent of each lane included is indicated 
by the green or purple bar in Figure 3-9 A, B, C. There were no statistically 
significant differences between the dog breeds in regards to chondrotin-4-sulphate 
high molecular weight stub, chondrotin-4-sulphate low molecular weight stub, 
chondroitin-0-sulphate high molecular weight stub, and keratan sulphate high 
molecular weight stub. However, chondroitin-6-sulphate stub was significantly 
higher in the Staffordshire bull terrier in relation to the greyhound CCLs (p=0.0144) 
(Figure 3-10). 
 
Figure 3-9: Western blot analysis of chondroitin sulphate and keratan sulphate stubs 
between two differentially predisposed dog breeds. 
The Figure shows A) chondroitin-6 sulphate stub mAb 3B3,  B) chondroitin-4 sulphate stub 
mAb 2B6, C) chondroitin-0 sulphate stubs mAb 1B5, and D) keratan sulphate stubs mAb 
5D4. The Figure compares two dog breeds with a different predisposition to CCLD/ R. The 
number refers to the donor animal, n= 5.  The high molecular weights of chondroitin -6, -4, -
0, keratan sulphate stubs (80-260 kDa), and chondroitin sulphate stubs (260 kDa and 
above)  are highlighted in green, and the low molecular weight of chondroitin -4 sulphate 
stubs (40 kDa) are highlighted in purple. (S= Staffordshire bull terrier; G= greyhound). 
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Figure 3-10: Densitometry analysis of proteoglycans and GAGs between two differentially predisposed dog breeds. 
A) Densitometry analysis for proteoglycans between two differentially predisposed dog breeds to CCLD/ R, n= 5.  Core proteins of all proteoglycans 
were measured unless stated. Decorin 80 kDa  band was significantly higher in greyhound (p=0.008) compared to Staffordshire bull terrier CCL, 
whilst fibromodulin was significantly higher in Staffordshire bull terrier (p=0.02) compared to greyhound CCLs. B) Densitometry analysis for GAG 
stubs between two differentially predisposed dog breeds to CCLD/ R. Chondroitin-6-sulphate was found to be significantly higher in Staffordshire bull 
terrier (p=0.0144) compared to greyhound CCL. (CS0= chondroitin-0 sulphate stubs; CS4= chondroitin-4 sulphate stubs; CS6= chondroitin-6 
sulphate stubs; KS= keratan sulphate stubs; MW= molecular  weight; SBT=  Staffordshire bull terrier; GH =greyhound).  * indicates a significant 
difference at p < 0.05. Comparisons shouls be made between samples and not between antibodies as the efficiencies of the primary antibodies vary 
from one another.
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Table 3-3: Densitometry results for Western blot analysis for proteoglycans and GAGs found in the CCL from  differentially predisposed 
dog breeds to CCLD/ R. 
Values shown as mean ± SEM of arbitrary units, n= 5 of each dog breed. * indicates a significant difference at p < 0.05 (SBT= Staffordshire bull 
terrier; GH= greyhound). 
Proteoglycan SBT arbitary units GH arbitary units 
Aggrecan core protein fragment at 50 kDa 530.7 ± 172.3 248.9 ± 112.9 
Versican core protein  fragments between 40-260 kDa 4873.6 ± 282.1 5335.8 ± 678.9 
Decorin core protein at 40-50 kDa  8283.8 ± 379.9 7902.5± 342.2 
Decorin band ~80 kDa* 3507.3± 482.9 5442.6 ± 175.3 
Biglycan core protein at 40-50 kDa 532.9 ± 42.7 764.3 ± 134.3 
Lumican core protein at 50 kDa 3314.1 ± 256.3 3145 ± 533.5 
Fibromodulin core protein at 50 kDa* 5084.5 ± 356.9 2554 ± 745.2 
Keratocan core protein at 30 kDa 4648.4 ± 481.3 3813.± 803.5 
Chondroitin-0-sulphate stub at 260 kDa and above 4848 ± 2699 1749 ± 439.9 
Chondroitin-4-sulphate stub (high molecular weight 80-260 kDa) 8945.6 ± 466.2 7408.6 ± 980.3 
Chondroitin-4-sulphate stub (low molecular weight 40-50 kDa) 7669.5 ± 624.1 6835.5 ± 392.1 
Chondroitin-6-sulphate stub 80-260 kDa* 6357.5 ± 605.5 3603.5 ± 645.1 
Keratan sulphate stub between 80-260 kDa 2842.5 ± 803.3 3596.9 ± 509.2 
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3.4.3 Real time RT-qPCR 
3.4.3.1     Large aggregating proteoglycans  
The gene expression of aggrecan was found to be significantly greater in 
Staffordshire bull terrier CCLs compared to those of the greyhound (p=0.0003) 
(Figure 3-11). However, the gene expression of versican in CCLs was not found to 
be statistically different between the two dog breeds but the mean value was higher 
in the greyhound (Figure 3-11). 
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Figure 3-11: Summary of large aggregating proteoglycans gene expression data 
performed on the CCLs from two dog breeds with a different predisposition to CCLD/ 
R. 
Data presented as MEAN ± SEM, n= 5 biological replicate of each dog breed. (SBT= 
Staffordshire bull terrier; GH= greyhound). Aggrecan was significantly higher in the 
Staffordshire bull terrier CCLs compared to those of the greyhounds (p=0.0003). * indicates 
a significant difference at p < 0.05. 
* 
* 
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3.4.3.2     Chondroitin/ dermatan sulphate proteoglycans 
The Staffordshire bull terrier CCLs had significantly reduced decorin gene 
expression in relation to greyhound CCLs (p=0.03) (Figure 3-12). Biglycan gene 
expression did not show any significance between the two dog breeds (Figure 3-
12). 
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Figure 3-12: Summary of chondroitin/ dermatan sulphate proteoglycans gene 
expression data performed on the CCLs from dog breeds with a different 
predisposition to CCLD/ R.  
Data presented as MEAN ± SEM, n= 5 biological replicate of each dog breed (SBT= 
Staffordshire bull terrier; GH= greyhound). Decorin was significantly reduced in the 
Staffordshire bull terrier CCLs compared to those of the greyhounds (p= 0.03). * indicates a 
significant difference at p < 0.05. 
* 
 
100 
 
3.4.3.3     Keratan sulphate proteoglycans  
Lumican gene expression showed no significant difference in the CCLs from two 
dog breeds but the mean value was higher in the greyhound (Figure 3-13). 
However, fibromodulin gene expression was found to be significantly higher in 
Staffordshire bull terrier CCLs in comparison to those of the greyhounds (p=0.03) 
(Figure 3-13). 
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Figure 3-13: Summary of keratan sulphate proteoglycans gene expression data 
performed on the CCLs from dog breeds with a different predisposition to CCLD/ R. 
Data presented as MEAN ± SEM, n= 5 biological replicate of each dog breed. (SBT= 
Staffordshire bull terrier, GH= greyhound). Fibromodulin was significantly higher in the 
Staffordshire bull terrier CCLs compared to those of greyhounds (p= 0.03). * indicates a 
significant difference at p < 0.05. 
* 
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3.4.3.4     Extracellular matrix proteases 
Staffordshire bull terrier CCLs had significantly reduced ADAMTS-4 gene 
expression in relation to greyhound (p=0.04) (Figure 3-14). However, the gene 
expression of ADAMTS-5 did not show any statistical significant differences in the 
CCLs from the two dog breeds (Figure 3-14). 
 
 
Figure 3-14: Summary of ADAMTS-4 and -5 gene expression data performed on the 
CCLs from dog breeds with a different predisposition to CCLD/ R. 
Data presented as MEAN ± SEM, n= 5 biological replicate of each dog breed. (SBT= 
Staffordshire bull terrier, GH= greyhound, ECM= extracellular matrix). ADAMTS-4 was 
significantly reduced in the Staffordshire bull terrier CCLs in relation to greyhounds (p=0.04). 
* indicates a significant difference at p < 0.05. 
* 
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Table 3-4: Gene expression levels of proteoglycans and ECM proteases in the CCLs from two dog breeds differentially predisposed to 
CCLD/ R. 
2^-dCT values are displayed (mean ± SEM), n= 5 of each dog breed. * indicates a significant difference at p < 0.05 in proteoglycans or ECM 
proteases gene expression between the two groups. 
Proteoglycan Staffordshire bull terrier Greyhound 
Aggrecan* 0.60 ± 0.01 0.14 ± 0.07 
Versican 1.45 ± 0.21 3.42 ± 1.24 
Decorin* 0.41 ± 0.01 259.99± 97.64 
Biglycan 0.49 ± 0.01 1.11 ± 0.47 
Lumican 0.48 ± 0.01 4.48 ± 1.99 
Fibromodulin* 9.68 ± 2.12 3.45 ± 1.01 
ADAMTS5 0.24 ± 0.09 0.74 ± 0.74 
ADAMTS4* 0.01 ± 0.00 0.65 ± 0.25 
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3.5 Discussion  
In this study, Western blot analysis showed that specific proteoglycans and GAGs 
varied between anatomical regions of the Staffordshire bull terrier CCL, indicating 
that these particular proteoglycans and GAGs have different roles at specific 
anatomical sites. Proteoglycans, GAGs, and aggrecanases (ADAMTS-4 and -5) 
have been characterised by Western blot and RT-PCR analysis between CCLs of 
two dog breeds differentially predisposed to CCLD/ R, the greyhound (low risk) and 
the Staffordshire bull terrier (moderate-high risk). Our results showed that the 
presence of certain key proteoglycans, GAGs, and aggrecanases significantly 
differed in the CCLs from dogs at a varied risk to CCLD/ R. These differences may 
be important as proteoglycans and their catabolites may contribute to the 
aetiopathogenesis of this condition by having different roles in low and high risk dog 
breeds. 
The results of our study showed that the molecular weights decorin, biglycan, 
fibromodulin, and lumican are similar to what has been previously reported in the 
canine CCL (Yang, Culshaw et al. 2012). Our findings are also consistent with 
previous reports of decorin, biglycan, lumican, fibromodulin, versican, and aggrecan 
molecular weights in ligament (Ilic, Carter et al. 2005), and keratocan, decorin, 
biglycan, aggrecan, versican, and GAGs stubs (3b3, 2b6, and 1b5) molecular 
weights in tendon (Rees, Flannery et al. 2000; Samiric, Ilic et al. 2004; Rees, 
Waggett et al. 2009). We were unable to measure aggrecan fragments with 
Western blot analysis between anatomical regions of the Staffordshire bull terrier 
CCL, as most of the bands were faded on the blot membrane when captured, and 
were therefore difficult to identify. The reason for this could be that the primary 
antibody did not detect aggrecan fragments at the level that was there. Another 
alternative antibody that may be used is aggrecan monoclonal anatibody 1C6, 
which recognises an epitope located at the G1 and G2 domains of aggrecan 
(Calabro, Hascall et al. 1992). In addition, the native keratan sulphate monoclonal 
antibody 5D4 could also detect high molecular weight bands on the aggrecan core 
protein (Caterson; Christner et al. 1983). Other studies have detected aggrecan 
fragments using an alternative anti-aggrecan monoclonal antibody mAb JD5 (Ilic, 
Carter et al. 2005). Using 4–15% gradient polyacrylamide/ Sodium Dodecyl 
Sulphate (SDS) slab gels, two discrete bands at 170 and 130 kDa were found in 
bovine collateral ligament (Ilic, Carter et al. 2005). Similar fragments have been also 
shown in tendon (Samiric, Ilic et al. 2004). The molecular weight of aggrecan 
fragments may vary due to tissue differences. In addition, antibodies specific for 
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aggrecan core protein may differ in that they may recognise aggrecan or aggrecan 
fragments at different locations of the aggrecan core protein (Samiric, Ilic et al. 
2004; Ilic, Carter et al. 2005). 
Western blotting analysis used to identify versican showed a range of bands from 
180 kDa to 260 kDa and above (Figure 3-1 B). A study on bovine collateral ligament 
has shown a similar molecular weight range for versican, from 18 to 260 kDa and 
above (Ilic, Carter et al. 2005). The bands generated in versican may indicate 
fragments of its core protein (Figure 3-1 B). Such fragments could be generated by 
ECM proteases, such as ADAMTS’s specific for cleaving versican (See Chapter 1 - 
Section 1.3.5.6.1) (Sandy, Westling et al. 2001; Kelwick, Desanlis et al. 2015). The 
core proteins of aggrecan and versican are likely to be too large to migrate into the 
SDS-PAGE gels, therefore we were only able to observe their fragments rather than 
the core protein. It would have been interesting to detect aggrecan and versican 
core proteins in the canine CCL by Western blotting. An alternative technique to 
quantify aggrecan and versican core protein is using composite agarose/ 
polyacrylamide gels, which allow native large proteoglycans to enter the gel 
(Varelas, Zenarosa et al.1991). 
Densitometry analysis of Western blots of different anatomical regions of 
Staffordshire bull terrier CCLs showed that versican fragments were significantly 
lower in both origin and insertion regions, when compared to the middle region. The 
middle anatomical region of the CCL has been shown to be fibrocartilaginous as it 
twists around the caudal cruciate ligament (CaCL) (Paatsama 1952; Vasseur, Pool 
et al. 1985; Comerford, Tarlton et al. 2006). This fibrocartilaginous site is likely to be 
secondary to physical compression, and the significant increase of versican 
fragments in this middle region could be that its specific to this anatomical area, as it 
has been previously shown that versican content is increased in fibrocartilaginous 
regions of tendon (Vogel and Koob 1989). 
Both decorin and biglycan monomeric core proteins were found to be around 40-50 
kDa, similar to what has been shown previously in several tissues such as ligament, 
tendon and articular cartilage (Rees, Flannery et al. 2000; Samiric, Ilic et al. 2004; 
Ilic, Carter et al. 2005; Young, Smith et al. 2005; Melrose, Fuller et al. 2008).  
An interesting band was found on the decorin Western blots at around 80 kDa, and 
we hypothesise that this band is likely to be a cross linked form of a decorin dimer 
(Milligan and Koshland 1988), as it is unlikely to be a complete dimer. Covalent 
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cross linking occurs when one polymer atoms attaches to another by sharing 
electron pais between atoms (Milligan and Koshland 1988; Talwar 2016). Covalent 
cross linking is essential for protein – protein interactions (Milligan and Koshland 
1988). Dimers are a complex of macromolecules that are generated by bound 
proteins, and are essential for creating more that one binding site for proteins or for 
enzyme activation (Marianayagam, Sunde et al. 2004). A previous study has 
similarly reported a decorin band at 90 kDa that could represent decorin dimer 
(Rees, Flannery et al. 2000). Dimers are formed by electrostatic interactions, 
hydrogen bonds or Van der waals forces (Frieden 1975), and are usually denatured 
during the heating process prior loading samples into the gel (Grabski and Novagen 
2010). It could be that these forces were very strong and were not overcome by 
heating. However, it seems more likely that covalent crosslinking of decorin 
occurred (Milligan and Koshland 1988), in which case no amount of boiling or 
reduction will separate them.  
Fibromodulin, lumican, and keratocan appeared as single bands respectively at 50, 
50, 30 kDa by Western blot analysis. Similar molecular weight bands for 
fibromodulin and lumican have been previously found in beagle CCLs (Yang, 
Culshaw et al. 2012). Amongst all SLRPs, Keratocan had the lowest molecular 
weight core protein at 30 kDa consistent to what has been previously observed in 
tendon (Rees, Waggett et al. 2009). 
Densitometry analysis between different anatomical regions of Staffordshire bull 
terrier CCLs by Western blot showed that keratocan was significantly higher in the 
middle region compared to the origin region. The significant increase of keratocan 
content in the middle anatomical region of the canine CCL could be due to similar 
reasons as explained for versican, in that the fibrocartilage area is increased in the 
middle site of canine CCL (Paatsama 1952; Vasseur, Pool et al. 1985; Comerford, 
Tarlton et al. 2006b). This result is consistent to what has been previously reported 
for keratocan, as it has been previously found to increase at the compressed/ 
fibrocartilaginous region in tendon (Rees, Wagget et al. 2009). 
Chondroitin-6 sulphate stub antibody produced bands ranging from 80-260 kDa by 
Western blot analysis in the canine CCL. Chondroitin -0 sulphate stub antibody also 
identified a band at 260 kDa and above. Chondroitin-6 sulphate stub and 
Chondroitin-0 sulphate stub antibodies have been shown to be expressed 
previously in adult bovine tendon, where heterogeneous bands were shown from 
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150-260 kDa (Rees, Flannery et al. 2000), and this was similar to what we found in 
this study. 
In our CCLs chondroitin-4 sulphate stub antibody detected two molecular weight 
species; the first was a high molecular weight band from 80-260 kDa, and the 
second species was a band at 40 kDa. In tendon, the low molecular weight of 
chondroitin-4 sulphate stub has been previously detected at approximately 50 kDa 
(Rees, Flannery et al. 2000).  
The small molecular weight (50 kDa) recognised by chondroitin-4 sulphate stub 
antibody may represent small molecular weight species such as decorin or biglycan 
(Rees, Flannery et al. 2000). The high molecular weight found on chondroitin-6 
sulphate stub (150-260 kDa), chondroitin-0 sulphate stub (150-260 kDa), and 
chondroitin-4 sulphate (80-260) may indicate that stubs present on high molecular 
weight proteoglycan species such as aggrecan or versican. Our assumption is that  
chondroitin -4, -6, and -0 sulphate stubs are mostly associated with large 
aggregating proteoglycans, whilst only chondroitin -4 sulphate stubs is mostly 
associated with small proteoglycans, as It has been previously shown with 
disaccharide analysis in tendon that large proteoglycans were mostly associated 
with chondroitin -4, -6, and -0 sulphate, and that small proteoglycans mostly had 
chondroitin-4 sulphate (Evanko and Vogel 1993). The molecular weight 
proteoglycan species found for keratan sulphate high molecular weight stubs (80-
260 kDa) are likely to be solely associated with aggrecan, as versican does not 
carry any keratan sulphate chains (Krusius, Gehlsen et al. 1987).  
Densitometry analysis between different anatomical regions of Staffordhsire bull 
terrier CCLs by Western blot showed that the high molecular weight bands detected 
by the anti-chondroitin-4 sulphate stub antibody showed to be significantly higher in 
middle and insertion regions compared to the origin. These findings might be 
explained by the fact that they are identifying a large aggregating proteoglycan, 
such as aggrecan or versican. The CCL insertion site onto the proximal tibia is 
another compressive site containing a fibrocartilaginous matrix (Arnoczky 1983). As 
mentioned earlier, aggrecan and versican are known to be located in 
fibrocartilaginous regions of tendon that encounters compression (Vogel and Koob 
1989; Benjamin and Ralphs 1998; Evako and Vogel 1993).  
Real time RT-PCR analysis in our study found the gene expression of aggrecan to 
be significantly increased in the Staffordshire bull terrier in relation to greyhound 
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CCLs, whilst Western blot analysis detected an aggrecan fragment at 55 kDa that 
appeared to be enriched in the Staffordshire bull terriers compared to greyhounds 
(Figue 3-6 A). The levels of this fragment were not statistically different upon 
densiometric analysis (p= 0.21). It is possible that increasing sample numbers could 
have demonstrated a significant difference in the 55 kDa fragment between breeds. 
These results may indicate that the Staffordshire bull terrier is more susceptible to 
compressive loads on its CCL, as increased aggrecan in regions susceptible to 
compressive loads in tendon has been previously determined (Vogel and Koob 
1989; Evanko and Vogel 1993; Huisman, Andersson et al. 2014), especially where 
type II collagen is increased (Vogel 2004; Smith, Shu et al. 2010). In addition, the 
increase of aggrecan gene expression and higher amount of the aggrecan fragment 
in the Staffordshire bull terrier CCL could lead to the progression of CCLD/ R, as 
several studies have found increased aggrecan gene expression levels in 
pathological tendons (Corps, Robinson et al. 2006; Samiric, Parkinson et al. 2009) 
and ligament (Clements, Carter et al. 2008).  
Gene expression data revealed that decorin was significantly higher in the 
greyhound CCL compared to Staffordshire bull terriers, while Western blot analysis 
did not show any significant differences between the two dog breed CCLs in regards 
to decorin core protein. However, when decorin dimer band at 80 kDa was 
measured, it was shown to be significantly higher in greyhounds when compared to 
Staffordshire bull terrier CCLs. Decorin dimer might have a role in regulating 
collagen fibrillogenesis (Weber, Harrison et al. 1996). It has been shown that 
decorin functions by inhibiting lateral collagen fibril fusion in vitro, thereby resulting 
in the formation of thinner collagen fibrils (Birk, Nurminskaya et al. 1995). It is 
interesting to know that decorin is increased 700 folds in the greyhound CCL, as this 
may show how decorin is essential for collagen fibrillogenesis and strength in the 
racing greyhound that rarely ruptures its CCL. The important role of decorin in 
collagen fibrillogenesis can be supported by the decorin knockout mice study in 
tendon, where collagen fibrils in cross sections have been known to contain 
irregular outlines and were variable in size compared to controls (Danielson, 
Baribault et al. 1997). In addition to this, electron microscopy was used to measure 
the cross sections of collagen fibril diameter in the greyhound (low risk to CCLD/ R) 
and the Labrador retriever CCLs (high risk to CCLD/ R), and found that the 
Labrador retriever contained a variation in collagen fibril size population ranging 
from small to large, and included a peak of distribution at 50 nm. Whereas 
greyhounds had a larger (100-150 nm) and more evenly shaped distribution of 
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collagen fibril sizes (Comerford, Tarlton et al. 2006b). The large fibrils in ex-racing 
greyhounds could be formed as a consequence of its racing activity, as it has been 
previously shown that the increase of fibril size is associated with physical activity 
(Tipton, Matthes et al. 1975). Dermatan sulphate, a GAG chain present on decorin 
and biglycan, has been previously shown to be associated with large sized fibrils 
(>150) (Parry, Flint et al. 1982). Previous reports also showed that decorin and 
hyaluronic acid content is increased with exercise in chicken gastrocnemius tendons 
(Hae Yoon, Brooks et al. 2003). These studies support why decorin expression may 
be greater in previously exercised greyhounds CCLs compared to the CCLs from 
the non-athletic Staffordshire bull terrier. In determining biglycan by Western blot 
analysis, we found a variation between the greyhound donors (Figure 3-7 B). Since 
greyhounds are known to be an exercising dog breed, it could be that these 
greyhounds have had different exercise regimes explaining their individual 
variability. However, we did not have any detailed information on the exercise 
history of the greyhound donors. Fibromodulin regulates collagen fibrillogenesis in 
normal tendon (Jepsen, Wu et al. 2002), and binds to growth factors such as TGF-β 
(Iozzo 1999). Both real time RT-PCR and Western blot analysis confirmed that 
fibromodulin was significantly upregulated in Staffordshire bull terrier compared to 
greyhound CCLs. It has been proposed that fibromodulin controls the mineralisation 
of the soft/ hard tissue border of human peridontal ligament (Cheng, Caterson et al. 
1999; Matias, Li et al. 2003). Furthermore, fibromodulin has been shown to be 
localised at the compressive sites that were fibrocartilaginous in human flexor carpi 
ulnaris tendon, pisometacarpal and pisohamate ligaments (Adamczyk, Milz et al. 
2008). Since the ACL does no not calcify (Arnoczky 1983), it could be the significant 
increase of fibromodulin in the Staffordshire bull terrier CCL indicate that It develops 
more sites of fibrocartilage secondary to compression, as it might be that 
fibromodulin functions to regulate fibrocartilaginous cells differentiation, as 
fibromodulin has been previously shown to regulate the differentiation of 
chondrocytes (Embree, Kilts et al. 2010). However, fibromodulin gene expression 
levels have been found to increase in human patellar tendinopathy (Samiric, 
Parkinson et al. 2009), and this could indicate that fibromodulin also contributes to 
CCLD/ R in the Staffordshire bull terrier. We have found that chondroitin-6 sulphate 
stubs were significantly higher in the Staffordshire bull terrier compared to 
greyhound CCLs. It is known that chondroitin-6 sulphate content increases 
compared to chondroitin-4 sulphate in areas associated with compressive loading in 
tendon (Evanko and Vogel et al. 1993). We have previously concluded that 
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Staffordshire bull terriers may exhibit more areas of compressive loading, and this 
could also be a similar reason for the increase of chondroitin-6 sulphate. ADAMTS4 
gene expression was shown to be significantly upregulated in greyhound compared 
to Staffordshire bull terrier CCLs. Evidence of increased catabolism in greyhounds 
CCLs associated with high expression of ADAMTS4 could be linked to increased 
expression and content of certain proteoglycans, such as decorin. The significant 
increase of decorin gene expression could be related to increased ADAMTS4 
activity since we have detected a catabolic fragment below the decorin core protein 
at 30 kDa (Figure 3-7 B). The significant increase of ADAMTS4 in greyhound CCLs 
could be required to degrade high anabolic rate of decorin that maintains the normal 
CCL metabolism, as the greyhound is an athletic and exercising dog breed that 
rarely ruptures its CCL. 
3.6 Conclusions 
Western blot analysis showed significant differences in certain proteoglycans of the 
Staffordshire bull terrier CCL anatomical regions. Versican and keratocan were 
significantly highest in the middle region, and the high molecular weight bands 
detected by the anti-chondroitin-4 sulphate stub antibody were found to be 
significantly higher in middle and insertion anatomical region compared to its origin. 
These results may indicate that versican, keratocan, and chondroitin-4 sulphate 
high molecular stubs serve the CCL at specific anatomical regions that are 
subjected to compressive loads. The gene expression of aggrecan content and 
Western blot analysis of chondroitin-6 sulphate was shown to be increased in 
Staffordshire bull terrier CCLs compared to those of the greyhounds, and could be 
due to increased areas of fibrocartilage as a result of compression in the CCLs of 
the Staffordshire bull terrier. The significant increase of fibromodulin by RT-PCR 
and Western blot analysis in the Staffordshire bull terrier CCLs could further confirm 
that the CCLs from this dog breed develop more fibrocartilaginous areas as a result 
of compressive loads, as it may have a role in controlling the differentiation process 
of fibrocartilaginous cells. We suggest that the increase of aggrecan and 
fibromodulin in the Staffordhsire bull terrier CCL may compromise the normal CCL 
mechanical and structural properties, and therefore leading to CCLD/ R. The 
significant increase of decorin shown by Western blot and RT-PCR in the 
greyhound CCL could be vital for its collagen fibril maintenance, orientation, and 
strength. Furthermore, the significant increase in ADAMTS-4 gene expression in the 
exercising, low risk greyhound CCLs indicates that these ligaments may have a 
higher rate of catabolism in order to maintain their normal function. 
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Chapter 4: Evaluating regional and breed 
differences in the glycosaminoglycan 
content of the canine cranial cruciate 
ligament. 
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4.1       Introduction  
Glycosaminoglycans (GAGs) are complex carbohydrate structures (Hardingham 
and Fosang 1992). There are seven major GAGs present in connective tissues; 
hyaluronic acid, chondroitin-6 sulphate, chondroitin-4 sulphate, dermatan sulphate, 
keratan sulphate, heparin, and heparan sulphate (Hardingham 1981).  
GAGs are repeating disaccharide units that contain sulphated hexosamine and 
hexuronic acid, with the exception of keratan sulphate, as it does not contain uronic 
acid (Hardingham and Fosang 1992). Hyaluronic acid is the only GAG that does not 
have a sulphate group on its disaccharide and, unlike other GAGs, it does not 
attach covalently to a proteoglycan core protein (Ajit Varki 2009). In addition, 
hyaluronic acid is not further epimerised from glucuronic acid to iduronic acid (Ajit 
Varki 2009). Sulphated glycosaminoglycans (sGAGs) have been reported to 
comprise of 0.081 % (Smith, Clegg et al. 2014) and 2% (Kharaz 2015) of the canine 
cranial cruciate ligament (CCL) dry weight. 
Tendons and ligaments that pass through or wrap around bony structures are 
subjected to compression and tensile forces depending on their mechanical 
demands (See Chapter 1 - Section 1.1.4). Increase in alcian blue staining, which is 
a stain specific to sGAGs, has been demonstrated in compressed regions of where 
tendon and ligament become fibrocartilaginous (Feitosa, Reis et al. 2006). 
Chondroitin -6 sulphate content was found to increase compared to chondroitin -4 
sulphate in tendon under cyclic compressive loading in vitro (Evanko and Vogel 
1993).  
In the dog, narrowing of the distal femoral intercondylar notch is thought to cause 
compression and impingement of the CCL, thus creating a CCL impingement 
region, and narrowing of the intercondylar notch has been found to occur in the 
Labrador retriever (a high risk dog breed to CCLD/ R) (Comerford, Tarlton et al. 
2006a) (See Chapter 1 – Section 1.4.6.3). sGAGs levels were found to increase 
significantly in the CCL impingement region of the high risk Labrador retriever 
compared to those of the greyhounds (low risk to CCLD/ R), suggesting that sGAGs 
may have increased in the high risk Labrador retriever as a result of the CCL 
compressing against the intercondylar notch (Comerford, Tarlton et al. 2006a).  
It has been demonstrated in tendon (Feitosa, Reis et al. 2006) and in Chapter 3 of 
this thesis that GAGs may differ between the anatomical regions of tendon and 
ligament. In addition, previous studies on these tissues have shown that the GAG 
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content is increased in pathological tendons and ligaments (Riley, Harral et al. 
1994a; Comerford, Innes et al. 2004; Halper, Kim et al. 2006; Fu, Chan et al. 2007; 
Samiric, Parkinson et al. 2009). Therefore, we hypothesis that GAGs may differ 
between the anatomical regions of the CCL and between two dog breeds with a 
differing predisposition to CCLD/ R. 
The aim of this work is to determine the GAG and water content in different regions 
of the CCL in two differentially predisposed dog breeds to CCLD/ R, and to further 
observe whether if there are any significant differences of GAGs and water content 
between these differentially predisposed dog breeds. The GAGs to be characterised 
for this chapter include sGAGs, uronic acid, hyaluronic acid, keratan sulphate, and 
sGAGs after chondroitinase ABC (eliminates chondroitin and dermatan sulphate) 
digestion. 
For this study, we have selected the Staffordshire bull terriers (moderate-high risk) 
and greyhounds (low risk) to CCLD/ R, in order to compare the individual GAGs and 
water content between them and within their anatomical regions. 
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4.2       Materials and methods 
 
4.2.1 Canine sample collection 
Staffordshire bull terrier CCLs (n=5) were divided into origin, middle, and insertion 
anatomical regions. Archived CCLs from ex-racing greyhounds (n=5) had been 
previously sectioned from the origin and insertion anatomical regions. These 
samples were obtained with ethical permission and full owner consent where 
appropriate (See Chapter 2 – Section 2.1.1 and 2.1.2). Inclusion/ exclusion criteria 
for samples are described in Chapter 2; Tables 2-1 and 2-2. Samples were stored at 
-20°C until required.  
 
4.2.2 Biochemical analysis 
Water content  
CCL samples were thawed at room temperature and the wet weight was then 
measured. This was followed by freeze drying the CCL samples over night in order 
to measure the dry weight and to calculate the CCL water content. The water 
content % of the CCL was calculated using the following equation; 
Water content % = ([wet weight – dry weight] / wet weight) x 100 
sGAGs 
The content of sGAGs was measured using the DMMB assay (Farndale, Buttle et 
al. 1986), either with or without enzymatic digestion using Chondroitinase ABC 
enzyme, as ChABC is used to remove chondroitin and dermatan sulphate GAG 
chains (Yamagata, Saito et al. 1968). Shark chondroitin sulphate (Sigma, UK) was 
used as the standard (See Chapter 2 - Section 2.3.2). 
 
Uronic acid assay 
Uronic acid concentration or content was determined using the carbazole assay 
(Bitter and Muir 1962). Glucuronic acid lactone was used as the standard (See 
Chapter 2 - Section 2.3.3). 
 
Hyaluronic acid 
The concentration of hyaluronic acid (HA) in the tissue was indirectly estimated by 
assuming that UA comprised 36 % of the dry weight of GAGs and 45 % of the dry 
weight of HA, as presented in the following equation (Riley, Harrall et al. 1994); 
 
[HA] = [UA] - ([Total sGAG] x 0.36)  
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 0.45 
 
Keratan sulphate 
Keratan sulphate content was measured using the competitive enzyme linked 
immunosorbent assay (ELISA) methodology obtained from Caterson and others 
(Caterson, Cristner et al. 1983). Bovine articular cartilage aggrecan was used as the 
standard (See Chapter 2 - Section 2.3.4). 
 
4.3       Statistical  analysis  
Data were tested for normality by using the Kolmogorov-Smirnov test. If distributed 
normally, a student t-test was performed to detect differences between two groups, 
and a One-Way ANOVA to compare three groups followed by a Bonferroni post hoc 
test. If data did not have a normal distribution, a Mann Whitney U test was selected 
for detecting differences between two groups, or a Kruskal-Wallis test for three 
groups followed by a Dunn’s post hoc test.  Results are presented as mean values ± 
SEM and a significance level of p <0.05 was used. The three groups selected for 
analysis were anatomical regions (origin, middle, and insertion) for the Staffordshire 
bull terrier CCL, whilst the two groups selected for analysis were either the 
anatomical regions (origin and insertion)  of the greyhoud CCL or the two dog 
breeds (Staffordshire bull terrier and greyhound). There were two unpaired goups 
chosen for analysis, as the first group was  Staffordshire bull terrier CCL vs. 
greyhound CCL after the mean value of the origin and insertion anatomical regions 
of the two dog breeds were averaged, and the second group was greyhound CCL 
origin anatomical region vs. greyhound CCL insertion anatomical region. Graphpad 
Prism (Version 6, GraphPad Software, La Jolla California, USA) software was used 
for statistical analysis of all data. 
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4.4       Results  
 
4.4.1 Canine CCL data summary 
The history of canine cadavers was recorded which consisted of the dog breed, 
age, bodyweight and gender where applicable. 
Table 4-1: Summary of the age, bodyweight and gender of canine cadaveric cranial 
cruciate ligament (CCLs) samples selected for biochemical analysis.  
(SBT= Staffordshire bull terrier; GH= greyhound; N/ A= not available) 
Breed Ligament Age Weight (Mean ± SEM) Male Female 
SBT N=10 2-5 years 20 ± 1.7 kg 4 1 
GH N=10 3-5 years N/ A N/ A N/ A 
 
4.4.2 Water and GAGs content 
4.4.2.1     Water content  
Staffordshire bull terrier (SBT): Water content % ranged from 67 to 73 %, (average 
70 ± 1.0 %). There were no statistically significant differences between regions 
(origin, middle, insertion) of the SBT CCLs (p=0.39) (Figure 4-1). 
Greyhound (GH): Water content % ranged from 61 to 68 %, (average 64 ± 1.2 %). 
There were no statistically significant differences between regions (origin vs. 
insertion) of the GH CCLs (p=0.2) (Figure 4-1). 
Staffordshire bull terrier vs. greyhound: Staffordshire bull terrier CCLs had a 
significantly higher water content % than greyhound CCLs after the values from the 
origin and insertion regions were averaged between the two dog breeds (p=0.002) 
(Figure 4-2). 
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Figure 4-1: Water content % in the different anatomical regions of the moderate-high 
risk Staffordshire bull terrier and low risk greyhound CCLs. 
CCL= cranial cruciate ligament, n= 5. 
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Figure 4-2: Water content % in the moderate-high risk Staffordshire bull terrier 
and low risk greyhound CCLs. 
Staffordshire bull terrier CCLs contained significantly higher WC % when compared to 
greyhound CCL (p=0.002). CCL= cranial cruciate ligament; SBT= Staffordshire bull 
terrier; GH = greyhound, n= 5. 
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4.4.2.2     Uronic acid 
Staffordshire bull terrier: Uronic acid content as a percentage of dry weight ranged 
from 1.3 to 4 %, (average 2.3 ± 0.5 %). There were no statistically significant 
differences between regions (origin, middle, and insertion) of the SBT CCLs 
(p=0.63) (Figure 4-3). 
Greyhound: Uronic acid as a percentage of dry weight ranged from 1.1 to 1.7 %, 
(average 1.4 ± 0.1 %). There were no statistically significant differences between 
regions (origin vs. insertion) of the GH CCLs (p=0.42) (Figure 4-4). 
Staffordshire bull terrier vs. greyhound: There were no statistically significant 
differences in uronic acid % between Staffordshire bull terrier and greyhound CCLs 
after the values from the origin and insertion regions were averaged between the 
two dog breeds (p=0.13). 
 
4.4.2.3     Hyaluronic acid  
Staffordshire bull terrier: Hyaluronic acid content as a percentage of dry weight 
ranged from 1.1 to 7.7 %, (average 3.8 ± 1.4 %). There were no statistically 
significant differences in hyaluronic acid content between regions (origin, middle, 
and insertion) of the SBT CCLs (p=0.6) (Figure 4-3). 
Greyhound: Hyaluronic acid as a percentage of dry weight ranged from 0.9 to 2.6 
%, (average 1.7 ± 0.3 %). There were no statistically significant differences between 
regions (origin vs. insertion) of the GH CCL (p=0.31) (Figure 4-4). 
Staffordshire bull terrier vs. greyhound: There were no statistically significant 
differences in hyaluronic acid % between Staffordshire bull terrier and greyhound 
CCLs after the values from the origin and insertion regions were averaged between 
the two dog breeds (p=0.23). 
 
4.4.2.4     sGAGs 
Staffordshire bull terrier: sGAG content as a percentage of dry weight ranged from 
1.3 to 2.2 %, (average 1.9 ± 0.2 %). There were no statistically significant 
differences between regions (origin, middle, and insertion) of the SBT CCLs 
(p=0.27) (Figure 4-3). 
Greyhound: sGAG content as a percentage of dry weight ranged from 1.3 to 2.1 %, 
(average 1.7 ± 0.2 %). There were no statistically significant differences between 
regions (origin vs. insertion) of the GH CCL (p=0.016) (Figure 4-4). 
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Staffordshire bull terrier vs. greyhound: There were no statistically significant 
differences in sGAG % between Staffordshire bull terrier and greyhound CCLs after 
the values from the origin and insertion regions were averaged between the two dog 
breeds (p=0.19). 
 
4.4.2.5     sGAGs after Chondroitinase ABC (ChABC) 
Staffordshire bull terrier: sGAGs after ChABC content as a percentage of dry weight 
ranged from 1.4 to 1.5 %, (average 1.4 ± 0.03 %). There were no statistically 
significant differences between regions (origin, middle, and insertion) of the SBT 
CCL (p=0.78) (Figure 4-3). 
Greyhound: sGAGs after ChABC content as a percentage of dry weight ranged from 
0.5 to 1 %, (average 0.7 ± 0.1 %) there were no statistically significant differences 
between regions (origin vs. insertion) of the GH CCL (p=0.57) (Figure 4-4). 
Staffordshire bull terrier vs. greyhound: Staffordshire bull terrier CCLs had a 
significantly higher sGAGs % after ChABC digestion than greyhound CCLs after the 
values from the origin and insertion regions were averaged between the two dog 
breeds (p= 0.0003) (Figure 4-5). 
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4.4.2.6     Keratan sulphate  
Staffordshire bull terrier: Keratan sulphate content as a percentage of dry weight 
ranged from 0.5 to 0.9 %, (average 0.7 ± 0.06 %). There were no statistically 
significant differences between regions (origin, middle, and insertion) of the SBT 
CCLs (p=0.3) (Figure 4-3). 
Greyhound: Keratan sulphate content as a percentage of dry weight ranged from 
1.2 to 0.3 %, (average 0.6 ± 0.1 %). There were no statistically significant 
differences between regions (origin vs. insertion) of the GH CCLs (p=0.3) (Figure 4-
4). 
Staffordshire bull terrier vs. greyhound: There were no statistically significant 
differences in keratan sulphate % between Staffordshire bull terriers and 
greyhounds CCLs after the values from the origin and insertion regions were 
averaged between the two dog breeds (p=0.34). 
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Figure 4-3: GAG content in the origin, middle, and insertion anatomical regions of the 
moderate-high risk Staffordshire bull terrier CCLs (% dry weight). 
UA= uronic acid; HA= hyaluronic acid; sGAG= sulphated glycosaminoglycans; ChABC= 
Chondroitinase ABC; KS= keratan sulphate, n= 5. 
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Figure 4-4: GAG content in the origin and insertion anatomical regions of the 
low risk greyhound CCLs (% dry weight). 
UA= uronic acid; HA= hyaluronic acid; sGAG= sulphated glycosaminoglycans; 
ChABC= Chondroitinase ABC; KS = keratan sulphate, n= 5. 
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Figure 4-5: sGAGs % of dry weight after ChABC digestion between the 
moderate-high Staffordshire bull terrier and low risk greyhound CCLs. 
Staffordshire bull terrier CCL contained significantly higher sGAGs after ChABC when 
compared to greyhound CCL (p= 0.0003). CCL= cranial cruciate ligament; SBT= 
Staffordshire bull terrier; GH= greyhound; sGAG= sulphated glycosaminoglycans; 
ChABC= chondroitinase ABC, n=5.
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Table 4-2: Water and GAG content % within different anatomical regions of the Staffordshire bull terrier CCLs.  
All GAG values in the CCLs were calculated as μg/ mg dry weight of tissue and then converted to a percentage. Values are  displayed as mean ± 
SEM, n= 5. 
 
Water content & GAGs 
 
CCL origin 
 
CCL middle 
 
CCL insertion 
Water content 71.3 ± 0.9 70.1 ± 1.0 69.1 ± 1.3 
Uronic acid  2.5 ± 0.6 2.7 ± 0.7 1.9 ± 0.5 
Hyaluronic acid 3.9 ± 1.4 4.7 ± 1.6 2.7 ± 1.2 
sGAGs 2.1 ± 0.2 1.6 ± 0.2 1.9 ± 0.1 
sGAG after ChABC 1.6 ± 0.2 1.4 ± 0.2 1.4 ± 0.1 
Keratan sulphate 0.9 ± 0.2 0.6 ± 0.1 0.7 ± 0.1 
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          Table 4-3: Water and GAG content %  in different  anatomical regions of the greyhound CCLs.  
All GAG values in the CCLs were calculated as μg/ mg dry weight of tissue and then converted to a percentage. Values are displayed as 
mean ± SEM, n= 5. 
       
            Water content & GAGs 
 
    CCL origin 
  
 CCl insertion 
 Water content 61.7 ± 1.95 65.4 ± 1.8 
Uronic acid 1.4 ± 0.3 1.3 ± 0.3 
 Hyaluronic acid 2.1 ± 0.5 1.3 ± 0.6 
sGAGs 1.3 ± 0.2 2.0 ± 0.2 
sGAG after ChABC 0.7 ± 0.1 0.8 ± 0.1 
Keratan sulphate 0.5 ± 0.1 0.7 ± 0.2 
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4.5       Discussion       
Determination of the levels of individual GAGs and water content in different 
anatomical regions of the canine CCL and between differentially predisposed dog 
breeds to CCLD/ R may help in understanding on how these GAGs may contribute 
to ligament structure and function. We have found differences in GAGs in the CCLs 
between the two dog breeds, but no significant differences in GAGs were found 
between the different anatomical regions of the Staffordshire bull terrier and 
greyhound CCLs. Significantly greater water content was found in the Staffordshire 
bull terrier compared to greyhound CCLs. Furthermore, sGAGs content after 
ChABC enzymatic digestion was significantly decreased in greyhound CCLs 
compared to those of the Staffordshire bull terrier.  
The ligament is known to be composed of two thirds water and one thirds solids 
(Frank 2004; Rumian, Wallace et al. 2007). We have determined the water content 
of the CCLs of the Staffordshire bull terrier and greyhound to be 70% and 64 % 
respectively. Our water content values are in agreement with previous studies 
(Smith 2010; Kharaz 2015). In addition, the water content has shown to be 
significantly increased in Staffordshire bull terrier CCLs in comparison to greyhound 
CCLs (p=0.002).  
The increased water content in Staffordshire bull terrier CCLs could indicate a high 
deposition of GAGs and proteoglycans that function to retain water in ligament. It 
has been previously indicated that sGAG removal with ChABC increased water 
permeability and decreased compressive stress in porcine medial collateral 
ligament (Henninger, Underwood et al. 2010). Aggrecan is a large aggregating 
proteoglycan that is known to retain water in order to provide resilience, space filling 
capacities, and hydration for the tissue (Hardingham and Bayliss 1990). An 
aggrecan monomer consists of approximately 100 chondroitin sulphate and 50 
keratan sulphate chains, with the addition of O- and N- linked oligosaccharides 
(Hardingham and Bayliss 1990). The Staffordshire bull terrier CCL has been 
previously shown to have significantly higher aggrecan gene expression in 
comparison to greyhounds (See Chapter 3), and we speculate that Staffordshire bull 
terrier CCL withstands higher compressive forces or forces that are changing the 
CCL structure to become more compressive than the greyhound CCLs. It could be 
that the higher water content in Staffordshire bull terrier CCL is linked with higher 
compressive forces. However, increased water content in Staffordshire bull terrier 
CCLs could also contribute to increase compressive loading of the CCL, thus 
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leading to CCLD/ R. This indicates that a pathological outcome may exist in the 
Staffordshire bull terrier, as no evident of pathology in the Staffordshire bull terrier 
has been previously reported. Comerford and others have shown that the water 
content significantly increased in ruptured CCLs compared to intact CCLs 
(Comerford, Innes 2004). In addition, increased water content and large aggregating 
proteoglycans in pathological tendons has been previously reported (Riley, Harrall 
et al. 1994b; Samiric, Parkinson et al. 2009).  
The hyaluronic acid disaccharide consists of glucuronic acid and N-acetyl 
glucosamine, and is known to be the only GAG that does not contain sulphate 
groups (Hardingham and Fosang 1992). It is known to attach non-covalently to the 
large aggregating proteoglycans (Ajit Varki 2009).  
In this part of study, hyaluronic acid averaged 3.4 % of the CCL dry weight in 
Staffordshire bull terriers and 1.7 % of the CCL dry weight in greyhounds. Although 
Staffordshire bull terriers CCLs had a higher mean content of hyaluronic acid than 
greyhound CCLs, statistical analysis did not show any significant differences 
between the breeds. The reason could be the high variability of hyaluronic acid 
observed in Staffordshire bull terrier donors (1.1-7.7 %). Hyaluronic acid has been 
previously determined in human supraspinatus tendon (0.9 % of tendon dry weight) 
and common biceps tendon (1.1 % of tendon dry weight) (Riley, Harrall et al. 
1994a). Hyaluronan could have a role in maintaining the viscosity and viscoelastic 
properties of the CCL, as it has been previously reported to function similarly in the 
eye and skeletal joints (Ajit Varki 2009). The high content of hyaluronic acid in ex-
racing greyhounds could be essential in order to strengthen their CCL, as increased 
levels of hyaluronic acid have been found in exercised chicken gastrocnemius 
tendon (Hae Yoon, Brooks et al. 2003). However, the high content of this non-
sulphated GAG could also contribute to CCLD/ R in the Staffordshire bull terrier, as 
hyaluronic acid content was found to increase in human pathological supraspinatus 
tendon (Riley, Harrall et al. 1994a). 
Uronic acid is known to be present in all GAGs with the exception of keratan 
sulphate, whereas sGAGs are present in all GAGs with the exception of hyluronic 
acid (Hardingham and Fosang 1992). The uronic acid and sGAG contents in the 
CCL were 2.3 and 1.9 % for Staffordshire bull terriers, as well as 1.4 and 1.7 % for 
greyhounds. There were no statistically significant differences of uronic acid levels 
between the Staffordshire bull terrier and greyhound CCL. Comerford and others 
also reported that there were no statistical significant differences of uronic acid 
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levels between the Labrador retriever (high risk dog breed to CCLD/ R) and 
greyhound (low risk dog breeds to CCLD/ R) CCLs (Comerford, Tarlton et al. 2005).  
The sGAG content was previously determined in the Staffordshire bull terrier CCL 
and was found to be 1.5% of the CCL dry weight (Kharaz 2015), which was close to 
our reported value of 1.9 % of the CCL dry weight. However, the sGAG value for 
greyhound CCLs in our study was slightly higher (1.4 % of the CCL dry weight) than 
what has been previously reported (0.081 % of the CCL dry weight) in greyhound 
CCLs (Smith, Clegg et al. 2014), and this could be due to the different exercise 
regime history between the two groups of greyhound donors.  
There were no statistically significant differences between different anatomical 
regions of Staffordshire bull terrier and greyhound in regards to sGAG content, and 
this agrees with other unpublished studies that attempted to detect regional 
differences in sGAG content between the canine CCL anatomical regions (Kharaz 
2015). Since sGAG content has been previously found to be significantly elevated in 
the fibrocartilaginous anatomical regions of the porcine superficial and deep digital 
flexor tendon (Fietosa, Ries et al. 2006), we anticipated to detect an increase of 
sGAG in the middle anatomical region, which has been found to mainly consist of 
fibrocartilaginous areas (Paatsama 1952; Vasseur, Pool et al. 1985; Comerford, 
Tarlton et al. 2006b). In addition, fibrocartilaginous areas are also present at the site 
where the CCL inserts into bone (Arnoczky 1983; Zhu, Zhang et al. 2012). This 
could suggest that sGAGs are distributed abundantly across the CCL anatomical 
regions which might have caused the sGAGs to be statistically insignificant across 
the regions.  
The chondroitin sulphate disaccharide consists of N-acetylgalactosamine and 
glucuronic acid (Hardingham and fosang 1992; Ajit Varki 2009). Dermatan sulphate 
arises from the same precursor of chondroitin sulphate as it is generated via 
epimerization of glucuronic acid into iduronic acid (Hardingham and Muir 1974; 
Hascall and Heinegard 1974). Chondroitinase ABC is a degrading enzyme which 
acts to remove chondroitin sulphate (-4, and -6) and dermatan sulphate (Yamagata, 
Saito et al. 1968). This may indicate that other GAG chains remain after 
chondroitinase ABC such as keratan sulphate, heparin, and heparan sulphate. 
In this part of study, greyhound CCLs had significantly reduced sGAGs content in 
comparison to Staffordshire bull terrier CCLs following digestion with ChABC. This 
finding could indicate that there is a higher dermatan/ chondrotin sulphate content in 
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the greyhound in comparison to Staffordshire bull  terrier CCLs. This results also 
supports findings in Chapter 3, where gene expression of the chondrotin/ dermatan 
sulphate proteoglycan decorin was significantly upregulated in greyhounds in 
comparison to Staffordshire bull terrier CCLs.  In addition, greyhound CCLs have 
been known to be associated with large (>150) and intermediate (150-100) collagen 
fibril diameters (Comerford, Tarlton et al. 2006b). A previous study has concluded 
that dermatan sulphate is associated with larger collagen fibril diameter (>150 nm), 
while tissues with intermediate sized collagen fibrils have been found to be rich with 
chondroitin sulphate (60-150 nm) (Parry, Flint et al. 1982). However, it could be that 
greyhounds CCLs only contain higher amounts of dermatan sulphate than 
Staffordshire bull terrier CCLs and not chondroitin sulphate. Since we have found in 
Chapter 3 that chondroitin-6 sulphate and the large chondroitin/ keratan sulphate 
proteoglycan, aggrecan, were both significantly increased in the Staffordshire bull 
terrier in relation to greyhound CCLs.  
Keratan sulphate is composed of disaccharide repeats of N-acetyl glucosamine and 
galactose (Hardingham and Muir 1974; Hascall and Heinegard 1974). Keratan 
sulphate content was low in the CCL, at 0.7 % of the CCL dry weight in the 
Staffordshire bull terriers and 0.6 % of the CCL dry weight in greyhounds CCLs 
indicating that keratan sulphate may be the GAG at lowest concentration in the 
CCLs. The keratan sulphate content has also been previously determined to be low 
in human supraspinatus (0.04 % of the tendon dry weight) and common biceps 
tendon (0.004 % of the tendon dry weight) (Riley, Harrall et al. 1994a).  
A limitation of this study is that we were unable to determine the individual content 
of chondroitin sulphate and dermatan sulphate. However, these two individual 
GAGs have been previously determined (Reily, Harrall et al. 1994a). The procedure 
involves digesting samples with chondroitinase ABC and chondroitinase AC 
(removes only dermatan sulphate) in order to calculate chondroitin sulphate and 
dermatan sulphate content (Reily, Harrall et al. 1994a). We have made an attempt 
to detect chondroitin and dermatan sulphate content individually by following this 
method, however, the results of most of our data appeared as negative values. 
Individual contents of chondrotitn sulphate and dermatan sulphate therefore still 
needs to be investigated in the canine CCL.  
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4.6       Conclusion  
 The significant increase of water content in Staffordshire bull terrier CCL 
could be linked to increase areas of compressive loads in the CCLs, and may 
further contribute to CCLD/ R in this moderate-high risk dog breeds.  
 sGAG content after ChABC enzymatic digestion was found to be 
significantly reduced in greyhound CCLs compared to those of the Staffordshire bull 
terriers, which might indicate higher levels of chondroitin/ dermatan sulphate 
proteoglycans such as decorin in the greyhound. 
 Hyaluronic acid content may be essential in order to maintain the 
viscoelastic properties and strength of the racing greyhound CCLs. However, it may 
also be a contributing factor to CCLD/ R in the Staffordshire bull terrier.  
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Chapter 5: The structural morphology 
and proteoglycan distribution in 
different regions of the canine cranial 
cruciate ligament and between dog 
breeds at a differing risk to CCL 
disease and rupture.  
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5.1      Introduction 
The microscopic hierarchical structure of ligament has been reported to be similar to 
that described in tendons consisting of collagen fibre bundles, fibres, subfibrils, 
microfibrils, and tropocollagen (See Chapter 1 – Figure 1-1) (Kastelic, Galeski et al. 
1978).   
In ligament, collagen fibre bundles are divided by cells (Amiel, Frank et al. 1984; 
Clark and Sidles 1990), and bundles are grouped into interdigitating membranes 
named fascicles (Clark and Sidles 1990). Fascicles are separated by septa (Clark 
and Sidles 1990). The septa separating the fascicles are referred as endoligament 
(Chowdhury, Matyas et al. 1991).  
Decorin, lumican and fibromodulin are members of the small leucine rich 
proteoglycan (SLRPs) that bind to collagen fibrils and organise collagen 
fibrillogenesis (Scott 1996). Aggrecan and versican are known as the large 
aggregating proteoglycans (Iozzo and Murdoch 1996; Iozzo and Schaefer 2015). 
Aggrecan allows tendon the capacity to withstand compressive forces associated 
with loading (Vogel and Koob 1989; Evanko and Vogel 1993; Huisman, Andersson 
et al. 2014), whereas versican regulates cell migration and adhesion as well as 
contributing to the ECM structural properties (Dours-Zimmermann and Zimmermann 
1994; Isogai, Aspberg et al. 2002). 
The cranial cruciate ligament (CCL) and the caudal cruciate ligament (CaCL) form 
the cruciate ligament (CL) complex in the canine stifle joint (Arnoczky and Marshall 
1977). Macroscopically, the CCL consists of two bands; the craniomedial band 
(CMB) and the caudolateral band (CLB), and the CaCL consists of the large cranial 
band and the smaller caudal band (Arnoczky and Marshall 1977).  
Tendons and ligaments that pass through or wrap around bony structures are 
subjected to compression and tensile forces depending on their mechanical 
demands, and at these points tendon and ligament become fibrocartilage as a result 
of compression (See Chapter 1 - Section 1.1.5). Fibrocartilage can be histologically 
distinguished from non-fibrocartilaginous sites, as the collagen fibre bundles 
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orientation change from parallel into different angles running into one another, and 
the cell shape alters from spindle to rounded, exhibiting a similar phenotype to 
cartilage (Vogel 2004).  
A fibrocartilaginous appearance in disease free CCLs has been observed in 
Labrador retriever (high in risk to CCLD/ R) and greyhound (low in risk to CCLD/ R) 
CCLs that was associated with increased Alcian blue staining, a dye which stains 
glycosaminoglycans (GAGs) (Comerford, Tarlton et al. 2006b). It was suggested 
that the fibrocartilage appearance in racing greyhounds is an adaptation to altered 
loads but was considered as a degenerative sign in Labrador retrievers. Since this 
study was only descriptive, it could be that semi-objective histology scoring analysis 
may have shown differences in tissue morphology and GAG deposition between 
different anatomical regions of the CCL and between two differentially predisposed 
dog breeds to CCLD/ R. Similar degenerative changes have been observed in 
CCLs of young beagles bred for laboratory use, and have been suggested to be a 
result of lacking exercise (Narama, Masuoka-Nishiyama et al. 1996). 
It has been reported that dogs over 5 years of age with an increased bodyweight 
15> kg exhibited a reduction in the CCL mechanical properties, and were found to 
have histological signs of fibrocartilage considered to be degenerative changes that 
occurred prior CCLD/ R (Vasseur, Pool et al. 1985). In ruptured canine CCLs, areas 
of cell loss accompanied with alterations in cellular phenotype (fibrocartilage 
progression) have been observed mostly in the middle anatomical region of the CCL  
(Hayashi, Frank et al. 2003).  Loss of cells as a result of apoptosis or necrosis has 
also been observed in ruptured and partially ruptured CCLs (Hayashi, Frank et al. 
2003; Gyger, Botteron et al. 2007; Krayer, Rytz et al. 2008). Loss of cells and 
altered cell phenotype was found to be associated with a reduction of crimp pattern 
(the periodic wave of collagen fibrils) in ruptured CCLs (Hayashi, Frank et al. 2003). 
Such degenerative changes might be primarily associated with high risk dog breeds 
predisposed to CCLD/ R. 
Differences in proteoglycans localisation have been detected between different 
anatomical regions in tendons using Western blot analysis (See Chapter 3 - Section 
3.1). In addition, immunohistochemical studies have previously found that certain 
proteoglycans are specifically localised within particular anatomical regions (tendon 
vs. compression) (Waggett, Ralphs et al. 1998; Vogel and Peters 2005). Aggrecan 
and biglycan have been mainly found in fibrocartilaginous areas where tendon is 
subjected to compression, and versican was found to mainly localise in the central 
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region where tendon is subjected to tension (Waggett, Ralphs et al. 1998). Decorin, 
on the other hand, was found to have a similar distribution in both compressed/ 
fibrocartilage and tensional regions of tendon (Vogel and Peters 2005). These 
studies demonstrate that proteoglycans have a functional role in different 
anatomical sites of tendon, and therefore may differ between various anatomical 
regions of the canine CCL and between dog breeds with a different predisposition to 
CCLD/ R.  
Therefore, we aim to use semi-objective histology measurements in order to identify 
the CCL structure, morphological characteristics and sulphated glycosaminoglycan 
(sGAG) deposition between three dog breeds with a different predisposition to 
CCLD/ R, and to assess whether there are differences between their anatomical 
regions. We hypothesise that the structural morphology and sGAG deposition may 
be altered between these differentially predisposed dog breeds to CCLD/ R. 
Furthermore, we aim to perform immunohistochemistry to characterise the 
localisation and distribution of large aggregating proteoglycans and SLRPs between 
different anatomical regions of the CCL, and between different dog breeds with a 
different predisposition to CCLD/ R. We hypothesise that each proteoglycan may 
have a unique localisation and distribution throughout the CCL that may alter 
between dog breeds at different risks to CCLD/ R. We further hypothesis that 
proteoglycans may differ between different anatomical regions of the CCL. 
For histological assessment, we have examined CCLs between three dog breeds 
with a different predisposition to CCLD/ R, these are the racing greyhound (low 
risk), the Staffordshire bull terrier (moderate-high risk), and the Labrador retriever 
(high risk) (Whitehair, Vasseur et al. 1993; Duval, Budsberg et al. 1999; Baird, 
Carter et al. 2014b). For immunohistochemistry staining, we have examined CCLs 
from the racing greyhound and the Staffordshire bull terrier. 
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5.2       Materials and methods 
5.2.1 Canine sample collection 
For histological analysis, Staffordshire bull terrier CCLs (n=6) were divided into 
origin, middle, and insertion regions. Archived CCLs from ex-racing greyhounds 
(n=8) and Labrador retrievers (n=7) that had been previously sectioned from the 
craniomedial band (CMB) or the caudolateral band (CLB) were used. Sections 
available for CMB were n=7 for greyhounds, and n= 6 for Labrador retrievers, whilst 
for CLB were n=6 for greyhounds, and n=2 for Labrador retrievers. For 
immunohistochemistry, Staffordshire bull terrier CCLs (n=6) were divided into origin, 
middle, and insertion regions. Archived CCLs from ex-racing greyhounds (n=5) 
were previously sectioned from the craniomedial band (CMB). These samples were 
obtained with ethical permission and full owner consent where appropriate. 
Inclusion/exclusion criteria for samples are described in Chapter 2; Tables 2-1 and 
2-2. See Chapter 2 - Section 2.1.1 and 2.1.2 for detailed sample collection. 
 
5.2.2 Histology and immunohistochemistry  
Samples obtained from Staffordshire bull terriers were fixed in 4% 
paraformaldyhyde overnight at 4°C, then were processed and embedded in paraffin 
wax. Tissue blocks embedded in paraffin obtained from Labrador retrievers and 
greyhounds were previously archived materials. All tissue blocks were sectioned at 
4 µm and mounted onto poly lysine coated slides. Images were captured using a 
Nikon Eclipse 80i microscope. For histological assessment, haematoxylin and eosin 
stain (H&E) was used to detect CCL structural morphology, and sGAGs were 
assessed by using Alcian blue and Toluidine blue dyes. An objective scoring system 
was developed and assessed by two independent observers blinded to tissue 
sections. The scoring sheet can be seen in Chapter 2, Tables 2-7, and 2-8. 
For immunohistochemistry, staining was performed with the following antibodies; 
aggrecan, versican, decorin, biglycan, lumican, fibromodulin, and keratocan. For 
more details about the immunohistochemistry protocol, see Chapter 2 – Section 
2.5.2. 
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5.3       Statistical analysis  
For histological analysis, data were checked for the normality with using 
Kolmogorov-Smirnov test. If they were normally distributed, a student-t test was 
performed to detect differences between two groups, and a one-way ANOVA was 
used to compare three groups followed by a Bonferroni post hoc test. If data were 
not normally distributed, a Mann Whitney U test was selected for detecting 
differences between two groups, or a Kruskal-Wallis test for three groups followed 
by a Dunn’s post hoc test. We have compared the histology scoring between the 
different regions of the CCL for each in dog breed, and further compared anatomical 
regions between greyhound (low in risk to CCLD/ R) and Labrador retriever (high in 
risk to CCLD/ R) CCLs. We were not able to analyse the CLB region for Labrador 
retriever as we had only two donors.  Results are presented as mean values ± 
standard error of the mean (SEM). Exact p-values are presented and a significance 
level of p <0.05 was used. Immunohistological observations were asessed 
subjectively based on the intesity of staining (heavy vs. faint), distribution within the 
CCL structure (interfascicular region, collagen bundles, and ligament substance), 
and if they were localised around (pericellular) or within (intracellular) the cells. 
Graphpad Prism (Version 6, GraphPad Software, La Jolla California, USA) software 
was used for statistical analysis of all data. 
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5.4       Results  
 
5.4.1 Canine data summary 
The history of canine cadavers was recorded which consisted of the dog breed, 
age, bodyweight and gender where applicable.  
Table 5-1: Summary of the age, bodyweight and gender of canine cadaveric cranial 
cruciate ligament (CCL) samples selected for histology/ immunohistochemistry 
analysis.  
(SBT= Stafford shire bull terrier; GH= greyhound; LR= Labrador retriever; N/ A= not 
available). 
Breed Ligament Age Weight (Mean ± SEM) Male Female 
SBT N=12 2-5 years 18.2 ± 2.3 kg 4 1 
GH N=8 3-5 years N/ A N/ A N/ A 
LR N=7 3-5 years N/ A N/ A N/ A 
 
 
5.4.2 Histology 
5.4.2.1     Inter- and intra- observer agreement of the histology scoring system 
Kendal’s coefficient of concordance analysis was used to assess the strength of 
agreement between inter- and intra- observer for each histology scoring criteria. 
Kendal coefficient agreement values lie between a scale from 0 to 1, where 0.6 to 
0.9 indicates a good agreement, whilst > 0.9 indicates an excellent agreement. 
Kendall’s coefficient concordance resulted in an average of 0.77 and 0.69 for ob1 
and ob2 intra-observer variation, whereas the value between the two observers was 
0.77. Details for Inter- and intra- observer agreement calculations are provided in 
appendix IV. 
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5.4.2.2     Haematoxylin and Eosin (H&E) staining  
5.4.2.2.1 Collagen architecture 
Results showed that CCLs from each dog breed exhibited a mixture of normal, 
reduced and abnormal collagen architecture. Normal collagen architecture was 
found to have a regular crimp pattern. In addition, collagen bundles seemed to have 
a parallel (Figure 5-1 A) or a helical distribution. Reduced collagen architecture was 
accompanied with a homogenous appearance of collagen bundles with a slightly 
disorganised collagen matrix (Figure 5-1 B), whilst abnormal collagen architecture 
had a disruptive appearance of collagen bundles with areas of cell loss (Figure 5-1 
A). The scoring data chart for the three dog breeds can be observed in Figure 5-2 
(A, B). There were no statistically significant differences between anatomical 
regions of the CCL or between different dogs with a differing predisposition to 
CCLD/ R. 
 
Figure 5-1: Histology image of collagen architecture in the canine CCL. 
A) Normal structure of collagen from greyhound CCLs where primary collagen bundles are 
present (black arrow). B) Reduced structure of collagen bundles from Staffordshire bull 
terrier CCLs (white arrow). C) Abnormal structure of collagen from Labrador retriever CCLs 
where collagen bundles are disrupted in association with cell loss (Bar 100µm, H & E). 
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Figure 5-2: The collagen architecture scores in differentially predisposed dog breeds. 
Histology results for collagen architecture with H&E staining in different anatomical regions for Staffordshire bull terrier (A), greyhound (B), and 
Labrador retriever (B) CCLs. (SBT= Staffordshire bull terrier; GH= greyhound; LR= Labrador retriever). A) The Staffordshire bull terrier had the 
highest scoring for normal and reduced collagen architecture. B) The greyhound had most scoring for normal collagen architecture, whilst the 
Labrador retriever had most scoring for reduced collagen architecture. 
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5.4.2.2.2 Cell shape  
In general, the CCLs from all dog breeds exhibited a mixture of cell nuclei shapes, 
ranging from spindle (Figure 5-3, A), mixed (spindle and rounded) (Figure 5-3, B), 
and rounded with halo formation (manifestation of cell border with cytoplasmic 
enlargement) (Figure 5-3, C). The scoring data chart for the three dog breeds can 
be observed in Figure 5-4 (A, B). There were no statistically significant differences 
found between anatomical regions of the CCL or between different dogs with a 
differing predisposition to CCLD/ R. 
 
Figure 5-3: Histology image of cell nuclei shapes in the canine CCL. 
A) Spindle shape (black arrow) from greyhound CCLs. B) Spindle (black arrow) and rounded 
(white arrow) shapes from Staffordshire bull terrier CCLs. C) Rounded shape (white arrow) 
from greyhound CCLs (Bar 100µm, H & E).
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Figure 5-4: The cell shape scores in differentially predisposed dog breeds. 
Histology results for cell shape with H&E staining in different anatomical regions in Staffordshire bull terrier (A), greyhound (B), and Labrador 
retriever (B) CCLs. (SBT= Staffordshire bull terrier; GH= greyhound; LR= Labrador retriever). 
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5.4.2.2.3 Cellular distribution 
The CCL exhibited different cellular distributions. Cells that were located at the 
surface of collagen bundles had a normal distribution (Figure 5-5, A), whereas cells 
associated with a homogenous collagen structure (loss of collagen bundles) had an 
orientation similar to rows of chains (Figure 5-5, B). The scoring data chart for the 
three dog breeds can be observed in Figure 5-6 (A, B). There were no statistically 
significant differences between anatomical regions of the CCL or between different 
dogs with a differing predisposition to CCLD/ R. 
 
Figure 5-5: Histology image of cell distribution in the canine CCL. 
A) Normally distributed cells located on the surface of collagen bundles. Image obtained 
from greyhound CCLs. B) Cell chain formation associated with a homogenous collagen 
structure. Image obtained from Staffordshire bull terrier CCLs (Bar 100µm, H & E). 
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Figure 5-6: The cell distribution scores in differentially predisposed dog breeds. 
Histology results for cell distribution with H&E staining in different anatomical regions in Staffordshire bull terrier (A), greyhound (B) and Labrador retriever (B) 
CCLs. (SBT= Staffordshire bull terrier; GH= greyhound; LR= Labrador retriever).  All dog breeds exhibit both normal distribution of cells and cell chains.  
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5.4.2.2.4 Vascularisation and inflammation 
The blood vessels in the CCL were monitered by size and quantity. The CCLs from 
all dog breeds exhibited mostly a low number and small sized blood vessels, and 
had a normal appearance (not dilated). Blood vessels were mostly observed in the 
interfascicular region of the CCL (Figure 5-7 A, B). The presence of inflammation in 
the tissues was scored based on the location of inflammatory cells such as 
neutrophils (granules in the cytoplasm and nucleus has 2-5 lobes), lymphocytes 
(rounded cytoplasm and nucleus that are slightly larger than ligementocytes) and 
macrophages (large cytoplasm and nucleus). Overall, there were little or no 
inflammatory cells in the CCLs from all dog breeds. The scoring data chart for the 
three dog breeds can be observed in Figure 5-8 (A, B). There were no statistically 
significant differences between anatomical regions of the CCL or between different 
dogs with a differing predisposition to CCLD/ R. 
 
Figure 5-7: Histology image of the blood vessel in the canine CCL. 
A) Blood vessels in the interfascicular region (black arrow) (Bar 100µm, H & E). B) A higher 
magnification of blood vessels in the interfascicular region (Bar 100µm, H & E). Image 
obtained from greyhound CCLs. 
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Figure 5-8: The vascularisation and inflammation scores in differentially predisposed dog breeds. 
Histology results for vascularisation and inflammation with H&E staining in different anatomical regions in Staffordshire bull terrier (A), greyhound 
(B), and Labrador retriever (B) CCLs. (SBT= Staffordshire bull terrier; GH= greyhound; LR= Labrador retriever).  
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5.4.2.3     Toluidine blue staining    
Toluidine blue is a thiazine metachromatic dye that stains sGAGs (Ball and Jackson 
1953; Sridharan and Shanker 2012). Metachromasia indicates a change in the color 
of staining in the tissue, as Toluidine blue stain changes from blue to purple or red 
depending on the glycosaminoglycan content (Ball and Jackson 1953). 
 
5.4.2.3.1 Overall staining 
Toluidine blue staining was observed in all CCL tissues. Toluidine blue had a faint 
or marked staining on the CCLs (Figure 5-9 A, B). The scoring data chart for the 
three dog breeds can be observed in Figure 5-10 (A, B). There were no statistically 
significant differences found between the CCL anatomical regions or between 
differentially predisposed dog breeds to CCLD/ R. 
 
Figure 5-9: The intensity of Toluidine blue staining in the canine CCL. 
A) Faint staining of collagen bundles (white arrow). Image obtained from greyhound CCLs. 
B) Marked staining of collagen bundles (white arrow) and interfascicular regions (black 
arrow). Image obtained from Staffordshire bull terrier CCLs (Bar 100µm). 
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Figure 5-10: Overall staining scores with Touidine blue in differentially predisposed dog breeds. 
Histology results for the overall staining with Toluidine blue in different anatomical regions in Staffordshire bull terrier (A), greyhound (B), and 
Labrador retriever (B) CCLs. (SBT= Staffordshire bull terrier; GH= greyhound; LR= Labrador retriever). All dog breeds had regions of both faint and 
heavy staining with Toluidine blue.  
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5.4.2.3.2 CCL structure 
Our observations showed that Toluidine blue staining in the CCLs of all dog breeds 
was deposited in collagen bundles, interfascicular region, and ligament substance 
(covering collagen bundle) in the CCL. Faint staining was associated with normal 
collagen structure and spindle shaped cells (Figure 5-11 A), whilst more intense 
staining was associated with regions of reduced collagen density with rounded 
shaped cells (Figure 5-11 B). The Staffordshire bull terrier CCLs had a significantly 
greater deposition of Toluidine blue in their ligament substance in the origin 
anatomical regional compared to the insertion anatomical region (p= 0.02). The 
scoring data chart for the three dog breeds can be observed in Figure 5-12 (A, B). 
 
Figure 5-11: Toluidine blue staining in the CCL structure. 
A) Faint staining of collagen bundles (white arrow), image obtained from greyhound CCLs. 
B) Marked staining of collagen bundles (white arrow) and interfascicular regions (black 
arrow). Image obtained from Staffordshire bull terrier CCLs (Bar 100µm). 
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Figure 5-12: The CCL structure scores for Toluidine blue staining in differentially predisposed dog breeds. 
Histology results for the CCL structure with Toluidine blue staining in different anatomical regions in Staffordshire bull terrier (A), greyhound (B), and 
Labrador retriever (B) CCLs. (SBT= Staffordshire bull terrier; GH= greyhound; LR= Labrador retriever).  Staffordshire bull terrier CCLs had a 
significantly higher deposition of Toluidine blue in its ligament substance in the origin anatomical regional compared to the insertion anatomical 
region (p= 0.02). All dog breeds had Toluidine blue staining in the interfascicular, interbundle, and ligament substance sites. 
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5.4.2.3.3 CCL cells  
Our observations showed that the CCLs from all dog breed demonstrated Toluidine 
blue staining around the cells (pericellular) and within the cell (intracellular). CCLs 
with rounded cells had the most pericellular and intracellular staining (Figure 5-13). 
Staffordshire bull terrier had significantly increased Toluidine blue staining within the 
cells of its origin region compared to its insertion region (p= 0.002). Althought 
Toluidine blue staining within the cells of the Labrador retriever craniomedial band 
appeared to be significantly higher than the greyhound craniomedial band, statistical 
analysis was not applicable due to the low number of the Labrador retriever 
biological replicates (n= 2). The scoring data chart for the three dog breeds can be 
observed in Figure 5-14 (A, B). 
 
Figure 5-13: Toluidine blue staining in the canine CCL cells. 
Toluidine blue staining is shown to be deposited around and within cells. Image obtained 
from greyhound CCLs (Bar 100µm).
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Figure 5-14: Scores for Toluidine blue staining in the CCL cells of differentially predisposed dog breeds. 
Histology results for the CCL cells with Toluidine blue staining in different anatomical regions in Staffordshire bull terrier (A), greyhound (B), and 
Labrador retriever (B) CCLs. (SBT= Staffordshire bull terrier; GH= greyhound; LR= Labrador retriever). Staffordshire bull terrier CCLs had 
significantly greater Toluidine blue staining within the cell of its origin anatomical region compared to its insertion region (p= 0.002). All dog breeds 
had Toluidine blue staining within and around the cells.  
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5.4.2.4     Alcian blue staining    
Alcian blue is a dye that has been reported to stain sGAGs at pH 2.5, and the blue 
colour is due to the existence of copper (Lin, Shuster et al. 1997). The significance 
of Alcian blue/ Eosin Y staining over Toluidine blue is that Eosin Y acts as a 
counterstain, which allows a clearer distinction of the sGAGs stained by Alcian blue. 
 
5.4.2.4.1 Overall staining  
Alcian blue staining was observed in all CCL tissues. Alcian blue had a faint or 
marked staining on the CCLs (Figure 5-15 A, B). Greyhounds had significantly 
higher marked staining for its craniomedial band compared to its caudolateral band 
(p=0.0006). The scoring data chart for the three dog breeds can be observed in 
Figure 5-16 (A, B). 
 
Figure 5-15: The intensity of Alcian blue staining in the canine CCL. 
A) Faint staining of collagen bundles (white arrow) and fascicular structure (black arrow). 
Image obtained from greyhound CCLs. B) Marked staining of collagen bundles (white arrow) 
and interfascicular regions (black arrow). Image obtained from Staffordshire bull terrier CCLs 
(Bar 100µm). 
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Figure 5-16: The overall staining of Alcian blue scores in differentially predisposed dog breeds. 
Histology results for overall staining with Alcian blue in different anatomical regions in Staffordshire bull terrier (A), greyhound (B), and Labrador 
retriever (B) CCLs. (SBT= Staffordshire bull terrier; GH= greyhound; LR= Labrador retriever). All dog breeds had both faint and heavy staining of 
Alcian blue. Greyhounds CCLs had a significantly higher marked staining for their craniomedial band compared to their caudolateral band 
(p=0.0006). 
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5.4.2.4.2 CCL structure 
Our observations showed that Alcian blue staining in the CCLs of all dog breeds 
was deposited in collagen bundles, interfascicular region, and ligament substance 
(covering collagen bundles) in the CCL. Faint staining was associated with normal 
collagen structure and spindle shaped cells (Figure 5-17 A), Whilst more intense 
staining was associated with regions of reduced collagen density with rounded 
shaped cells (Figure 5-17 B), The greyhounds had a significant increase in ligament 
substance staining in its craniomedial band anatomical region compared to its 
caudolateral band (p=0.0389). The scoring data chart for the three dog breeds can 
be observed in Figure 5-18 (A, B). 
 
Figure 5-17: Alcian blue staining in the canine CCL structure. 
A) Faint staining of collagen bundles (white arrow) and fascicular region (black arrow). 
Image obtained from Staffordshire bull terrier CCLs. B) Marked staining of collagen fibril 
bundles (white arrow) and interfascicular regions (black arrow). Image obtained from 
Staffordshire bull terrier CCLs (Bar 100µm). 
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Figure 5-18: The CCL structure scores for Alcian blue staining in differentially predisposed dog breeds. 
Histology results for the CCL structure with Alcian blue staining in different anatomical regions in Staffordshire bull terrier (A), greyhound (B), and 
Labrador retriever (B) CCLs. (SBT= Staffordshire bull terrier; GH= greyhound; LR= Labrador retriever).  Greyhounds CCLs had a significant 
increase in ligament substance staining in their craniomedial band anatomical regions compared to their caudolateral band (p=0.0389). 
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5.4.2.4.3 CCL cells 
Our observations showed that the CCLs from all dog breed had Alcian blue staining 
around the cells (pericellular) and within the cell (intracellular). CCLs with rounded 
cells had the most pericellular and intracellular staining (Figure 5-19). The scoring 
data chart for the three dog breeds can be observed in Figure 5-20 (A, B). There 
were no statistically significant differences between anatomical regions of the CCL 
or between different dogs with a differing predisposition to CCLD/ R. 
 
Figure 5-19: Alcian blue staining in the canine CCL cells. 
Alcian blue staining is shown to be deposited around and within cells. Image obtained from 
greyhound CCLs (Bar 100µm). 
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Figure 5-20: Alcian blue staining in the CCL cells in differentially predisposed dog breeds. 
Histology results for CCL cells with Alcian blue staining in different anatomical regions in Staffordshire bull terrier (A), greyhound (B), and Labrador 
retriever (B) CCLs. (SBT= Staffordshire bull terrier; GH= greyhound; LR= Labrador retriever). All dog breeds had Alcian blue staining within and 
around the cells. 
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Table 5-2: Histology scoring results for Staffordshire bull terrier.  
Results are displayed for H & E, Alcian blue, and Toluidine blue staining (mean ± SEM), n= 
6 for all anatomical regions. (H&E= Haematoxylin and Eosin; TB= Toluidine blue; AB= Alcian 
blue; SBT= Staffordshire bull terrier). * indicates a significant difference at p < 0.05. 
 
 
 
 
 
 
 
Stain  SBT origin SBT middle SBT insertion 
H & E Normal collagen architecture 2.25±0.25 2.33±0.08 2.50±0.08 
Reduced collagen architecture 2.42±0.08 2.29±0.13 2.33±0.00 
Abnormal collagen architecture 0.13±0.04 0.21±0.04 0.33±0.00 
Spindle cells 1.38±0.04 1.50±0.08 1.67±0.17 
Mixed cells 2.83±0.08 2.88±0.04 2.92±0.00 
Rounded cells 2.46±0.21 2.25±0.25 2.42±0.25 
Normal distribution of cells 2.50±0.08 2.88±0.13 2.79±0.04 
Formation of cell chains 1.92±0.00 2.04±0.04 1.58±0.17 
Hypovascularised 0.50±0.13 2.88±0.00 3.00±0.04 
Hypervascularised 2.96±0.04 0.63±0.04 1.29±0.08 
No inflammation 3.00±0.00 3.00±0.00 2.75±0.25 
Evidence of inflammatory cells 0.13±0.04 0.13±0.04 0.13±0.04 
TB Faint staining 2.13±0.04 2.25±0.08 2.13±0.13 
Heavy staining 2.58±0.08 2.38±0.13 2.21±0.21 
Interfascicular 2.54±0.21 2.46±0.21 2.04±0.13 
Interbundle 2.50±0.25 2.50±0.17 2.13±0.21 
Ligament substance* 1.92±0.25 2.04±0.46 1.50±0.33 
Around the cells 2.38±0.13 2.08±0.08 2.00±0.17 
Within the cells* 1.08±0.08 1.08±0.08 0.88±0.13 
AB Faint staining 1.75±0.17 1.96±0.21 1.83±0.17 
Heavy staining 2.79±0.04 2.67±0.17 2.54±0.13 
Interfascicular 2.79±0.04 2.67±0.00 2.58±0.08 
Interbundle 2.79±0.04 2.71±0.04 2.42±0.08 
Ligament substance 2.29±0.21 2.21±0.13 1.92±0.08 
Around the cells 2.50±0.33 2.54±0.37 2.29±0.54 
Within the cells 1.42±0.25 1.50±0.23 1.58±0.22 
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Table 5-3: Histology scoring results for greyhound and Labrador retriever.  
Results are displayed for H & E, Alcian blue, and Toluidine blue staining (mean ± SEM). The 
number of donors for each breed and anatomical region are; GH CMB (n= 7); GH CLB (n= 
6); LR CMB (n= 6); and LR CLB (n= 2). (H&E= Haematoxylin and Eosin; TB= Toluidine blue; 
AB= Alcian blue; GH= greyhound; LR= Labrador retriever; CMB= craniomedial band; CLB= 
caudolateral band). * indicates a significant difference at p < 0.05. 
Stain  GH CMB GH CLB LR CMB LR CLB 
H & E Normal collagen architecture 2.32±0.11 2.88 ±0.04 1.50±0.00 0.63±0.13 
Reduced collagen architecture 1.46±0.04 1.29±0.04 2.08±0.17 2.08±0.38 
Abnormal collagen architecture 0.21±0.07 0.00±0.00 1.13±0.13 1.25±0.13 
Spindle cells 1.50±0.00 1.71±0.13 1.25±0.08 1.00±0.00 
Mixed cells 2.61±0.04 2.67±0.00 2.46±0.13 2.25±0.25 
Rounded cells  1.89±0.04 1.67±0.17 2.29±0.04 2.75±0.25 
Normal distribution of cells 2.54±0.04 2.75±0.00 2.96±0.04 2.00±0.00 
Formation of cell chains 1.43±0.00 1.25±0.00 1.04±0.04 1.13±0.13 
Hypovascularised 2.64±0.07 2.63±0.04 2.92±0.00 3.00±0.00 
Hypervascularised 0.71±0.00 1.04±0.04 0.00±0.00 0.38±0.13 
No inflammation 2.93±0.07 2.96±0.04 3.00±0.00 3.00±0.00 
Evidence of inflammatory cells 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
TB Faint staining  2.04±0.18* 2.63±0.04* 1.96±0.21 1.38±0.13 
Heavy staining  1.96±0.18* 1.38±0.04* 1.96±0.13 2.63±0.13 
Interfascicular 1.93±0.29 1.58±0.17 1.83±0.42 2.63±0.13 
Interbundle 1.82±0.39 1.38±0.29 1.83±0.42 2.63±0.13 
Ligament substance  1.18±0.39* 0.71±0.13* 1.17±0.50 2.38±0.13 
Around the cells 1.61±0.04 1.46±0.13 1.58±0.08 1.63±0.38 
Within the cells  0.86±0.14 0.21±0.21 0.21±0.21 2.75±0.25 
AB Faint staining 1.75±0.04 2.29±0.21 1.71±0.21 1.63±0.13 
Heavy staining 2.25±0.04 1.71±0.21 2.29±0.21 2.63±0.13 
Interfascicular 2.18±0.04 2.08±0.08 2.50±0.17 2.63±0.13 
Interbundle 2.00±0.14 1.71±0.29 2.29±0.04 2.38±0.13 
Ligament substance 1.50±0.07 2.32±0.00 1.63±0.04 2.38±0.13 
Around the cells 1.64±0.29 1.58±0.08 1.71±0.21 2.13±0.88 
Within the cells 0.96±0.04 1.08±0.08 0.88±0.13 1.13±0.13 
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5.4.3 Immunolocalisation of proteoglycans and their distribution in the CCL 
tissue  
5.4.3.1     Negative controls 
Negative controls were included for every antibody immunostaining. Primary 
antibodies used were raised either in rabbit or mouse. No immunostaining was 
detected with negative controls using non-specific rabbit IgG or mouse IgG and IgM 
immunoglubulins or in the absence of primary antibodies (Figures 5-21, 5-22, and 5-
23). 
 
5.4.3.2     Large aggregating proteoglycans (aggrecan and versican) 
In different anatomical regions of the Staffordshire CCLs 
Aggrecan immunostaining was found in the interfascicular regions and collagen 
bundles in all anatomical regions. In addition, aggrecan was increased in 
fibrocartilaginous regions and was shown to localise within the fibrocartilaginous 
cells (rounded nuclei with halo formation) cells (intracellular), (Figure 5-24, A-C). 
Aggrecan mainly stained the fibrocartilaginous cells (rounded nuclei with halo 
formation) intracellularly compared to spindled shaped nuclei (Figure 5-25, A, B). 
Versican was mainly located in the interfascicular regions rather than the collagen 
bundles (Figure 5-26, A-C).  
 
In CMB of greyhound CCLs 
Aggrecan had a faint staining for the interfascicular regions and collagen bundles. In 
addition, aggrecan in greyhounds were rarely seen localised in the fibrocartilaginous 
cells intracellularly (Figure 5-34, A). Versican in all donors was mainly located in the 
interfascicluar regions and to a lesser extent in collagen bundles (Figure 5-34, B). 
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5.4.3.3     Chondroitin sulphate proteoglycans (decorin and biglycan)  
In different anatomical regions of the Staffordshire CCLs 
Decorin stained fascicular regions and collagen bundles which covered the ligament 
substance (Figure 5-27, A-C), whilst biglycan had less staining for collagen bundles 
(Figure 5-28, D-F). However, biglycan showed increased staining in the 
fibrocartilaginous regions and showed positive staining for fibrocartilaginous cells 
intracellularly compared to spindle shaped nuclei (Figure 5-29, A, B).  
 
In CMB of greyhound CCLs  
Decorin mainly stained the interfascicular region and collagen bundles covering the 
ligament substance (Figure 5-35, A). Biglycan faintly stained the collagen bundles, 
and also rarely stained the fibrocartilaginous cells intracellularly (Figure 5-35, B). 
 
5.4.3.4     Keratan sulphate proteoglycans (lumican, fibromodulin, keratocan) 
In different anatomical regions of the Staffordshire CCLs 
Lumican (Figure 5-30, A-C) and fibromodulin (Figure 5-31, A-C) mainly stained the 
collagen bundles rather than the interfascicular regions. In addition, fibromodulin 
additionally was found to surround the fibrocartilaginous cells, and stained some 
cells pericellularly and intracellularly (Figure 5-32, A, B). Keratocan also stained the 
collagen bundles rather than the fascicular regions. (Figure 5-33, A-C). 
 
In CMB of greyhound CCLs 
Lumican, fibromodulin, and keratocan mainly stained the collagen bundles, and to a 
lesser degree stained the interfascicular regions. (Figure 5-36 A, B, and C).
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Figure 5-21: Representative immunostaining pictures of negative controls In Staffordshire bull terrier CCLs obtained by omitting the 
addition of the primary antibody. 
(A) Origin part stained with secondary goat-anti mouse IgG. (B) Middle part stained with secondary goat-anti mouse IgG. (C) Insertion part stained 
with secondary goat-anti mouse IgG. (D) Origin part stained with secondary goat-anti mouse IgM. (E) Middle part stained with secondary goat-anti 
mouse IgM. (F) Insertion part stained with secondary goat-anti mouse IgM. (G) Origin part stained with secondary goat-anti rabbit IgG. (H) Middle 
part stained with secondary goat-anti rabbit IgG. (I) Insertion part stained with secondary goat-anti rabbit IgG (Bar 100μm). 
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Figure 5-22: Representative immunostaining pictures of negative controls In Staffordshire bull terrier CCLs by substituting the primary 
antibody with immunoglobulins. 
(A) Origin part stained with mouse IgG. (B) Middle part stained with mouse IgG. (C) Insertion part stained with mouse IgG. (D) Origin part stained 
with mouse IgM. (E) Middle part stained with mouse IgM. (F) Insertion part stained with mouse IgM. (G) Origin part stained with rabbit IgG. (H) 
Middle part stained with rabbit IgG. (I) Insertion part stained with rabbit IgG (Bar 100μm). 
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Figure 5-23: Representative immunostaining pictures of negative controls in greyhound CCLs by substituting the primary antibody with 
immunoglobulins or by omitting the addition of primary antibody. 
(A) Craniomedial band stained with secondary goat-anti mouse IgG. (B) Craniomedial stained band with secondary goat-anti mouse IgM. (C). 
craniomedial band stained with secondary goat-anti rabbit IgG. (D) Craniomedial band stained with mouse IgG. (E) Craniomedial band stained with 
mouse IgM. (F) Craniomedial band stained with rabbit IgG (Bar 100μm). 
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Figure 5-24: Representative immunostaining of aggrecan in different anatomical regions of the Staffordshire bull terrier CCL. 
(A) Aggrecan at origin site. (B) Aggrecan at middle site. (C) Aggrecan at insertion site. Aggrecan was shown to stain the fibrocartilaginous cells 
intracellularly (blue arrow), interfascicular region (black arrow), and collagen bundles (white arrow) (Bar 100μm).
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Figure 5-25: Representative immunostaining of aggrecan in the Staffordshire bull terrier CCL. 
(A) Aggrecan shows little or no staining for spindle shaped nuclei as it mainly stained the collagen bundles (white arrow). (B) Aggrecan shows 
staining for the collagen bundles (white arrow) and intracellular staining for the fibrocartilaginous cells (blue arrow) (Bar 100μm). 
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Figure 5-26: Representative immunostaining of versican in different anatomical regions of the Staffordshire bull terrier CCL. 
 (A) Versican at origin site. (B) Versican at middle site. (C) Versican at insertion site. Versican was mainly present in the interfascicular region (black 
arrow) and to a lesser extent in collagen bundles (white arrow) (Bar 100μm). 
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Figure 5-27: Representative immunostaining of decorin in different anatomical regions of the Staffordshire bull terrier CCL. 
(A) Decorin at origin site. (B) Decorin at middle site. (C) Decorin at insertion site. Decorin staining was found over collagen bundles (white 
arrow) covering the ligament substance, and in the interfascicular region (black arrow) (Bar 100μm). 
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Figure 5-28: Representative immunostaining of biglycan in different anatomical regions of the Staffordshire bull terrier CCL. 
 (A) Biglycan at origin site. (B) Biglycan at middle site. (C) Biglycan at insertion site. Biglycan shows faint staining over collagen bundles (white 
arrow) and in the interfascicular region (black arrow) (Bar 100μm). 
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Figure 5-29: Representative immunostaining of biglycan in the Staffordshire bull terrier CCL. 
(A) Biglycan shows no staining of spindle shaped nuclei. (B) Biglycan shows intracellular staining for the fibrocartilaginous cells (blue arrow) (Bar 
100μm). 
 
 
168 
 
 
Figure 5-30: Representative immunostaining of lumican in different anatomical regions of the Staffordshire bull terrier CCL. 
(A) Lumican at origin site. (B) Lumican at middle site. (C) Lumican at insertion site. Lumican staining was mostly observed over the collagen bundles 
(white arrow), and showed some staining for the interfascicular region (black arrow) (Bar 100μm). 
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Figure 5-31: Representative immunostaining of fibromodulin in different anatomical regions of the Staffordshire bull terrier CCL. 
(A) Fibromodulin at origin site. (B) Fibromodulin at middle site. (C) Fibromodulin at insertion site. Fibromodulin staining was mostly present over the 
collagen bundles (white arrow), and showed minor staining in the interfascicular region (black arrow) (Bar 100μm). 
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Figure 5-32: Representative immunostaining of fibromodulin in the Staffordshire bull terrier CCL. 
(A) Fibromodulin staining is present over the collagen bundles (white arrow) shows no positive staining for the spindle shaped nucleus. (B) 
Fibromodulin stained the collagen bundles and surrounded a group of fibrocartilaginous cells (white arrow), and stained some of the 
fibrocartilaginous cells pericellularly (black arrow) and intracellularly (blue arrow) (Bar 100μm). 
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Figure 5-33: Representative immunostaining of keratocan in different anatomical regions of the Staffordshire bull terrier CCL. 
 (A) Keratocan at origin site. (B) Keratocan at middle site. (C) Keratocan at insertion site. Keratocan staining was mostly present over the 
collagen bundles (white arrow), and showed minor staining for the interfascicular region (black arrow) (Bar 100μm). 
 
172 
 
 
Figure 5-34: Representative immunostaining of large aggregating proteoglycans (aggrecan and versican) in the craniomedial band 
anatomical region of the greyhound CCL. 
(A) Aggrecan. (B) Versican. Aggrecan staining was present over some rounded (fibrocartilaginous) cells intracellularly (blue arrow), and versican 
staining was present over the interfascicular region (black arrow) and to a lesser extent the collagen bundles (white arrow) (Bar 100μm). 
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Figure 5-35: Representative immunostaining of chondroitin/ dermatan sulphate proteoglycans (decorin and biglycan) in the craniomedial 
band anatomical region of the greyhound CCL. 
(A) Decorin. (B) Biglycan. Decorin staining was present over collagen bundles (white arrow) covering the ligament substance, and biglycan stained 
some of the fibrocartilaginous cells intracellularly (blue arrow) (Bar 100μm). 
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Figure 5-36: Representative immunostaining of keratan sulphate proteoglycans (lumican, fibromodulin, and keratocan) in the 
craniomedial band anatomical region of the greyhound CCL. 
(A) Lumican. (B) Fibromodulin. (C) Keratocan.  Fibromodulin, lumican, and keratocan showed staining was mainly present over the collagen bundles 
(white arrow), and to a lesser extent the interfascicular region (black arrow shown for fibromodulin only) (Bar 100μm).
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5.5       Discussion 
In this Chapter, we have characterised the morphological structure of the CCL and 
sGAG content histologically by performing semi-objective histology scoring in 
different anatomical regions of three dog breeds with a differing predisposition to 
CCLD/ R. We have found increased sGAGs in areas with reduced collagen 
architecture and rounding of cells, thus displaying areas of fibrocartilage in the CCL.  
Immunohistochemistry was performed to characterise proteoglycans and their 
distribution in the greyhound CCL (low risk to CCLD/ R) and in different anatomical 
regions of the Staffordshire bull terrier CCL (moderate-high risk to CCLD/ R). 
Interestingly, each proteoglycan had a unique distribution across the CCL.  
 
5.5.1 Histology of canine CCLs  
Staining with H&E showed that all dog breed CCLs mainly had a normal and 
reduced architecture of collagen fibrils. The normal collagen architecture had a 
parallel and helical arrangement of collagen fibrils (Yahia and Drouin 1989; Zhu, 
Zhang et al. 2009), whilst the reduced collagen architecture had a homogenous 
structure of collagen fibrils with loss of some collagen bundles (Narama, Masuoka-
Nishiyama et al. 1996; Zhu, Zhang et al. 2009). Abnormal collagen architecture had 
a disorganised collagen matrix with areas of cell loss (Vasseur, Pool et al.1985). 
Furthermore, normal collagen fibrils were associated with spindle shaped nuclei, 
whereas regions with reduced collagen architecture had a mixture of spindle and 
rounded nuclei, and this agrees with previous studies performed in beagle (Narama, 
Masuoka-Nishiyama et al. 1996), greyhound, and Labrador retriever CCLs 
(Comerford, Tarlton et al. 2006b). Overall, all dog breed has a low number of blood 
vessles, which agrees with a previous that showed that the normal intact canine 
CCL is hypovascular in nature (Hayashi, Bhandal et al. 2011) Immunohistochemical 
techniques with antibodies such as factor VIII (for endothelial cell) and laminin (for 
basement membrane) may be used to detect blood vessels.  
We also observed increased degrees of Toluidine blue and Alcian blue staining (two 
dyes that stain sGAGs) in areas of fibrocartilage in the CCL (Figure 5-11, B and 5-
17, B). Areas of fibrocartilage have been shown in the CCL of dogs over 5 years 
with a body weight of >15 kg, suggesting it to be a degenerative outcome for older 
dogs prior CCLD/ R (Vasseur, Pool et al. 1985). In addition, fibrocartilage and 
increased Alcian blue staining has been observed in the CCL of young beagles bred 
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for laboratory use speculated by the authors to be a degenerative sign due to lack of 
exercise (Narama, Masuoka-Nishiyama et al. 1996).  
However, other aurthors have suggested that the formation of fibrocartilage in the 
CCL is an adaptive response to compressive loads, and not a sign of degeneration 
(Comerford, Tarlton et al. 2006b; Zhu, Zhang et al. 2012). This suggestion was also 
supported studies in tendon (Vogel, Ordog et al. 1993; Benjamin and Ralphs 1998; 
Vogel 2004). 
Comerford and others found fibrocartilage with increased Alcian blue staining to 
occur in the ex-racing greyhound CCL (low risk to CCLD/ R) and in the Labrador 
retriever (high risk to CCLD/ R) CCL (Comerford, Tarlton et al. 2006b). Increased 
evidence of fibrocartilage was demonstrated not to be a degenerative sign in CCLs 
of the greyhound, but might be an adaptation to their physiological demands 
requiring greater CCL strength (Tipton, Matthes et al. 1975), whereas it was 
suggested to be a mild degenerative change in CCLs of the non-athletic Labrador 
retriever (Comerford, Tarlton et al. 2006b).  
We have observed in our study that fibrocartilage occurred mostly in the 
Staffordshire bull terrier and Labrador retriever CCL (predisposed breeds to CCLD/ 
R) compared to the greyhound CCL (not predisposed to CCLD/ R). However, no 
significant differences were observed in CCL structural morphology between the low 
risk dog breed (greyhound) and high risk dog breed (Labrador retriever). It is 
possible that this study requires a greater power and increasing the number of 
donors to 10 biological replicates could result in significant differences between 
breeds being achieved.  
Statistical analysis of Toluidine blue scoring data showed that the Staffordshire bull 
terrier CCL origin anatomical region had more Toluidine blue staining in the 
ligament substance (covering collagen bundles) and within cells in comparison to its 
insertion site of the CCL. However, Alcian blue staining showed different statistically 
significant results, where the craniomedial band of the greyhound CCL had 
significantly higher Alcian blue staining in the ligament substance and a higher 
marked overall staining of Alcian blue compared to the caudolateral band.  
One possible reason for the differences between the Toluidine blue and Alcian blue 
data could be that Eosin Y was used as a counter staining for Alcian blue, and thus 
sGAG were more easily distinguished than in the Toluidine blue sections. Therefore, 
the lack of counter stain for Toluidine blue might have created some confusion when 
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Toluidine blue staining was assessed. Therefore, we suggested that assessing 
sGAGs with Alcian blue might have been more accurate. It had been previously 
shown that the CCL of the porcine craniomedial and caudolateral band had 
structural differences in terms of their collagen fibre bundle orientation (Zhou, 
Grimshaw et al. 2009), and might be that they also exhibit structural differences in 
terms of cell shape and sGAGs. Our statistical data could indicate that there are 
morphological structural differences between the functional craniomedial band and 
the caudolateral band of the greyhound. However, further studies are required to 
evaluate the structural differences of these two CCL bands. 
 
5.5.2 Immunohistochemistry of canine CCLs 
Our first aim of the immunohistochemical study was observe whether there were 
differences in the proteoglycan distribution between the anatomical regions of the 
Staffordshire bull terrier. However, our subjective observations made it difficult for 
us to detect whether the proteoglycan distribution differed between the origin, 
middle and insertion sites of Staffordshire bull terrier. 
Our second aim of the immunohistochemical study was to characterise the 
distribution and localisation of proteoglycans throughout the CCL in two dog breeds 
differentially predisposed to CCLD/ R. 
Our study has shown that aggrecan, versican, decorin, biglycan, lumican, 
fibromodulin, and keratocan were expressed in the Staffordshire bull terrier 
(moderate-high risk) and greyhound (low risk) CCL, with each proteoglycan having 
a unique distribution within the CCL tissue. Such proteoglycans have been 
previously immunolocalised in the canine CCL (Yang, Culshaw et. al. 2011; Kharaz 
2015).  
In the Staffordshire bull terrier CCL, aggrecan was found to stain the interfascicular 
region and collagen bundles. In addition, it showed increased staining for the 
fibrocartilage matrices and stained fibrocartilaginous cells intracellularly (Figure 5-25 
B). Greyhounds CCLs had a faint staining for aggrecan at the interfascicular region 
and collagen bundles. In addition, there was less intracellular staining for the 
fibrocartilaginous cells. The increase of aggrecan staining in Staffordshire bull terrier 
compared to greyhound CCLs could be that they encounter more areas of 
fibrocartilaginous matrices that are secondary to compression, as aggrecan has 
been previously shown to withstanding compressive forces in tendon (Vogel and 
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Koob 1989; Evanko and Vogel 1993; Robbins, Evanko et al. 1997). The deposition 
of aggrecan between collagen bundles may indicate that it facilitates sliding of 
collagen bundles relative to one another thus preventing damage of fibrils during 
extreme loading, and this role for aggrecan has been similarly reported in tendon 
(Vogel and Peters 2005). The intracellular staining for aggrecan in fibrocartilaginous 
cells could indicate its important role in withstanding compressive forces applied to 
the CCL. Aggrecan has been similar shown to stain intracellularly in cartilage 
(Melrose, Smith et al. 2005; Smith, Shu et al. 2010).  
Versican is known to be the major large aggregating proteoglycan in ligament (Ilic, 
Carter et al. 2005). Versican mainly stained the interfascicular regions of the CCL 
more than collagen bundles, which agrees with a previous study (Kharaz 2015). In 
addition, versican was similarly distributed in the Staffordshire bull terrier and 
greyhound CCLs. The deposition of aggrecan and versican in the interfascicular 
region of the CCL could suggest that the may lubricate this structural region. 
Decorin was shown to stain interfascicular regions and over collagen bundles thus 
covering the ligament substance. A similar distribution of decorin was also found in 
the rabbit anterior cruciate ligament (ACL) (Kavanagh and Ashhurst 2001). This 
broad distribution for decorin is not surprising since it is the most abundant 
proteoglycan found in ligament (Ilic, Carter et al. 2005), and its main role is to 
regulate collagen fibrillogenesis by interacting with collagen fibres (Vogel, Paulsson 
et al. 1984; Birk, Nurminskaya et al. 1995; Danielson, Baribault et al. 1997). Decorin 
distribution was found to be similar in the Staffordshire bull terrier and the 
greyhound CCL. 
In the Staffordshire bull terrier and greyhound CCL, biglycan showed minor staining 
for collagen bundles. However, biglycan was increased in fibrocartilaginous regions 
of the CCL and was found to predominantly stain the fibrocartilaginous cells 
intracellularly (Figure 5-29 B), which is consistent with a previous study where 
biglycan was found to stain collagen bundles and fibrocartilaginous cells of the the 
rabbit ACL (Kavanagh and Ashhurst 2001). The positive staining for biglycan in 
collagen bundles could indicate that it interacts with collagen type I (Schonherr, 
Witschprehm et al. 1995), whilst the increase of biglycan in the fibrocartilaginous 
matrix could be secondary to compressive forces applied to the CCL, as biglycan 
has been shown to increase in compressed regions of tendon (Evanko, Vogel et al. 
1993; Vogel, Ordog et al. 1993; Robbins, Evanko et al. 1997). Staffordshire bull 
terrier CCLs showed more biglycan staining in the fibrocartilaginous regions 
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compared to greyhound CCLs, and could be due to increased fibrocartilaginous 
matrices in the Staffordshire bull terrier CCL. The cellular staining of biglycan in 
fibrocartilage cells also agrees with other studies that stained biglycan in tendon 
(Vogel and Petres 2005). Biglycan could have a role in morphogenesis and 
differentiation of fibrocartilaginous cells (Bianco, Fisher et al. 1990; Embree, Kilts et 
al. 2010). 
Fibromodulin, lumican, and keratocan were mainly located along the collagen fibre 
bundles of the CCL, and showed to be similarly distributed in Staffordshire bull 
terriers and greyhounds. Collagen type I is the predominant collagen in ligament 
(Frank 2004). Fibromodulin and lumican are known to attach to collagen type I 
(Svensson, Narlid et al. 2000), and keratocan has been shown to co-localised with 
type I collagen in tendon (Rees, Wagget et al. 2009). The specific 
immunolocalisation of fibromodulin, lumican, and keratocan in collagen bundles 
could indicate their importance in regulating collagen fibrillogenesis.  
Fibromodulin stained around and within the rounded shaped cells in the 
fibrocartilage region (Figure 5-32 B), which were mainly detected in Staffordshire 
bull terriers compared to greyhound CCLs, which could also indicate that the 
Staffordshire bull terrier CCL consists of more fibrocartilaginous matrices. Similar 
deposition of fibromodulin was also found in the fibrocartilage zone of tendon and 
ligament (Adamczyk, Milz et al. 2008). This could suggest that fibromodulin may 
have a similar role to biglycan in that it may regulate cellular differentiation and 
morphogenesis, as fibromodulin and biglycan have been shown to regulate cellular 
differentiation and morphogenesis in chondrocytes (Embree, Kilts et al. 2010).  
A limitation to this part of study was that the greyhound CCL tissue sections were 
much smaller compared to Staffordshire bull terriers, and therefore it was difficult for 
us to observe clearly if there were any differences in terms of proteoglycan 
distribution between the two differentially predisposed dog breeds. Furthermore, we 
were unable to quantify whether there were any significant differences in 
proteoglycans distribution between the three anatomical regions of the Staffordshire 
bull terriers. In general, our immunohistochemical observation was qualitative, 
allowing us to determine general distributions of proteoglycans in the ligament 
tissue. However, the distribution of proteoglycan quantity between anatomical 
regions of the canine CCL and within dog breeds with a differing risk to CCLD/ R 
needs yet to be determined. We further aim to undertake semi-quantitative 
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immunohistochemistry analysis by measuring the staining intensity of 
proteoglycans. 
 
 
 
5.6       Conclusion  
 Increase in sGAG staining is associated with increased fibrocartilaginous sites in 
the CCL, which may be a result of compression. 
 The distribution of the large aggregating proteoglycans (aggrecan and versican) 
in the CCL could indicate that they may lubricate the interfascicular regions and 
aid in sliding between collagen bundles thus preventing damage of fibrils during 
increased compressive loading. 
 The distribution of decorin, lumican, fibromodulin and keratocan in the 
collagenous matrix in both dog breeds may indicate their importance in 
regulating collagen fibrillogenesis in the CCL.  
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Chapter 6: General discussion and future 
work. 
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6.1      General discussion  
The ligament extracellular matrix (ECM) is composed of two thirds of water, and one 
third of solids, such as collagen, elastin, proteoglycans, and glycoproteins (Frank 
2004; Rumain, Wallace et al. 2007). Proteoglycans consist of a core protein 
attached to one or more glycosaminoglycan (GAG) chain (Hardingham and Fosang 
1992; Iozzo and Schaefer 2015). 
Cranial cruciate ligament (CCL) disease and rupture (CCLD/ R) is one of the most 
common orthopaedic conditions to affect dogs leading to stifle joint osteoarthritis 
(Bennett, Tennant et al. 1988). Previous studies have shown that different dog 
breeds have a different predisposition to CCLD/ R. Such breeds are the Labrador 
retriever (high risk), and the racing greyhound (low risk) (Whitehair, Vasseur et al. 
1993; Duval, Budsberg et al. 1999). Other dog breeds are known to be moderate-
high in risk such as the Staffordshire bull terrier (Baird, Carter et al. 2014b).  
The aim of this work was to detect whether proteoglycans and GAGs varied 
between different anatomical regions of dog breeds with a different predisposition to 
CCLD/ R. In addition, we further aimed to identify whether certain proteoglycans 
and GAGs differed between dog breeds that have different risks to this disease. We 
hypothesised that certain proteoglycans and GAGs may differ significantly between 
anatomical regions of the CCL and between dog breeds with a different 
predisposition to CCLD/ R.  
Therefore, our objectives were to use semi-quantitative Western blot analysis, 
biochemical analysis, semi-objective histology scoring analysis, and 
immunohistochemistry to determine if there were differences with proteoglycans and 
GAGs in different anatomical regions of the canine CCL and between dog breeds 
with a different predisposition to CCLD/ R. 
Previous studies using Western blot analysis have identified proteoglycans and 
GAGs in different anatomical regions of tendon tissues (Robbins, Evanko et al. 
1997; Waggett, Ralphs et al. 1998; Rees, Flannery et al. 2000; Samiric, Ilic et al. 
2004; Ilic, Carter et al. 2005; Rees, Wagget et al. 2009). The Western blot results of 
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this study showed that the core protein of versican fragments and keratocan were 
significantly higher in the middle anatomical region in comparison to other 
anatomical regions of the Staffordshire bull terrier CCL, and that chondroitin -4 
sulphate high molecular weight stubs were found to increase significantly at the 
insertion and middle region of the Staffordshire bull terrier CCL compared to its 
origin region. The middle (Paatsama 1952; Vasseur, Pool et al. 1985; Comerford, 
Tarlton et al. 2006b) and insertion (Arnoczky 1983; Zhu, Zhang et al. 2012) 
anatomical regions of the CCL have been shown to be fibrocartilaginous. This 
fibrocartilaginous site is likely to be secondary to physical compression. Therefore, it 
is likely that these proteoglycans (versican and keratocan) and GAGs (chondroitin-4 
sulphate) are specific for fibrocartilaginous regions as a result of compression 
(Vogel and Koob 1989; Evanko and Vogel 1993; Rees, Wagget et al. 2009; 
Huisman, Andersson et al. 2014). Our limitations of this part of study is that we were 
unable to obtain enough CCLs from greyhounds in order to study the anatomical 
variation of proteoglycans and GAGs, as it would have been interesting to detect 
whether the anatomical regions of the greyhound CCLs differed in their 
proteoglycan and GAG composition compared to Staffordshire bull terrier CCLs. 
However, Western blot analysis is only semi-quantitative for proteins, we further aim 
to use other techniques such as matrix assisted laser desorption ionisation mass 
spectrometry imaging (MALDI-MSI), which is a special proteomic method in order to 
detect proteoglycans in different anatomical region of the Staffordshire bull terrier 
and greyhound CCL, as proteomic analysis has shown to be a sensitive and 
quantitative technique to detect specific proteins (Beine, Diehl et al. 2016).  
Certain GAGs and proteoglycans have been shown to increase in tendon/ ligament 
pathology (Riley, Harral et al. 1994a; Lo, Marchuk et al. 1998; Corps, Robinson et 
al. 2006; Halper, Kim et al. 2006; Fu, Chan et al. 2007; Samiric, Parkinson et al. 
2009), and sulphated glycosaminoglycans (sGAGs) have been shown to increase in 
the CCLs from high risk dog breeds to CCLD/ R (Comerford, Tarlton et al. 2006a). 
In Chapter 3, Western blot and gene expression analysis of fibromodulin, gene 
expression of aggrecan, and Western blot analysis of chondroitin-6 sulphate stubs 
were significantly higher in Staffordshire bull terrier CCLs compared to those of the 
greyhounds. Aggrecan and chondroitin-6 sulphate have been shown to increase in 
regions of tendon subjected to compression (Vogel and Koob 1989; Evanko and 
Vogel 1993; Huisman, Andersson et al. 2014). The significant increase of aggrecan 
and chondroitin-6 sulphate stubs in Staffordshire bull terriers CCLs compared to 
greyhound CCLs could be that it develops more sites of fibrocartilage secondary to 
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compression, and may both function to withstand compressive loading in the 
Staffordshire bull terrier CCLs.  
Fibromodulin has been previously shown to localise at the fibrocartilaginous sites of 
human flexor carpi ulnaris tendon, pisometacarpal and pisohamate ligaments 
(Adamczyk, Milz et al. 2008). In addition, we found in Chapter 5 that fibromodulin 
surrounded the fibrocartilaginous cells with some pericellular/ intracellular staining. 
Therefore, the significant increase of fibromodulin in the Staffordshire bull terrier 
CCL could be that this moderate-high risk dog breed develops more sites of 
fibrocartilage, which may be a result of compression. Fibromodulin may have a role 
in promoting cellular differentiation in the CCL fibrocartilaginous region, as a similar 
role for fibromodulin has been shown in cartilage tissue (Embree, Kilts et al. 2010). 
The increase of compressive regions in the Staffordshire bull terrier CCL is likely to 
be due to a narrowed intercondylar notch, and it could be that the Staffordshire bull 
terrier has a narrowed intercondylar notch that compresses against the CCL. The 
intercondylar notch index and femoral condyle height and width have been shown to 
be significantly lower in Labrador retriever and Golden retriever CCLs (high risk to 
CCLD/ R) compared to those of the greyhounds (low risk to CCLD/ R) (Comerford 
and Tarlton et al. 2006a). In addition, narrowing of the intercondylar notch has been 
associated with CCLD/ R and osteoarthritis in the dog (Aiken, Kass et al. 1995; 
Wada, Tatsuo et al. 1999), and the normal ACL function in humans has been shown 
to be impeded when it passes through a narrowed intercondylar notch, resulting in 
damage to the ACL (Muneta, Takakuda et al. 1997). The intercondylar notch index 
in the Staffordshire bull terrier has not been determined yet, as we only made an 
assumption that it may have a narrowed intercondylar notch compared to what has 
been reported for the narrowed intercondylar notches of high risk dog breeds 
(Comerford, Tarlton et al. 2006a). Therefore, it would be worth measuring the 
intercondylar notch height and width index in the moderate-high risk Staffordshire 
bull terrier. 
However, the significant increase in aggrecan and fibromodulin could also be 
associated CCLD/ R in the moderate-high risk Staffordshire bull terrier, as 
fibromodulin (Samiric, Parkinson et al. 2009), and aggrecan (Corps, Robinson et al. 
2006; Samiric, Parkinson et al. 2009) gene expression have been found to increase 
in tendon pathology. In addition, aggrecan gene expression has been found to 
increase in ruptured CCLs of the Labrador retrievers (high risk to CCLD/ R) 
(Clements, Carter et al. 2008). The increase of aggrecan in the Staffordshire bull 
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terrier could also be related to the significant increase of water content compared to 
those of the greyhound CCLs (See Chapter 4), as one of the functions for aggrecan 
is to retain water in the tissue matrix (Hardingham and Bayliss 1990). Conversely, 
the significant increase of the water content in the Staffordshire bull terrier CCL may 
be a pathological sign for the contribution to CCLD/ R, as Comerford and others 
have shown that the increase of water content was statistically significant in 
ruptured CCLs compared to intact CCLs of the high-risk Labrador retriever 
(Comerford, Innes 2004). Studies have shown that pathological tendons are also 
accompanied with increased water content (Riley, Harral et al. 1994b; Samiric, 
Parkinson et al 2009). 
Gene expression and Western blot analysis showed that the low-risk greyhound had 
a significant increase of decorin compared to those of the Staffordshire bull terrier 
CCLs. In a decorin knockout mice study, tendon collagen fibrils in cross-section had 
uneven outlines with variability in fibril size (Danielson, Baribault et al. 1997). In 
addition, transmission electron microscopy (TEM) has shown that the Labrador 
retriever (high risk dog breed to CCLD/ R) had non-uniform and small collagen fibril 
sizes (approximately 50 nm), whereas the collagen fibril diameter measured in 
greyhound (from 100-150 nm) (low risk dog breed to CCLD/ R) were more uniform 
and larger in size (Comerford, Tarlton et al. 2006). Decorin might have a role in 
regulating collagen fibrillogenesis in the greyhound CCL, by maintaining its size and 
strength, thus preventing it from CCLD/ R, and we predict that decorin content is 
less in the Staffordshire bull terrier (moderate-high risk to CCLD/ R) as it may have 
irregular and small fibril diameters similar to the Labrador retriever (high risk to 
CCLD/ R). However, our further work is to perform TEM to identify the collagen fibril 
morphology with cross sections and to measure the fibril diameter in Staffordshire 
bull terriers. 
It is interesting to highlight that several studies which determined the gene 
expression levels of proteoglycans in pathological tendons and ligaments, have 
observed an increase in proteoglycans such as aggrecan, biglycan, fibromodulin, 
but not decorin (Lo, Marchuk et al. 1998; Corps, Robinson et al. 2006; Clements, 
Carter et al. 2008; Samiric, Parkinson et al. 2009) This could indicate that decorin is 
a proteoglycan that is not associated with pathology, and may solely function to 
maintain collagen fibrils in tendons (Vogel, Paulsson et al. 1984; Birk, Nurminskaya 
et al. 1995; Danielson, Baribault et al. 1997) and ligament. 
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ADAMTS4 is secreted as an active enzyme and is known to cleave proteoglycans 
within specific sites of their core protein (Kashiwagi, Enhild et al. 2004). The gene 
expression of ADAMTS-4 was shown to be significantly upregulated in greyhounds 
CCLs compared to Staffordshire bull terriers. Evidence of increased catabolism in 
greyhounds CCLs associated with high expression of ADAMTS-4 could be linked to 
increased expression and anabolism of its proteoglycan substrates, such as decorin 
(Kashiwagi, Enhild et al. 2004; Porter, Clark et al. 2005). The significant increase of 
decorin gene expression could be related to increased ADAMTS-4 activity since we 
have detected a catabolic fragment below the decorin core protein at 30 kDa (Figure 
3-7 B), and we predict that this fragment could be generated from ADAMTS-4 
activity. To confirm whether the decorin fragment is generated by ADAMTS4 
acitivity, we further aim to incubate the CCLs with an ADAMTS4 inhibitor such as 
tissue inhibitor of metalloproteinase-3 (Hashimoto, Aoki et al. 2001), and then 
perform Western blot analysis on the CCLs with decorin antibody in order to 
observe whether the 30 kDa fragment of decorin is absent due to the degradation of 
ADAMTS4 by tissue inhibitor of metalloproteinase-3 (Porter, Clark et al. 2005), 
versican (Sandy, Westling et al. 2001), biglycan (Melching, Fisher et al. 2006), and 
fibromodulin (Porter, Clark et al. 2005). However, it could be that ADAMTS-4 is 
more efficient in cleaving decorin due to its gene levels being highly expressed in 
normal greyhound CCL. The significant increase of ADAMTS-4 in greyhound CCLs 
thus could be required to maintain normal CCL metabolism, as it is an exercising 
dog breed that rarely ruptures its CCL. Further work includes performing Western 
blotting with ADAMTS-4 antibody to identify whether there are significant differences 
in ADAMTS-4 catabolic fragments in the Staffordshire bull terrier and greyhound 
CCL. This will give us a better understanding on how ADAMTS-4 is affecting the 
metabolism of its substrates in the CCL of the different predisposed dog breeds.  
Glycosaminoglycans (GAGs) are covalently attached to a proteoglycan core protein 
with the exception of hyaluronic acid (Hardingham 1981; Ajit Varki 2009). GAGs are 
known to be comprised of a hexosamine (i.e. glucosamine or galactosamine), and 
an uronic acid (glucoronic acid and or iduronic acid) or galactose (Hardingham and 
Fosang 1992). The results of this study showed that hyaluronic acid was one of the 
major GAGs of the CCL in both dog breeds, whereas keratan sulphate was one of 
the lowest GAGs (See Chapter 4). We conclude that the high content of hyaluronic 
acid could have a role in maintaining the viscosity and viscoelastic properties of the 
CCL, as has been reported for other tissues (eye and skeletal joints) (Ajit Varki 
2009). It would have been useful to determine the rest of the individual GAG 
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contents in the CCL, such as chondroitin sulphate-6, chondroitin sulphate-4, 
dermatan sulphate, and heparin sulphate, as we might have observed statistical 
significant differences with these individual GAGs between the regions of the CCL 
and between the CCL of dog breeds with a different predisposition to CCLD/ R. 
Therefore, we further aim to use other techniques such as disaccharide analysis 
with high liquid performance chromatography to determine the individual contents of 
chondroitin sulphate-6, chondroitin sulphate-4, dermatan sulphate, and heparan 
sulphate in the CCLs of the Staffordshire bull terrier and greyhound (Hae Yoon, 
Brooks et al. 2003). 
In Chapter 5, we have performed semi objective histology scoring analysis in order 
to determine the CCL structural morphology and sGAG deposition between 
anatomical regions of three dog breeds with a different predisposition to CCLD/ R 
namely the greyhound (low in risk), the Staffordshire bull terrier (moderate – high in 
risk), and the Labrador retriever (high in risk).  
H & E staining showed that each dog breed had differences in the collagen 
architecture of their CCL, where most displayed normal (Yahia and Drouin 1989; 
Zhu, Zhang et al. 2009) and reduced (Narama, Masuoka-Nishiyama et al. 1996; 
Zhu, Zhang et al. 2009) collagen architectures. Furthermore, a heterogeneous 
population of cell nuclei (spindle and rounded) was observed in the CCL of all dogs, 
where spindle shaped cells were mostly seen with normal collagen bundles, and 
rounded cells were mainly seen in areas with reduced/ homogenous collagen 
bundles (Narama, Masuoka-Nishiyama et al. 1996; Comerford, Tarlton et al. 
2006b), thus demonstrating areas of fibrocartilage. 
An increase in Toluidine blue and Alcian blue staining were present in 
fibrocartilaginous regions of the CCL (Figure 5-11, B and 5-17, B), which is in 
agreement with other studies (Comerford, Tarlton et al. 2006b; Feitosa, Reis et al. 
2006). H&E staining showed that fibrocartilage regions occurred mainly in the 
Staffordshire bull terrier and Labrador retriever CCLs (breeds predisposed to CCLD/ 
R) compared to those of the greyhounds (not predisposed to CCLD/ R) (Figure 5-1), 
the increase in fibrocartilaginous matrices in the Staffordshire bull terrier and 
Labrador retriever could be secondary to compressive forces applied to the CCL. 
However, no significant differences were observed in CCL structural morphology 
between non-predisposed dog breeds (greyhound), and predisposed dog breeds 
(Staffordshire bull terrier and Labrador retriever), and it could be possible that with 
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performing a power calculation and increasing the number of donors accordingly 
could have showed significance between the differentially predisposed dog breeds.  
Further in Chapter 5, we have performed immunohistochemistry staining with 
proteoglycan antibodies in the Staffordshire bull terrier and greyhound CCL. We 
found that aggrecan was distributed in the CCL interfascicular and collagen 
bundles. In addition, aggrecan was increase in the fibrocartilage regions and stained 
the fibrocartilaginous cells intracellularly which was more evident in Staffordshire 
bull terrier CCLs. Immunolocalisation of aggrecan in cells has been similarly shown 
in cartilage tissue (Melrose, Smith et al. 2005; Smith, Shu et al. 2010). The increase 
of aggrecan in the fibrocartilaginous matrix of the Staffordshire bull terrier CCLs may 
indicate that it has a role in withstanding compressive forces in tendon (Vogel and 
Koob 1989; Evanko and Vogel 1993; Huisman, Andersson et al. 2014) and 
ligament. 
Versican, on the other hand, mainly stained the interfascicular regions of the CCL, 
and showed less staining over collagen bundles (Kharaz 2015). The location of 
aggrecan and versican at the interfascicular region of the CCL could indicate that 
they both have a role in lubricating the interfascicular matrix. 
Decorin was found to stain the interfascicular region and collagen bundles, which 
covered the ligament substance, whilst biglycan showed minor staining for collagen 
bundles. However, biglycan was increased in fibrocartilaginous regions and stained 
the fibrocartilaginous cells. Overall, biglycan staining in fibrocartilaginous regions 
was more apparent in Staffordshire bull terrier CCLs compared to those of the 
greyhounds 
The broad distribution of decorin in the collagen bundles could indicate its key 
essential role in regulating collagen fibrillogenesis in the canine CCL, as several 
studies have indicated of the important role of decorin in regulating collagen 
fibrillogenesis in tendon (Vogel, Paulsson et al. 1984; Birk, Nurminskaya et al. 1995; 
Danielson, Baribault et al. 1997). The positive staining for biglycan in collagen 
bundles could indicate that it may interact with collagen type I (Schonherr, 
Witschprehm et al. 1995) in the CCL, whilst the increase of biglycan in the 
fibrocartilaginous matrix of the Staffordshire bull terrier could be secondary to 
compressive forces in the CCL, as biglycan has been shown to increase in 
compressed regions of tendon (Evanko, Vogel et al. 1993; Vogel, Ordog et al. 1993; 
Robbins, Evanko et al. 1997). The cellular staining of biglycan in fibrocartilage cells 
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agrees with other studies that stained tendon with biglycan antibody (Vogel and 
Petres 2005). Biglycan could have a role in morphogenesis and differentiation of 
fibrocartilaginous cells, as biglycan has been shown to regulate cells of cartilage 
and other tissues (cornea and skin) (Bianco, Fisher et al. 1990; Embree, Kilts et al. 
2010). 
Fibromodulin, lumican, and keratocan mainly stained in the collagen bundles of the 
CCL. The staining over collagen bundles for lumican and fibromodulin could indicate 
that they have a similar role to decorin in the CCL, in which they regulate collagen 
fibrillogenesis in tendon (Svensson, Aszodi et al. 1999; Ezura, Chakravarti et al. 
2000). In addition, keratocan has been found to co-localise with type I collagen in 
bovine deep digital flexor tendon (Rees, Wagget et al. 2009). Therefore, keratocan 
may also play a role in regulating collagen fibrollogenesis in the CCL tissue.  
Overall Staffordshire bull terriers had more aggrecan and biglycan staining in their 
CCLs in comparison to greyhounds. However, the limitations of this study is that we 
were unable to obtain similar tissue sections from the Staffordshire bull terrier and 
greyhound, as the tissue sections of the greyhound were much smaller, and 
therefore made it difficult to compare the differences between the two dog breeds. 
However, further work includes obtaining similar CCL sections from the greyhound 
and Staffordshire bull terrier and performing semi quantitative measurements of 
immunohistochemistry staining in order to detect statistical significant differences of 
proteoglycans between the two dog breeds and between their anatomical regions.  
6.2       Conclusion  
The significant elevated levels of decorin in greyhounds could be compulsory for 
maintaining its collagen fibril strength, whilst the significant increase of ADAMTS4 
levels in the ex-racing greyhound could be essential to maintain its regular CCL 
homeostasis. The significant Increase of aggrecan, fibromodulin, and chondroitin-6 
sulphate in Staffordshire bull terriers CCLs could be that this dog breed has an 
increase in fibrocartilage regions as a result of compressive loads. High 
compressive loading in the Staffordshire bull terrier might encounter the CCL to 
develop higher stress levels and therefore compromising the CCL to disease and 
rupture. 
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6.3       Future Work 
 Recommendations for further work to determine proteoglycans and GAGs of 
the CCL in different anatomical regions and between dog breeds at different 
risks to CCLD/ R include; 
 
̶ Accurate determination of proteoglycans between anatomical regions by 
performing MALDI-MSI. 
̶ To measure the intercondylar notch width and height of the moderate-
high risk Staffordshire bull terrier. 
̶ To measure and determine the collagen fibril diameter in the moderate-
high risk Staffordshire bull terrier. 
̶ To detect other individual contents of GAGs (chondroitin sulphate -6. 
chondroitin sulphate -4, dermatan sulphate, and heparin sulphate) by 
performing disaccharide analysis with high liquid performance 
chromatography. 
̶ Semi quantitative measurements of immunohistochemical staining. 
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APPENDIX I – MATERIALS   
1-bromo-3-chloropropane                                B9673                          Sigma-Aldrich, UK 
2-mercaptoethanol                                           M-6250                        Sigma-Aldrich, UK 
2-propanol                                                        19030                          Sigma-Aldrich, UK 
3, 3′-Diaminobenzidine tablets                          D4293                         Sigma, UK 
6-aminohexanoic acid                                       07260                          Sigma-Aldrich, UK 
Acid-Phenol: Chloroform, pH 4.5                      AM9720                       Ambion, USA 
Alcian Blue solution, pH 2.5                       B8438                          Sigma, UK 
Ammonium Acetate 5 M                                    AM9070G                    Ambion, USA 
Anti-Mouse IgG AP Conjugate                          S372B                         Promega, UK 
Benzamidine                                                     12072                          Sigma-Aldrich, UK 
Bovine Serum Albumin                                      B4287                         Sigma, UK 
Carbazole                                                          C5132                         Sigma, UK     
Cellulose Dialysis Membrane                            133336                        Spectrum labs, NL 
Chondroitinase ABC                                          C2905                         Sigma, UK 
Chondroitinase AC                                            C2780                         Sigma, UK                            
Cover slip 24x40 mm                                    12362118                    Fisher scientific, UK 
Cyanogen bromide                                            C91492                       Sigma, UK           
D-(+)-Glucuronic acid γ-lactone                         05566                         Sigma, UK 
Diethanolamine buffer 10X                                D8885                         Sigma, UK 
DNase I                                                              AM2222                     Ambion, USA 
DNase I Buffer 10X                                            AM8170G                  Ambion, USA 
dNTP mix 100mM                                              BIO-39029                  Bioline, UK 
DPX Mountant for histology                               06522                         Sigma, UK 
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Eosin Y solution                                      318906-500ML           Sigma, UK 
Formic acid                                                        F0507                         Sigma, UK      
GlycoBlue™ Coprecipitant                                 AM9515                     Ambion, USA 
Goat serum                                                        G9023                        Sigma, UK 
GoTaq(R) qPCR Master Mix                              A6002                        Promega, UK 
Hematoxylin solution                                         03971                         Sigma, UK 
Hydrochloric acid                                               435570                       Sigma, UK 
Hydrogen peroxide solution                               31642                         Sigma, UK 
Isopentane                                                         270342                       Sigma, UK 
Keratanase I                                                      100-810-1                   AMS, UK 
Keratanase II                                                     100-812-1                   AMS, UK 
M-MLV-RT                                                         M1701                         Promega, UK 
M-MLV-RT 5X                                                    M531A                        Promega, UK 
Mouse monoclonal IgG                                      ab37355                     Abcam, UK 
Mouse monoclonal IgM                                     ab18401                     Abcam, UK 
N-Ethylmaleimide                                               E3876                        Sigma-Aldrich, UK 
Normal goat serum                                            S-1000                        Vector laboratories, UK 
Novex® Sharp Pre-stained Protein Standard    LC5800                       Life technologies, UK 
NUPAGE MES SDS Running Buffer (20x)        NP0002                       Life technologies, UK 
NUPAGE transfer buffer (20x)                           NP0006-1                    Life technologies, UK 
NuPAGE® Novex 4-12% Bis-Tris Gel-10 well   NP0321BOX               Life technologies, UK 
NuPAGE® Novex 4-12% Bis-Tris Gel-12 well   NP0322BOX               Life technologies, UK  
Papain                                                                P4762                         Sigma-Aldrich, UK   
Paraformaldehyde                                              28794.295                   Prolabo, UK 
Peroxidase conjugate-goat anti-mouse IgG      A8924                          Sigma-Aldrich, UK 
Peroxidase conjugate-goat anti-mouse IgM      A8786                          Sigma-Aldrich, UK 
Peroxidase conjugate-goat Anti-Rabbit IgG      A0545                          Sigma-Aldrich, UK 
PNPP tablets                                                     37620                           Fischer scientific, UK 
POLY FROST                                                    MSS61012S                 Solmedia, UK 
Rabbit polyclonal IgG abcam                             ab27472                       Abcam, UK 
Random primers                                                C1181                           Promega, UK 
RNasin® Plus RNase Inhibitor                        N2611                           Promega, UK 
Sodium azide                                                     S2002                           Sigma, UK   
Sodium chloride                                                 32038                           Sigma, UK       
Sodium hydroxide                                              S5881                           Sigma, UK    
Sodium tetraborate                                            221732                          Sigma, UK 
Sulphuric acid                                                    450061Q                       VWR, UK                   
TE, pH 8.0                                                  AM9858                        Ambion, USA 
Trizol                                                                  15596-026                     Life technologies, UK 
Versican                                                             12C5                             DSHB, USA 
Western Lightning Plus_ECL                             NEL105001EA              Perkin Elmer, NL 
Xylenes                                                              534056                          Sigma, UK 
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APPENDIX II – PRIMERS STANDARD CURVE PLOT   
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Plate II 
 
 
 
 
 
 
 
 
y = 1.0626x - 0.2012
R² = 0.9967
-5
0
5
10
0 2 4 6 8
B2M
y = 1.3609x - 0.108
R² = 0.9953
-2
0
2
4
6
8
10
0 2 4 6 8
GAPDH
y = 1.072x - 0.1538
R² = 0.9982
-2
0
2
4
6
8
0 2 4 6 8
Versican
 
222 
 
 
Plate III 
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Plate IV 
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Plate V 
 
 
 
 
y = 1.128x - 0.5038
R² = 0.9837
-2
0
2
4
6
8
10
0 2 4 6 8
B2M
y = 1.1341x + 0.1331
R² = 0.9876
0
2
4
6
8
10
0 2 4 6 8
GAPDH
y = 1.1836x - 0.0836
R² = 0.9983
-2
0
2
4
6
8
10
0 2 4 6 8
Fibromodulin
y = 1.2068x - 0.3498
R² = 0.9896
-2
0
2
4
6
8
10
0 2 4 6 8
ADAMTS5
y = 1.0597x - 0.0109
R² = 0.9908
-2
0
2
4
6
8
0 2 4 6 8
ADAMTS4
 
225 
 
APPENDIX II – MELT CURVE ANALYSIS  
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APPENDIX IV – NEGATIVE CONTROLS FOR WESTERN BLOT ANALYSIS 
 
Figure 1. Anatomical regions of Staffordshire bull terrier CCL. Membrane probed with goat 
anti-mouse IgG secondary antibody (O=origin; M= middle; I= insertion). 
 
 
Figure 2. Anatomical regions of Staffordshire bull terrier CCL. Membrane probed with goat 
anti-mouse IgM secondary antibody (O=origin; M= middle; I= insertion). 
 
 
Figure 3. Anatomical regions of Staffordshire bull terrier CCL. Membrane probed with goat 
ant-rabbit IgG secondary antibody (O=origin; M= middle; I= insertion). 
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Figure 4. CCLs of two differentially predisposed dog breeds. Membrane probed with goat 
anti-mouse IgG secondary antibody (S= Staffordshire bull terrier; G= greyhound). 
 
 
Figure 5. CCLs of two differentially predisposed dog breeds. Membrane probed with goat 
anti-mouse IgM secondary antibody (S= Staffordshire bull terrier; G= greyhound). 
 
 
Figure 6. CCLs of two differentially predisposed dog breeds. Membrane probed with goat 
anti-rabbit IgG secondary antibody (S= Staffordshire bull terrier; G= greyhound).
 
232 
 
APPENDIX V – KENDALL’S COEFFICIENT OF CONCORDANCE RESULTS FOR HISTOLOGY SCORING 
Stain Intra observer 1 Intra observer 2 Inter observer 
H & E 0.8 
 
0.8            0.8 
Toluidine blue 
 
0.3 0.4 0.2 
Alcian blue 0.3 
 
0.5 0.3 
 
 
